

**ONTOGENY AND EFFECT OF WEANING ON mRNA LEVELS OF
IGFs, EGF AND bFGF IN VARIOUS TISSUES OF THE PIG**

By

Manli Peng

Thesis submitted to Department of Biology to obtain Ph.D. Degree

FACULTÉ DES SCIENCES
UNIVERSITÉ DE SHERBROOKE

Sherbrooke, Québec, Canada, December, 1996

To my motherland P.R. China

RÉSUMÉ

Ce travail porte sur l'étude de trois facteurs de croissance qui peuvent être importants dans le développement d'organes particuliers du porc soit le pancréas, le foie, les reins et le muscle strié. On croit que ces facteurs de croissance seraient directement impliqués dans la croissance de ces tissus. Ces trois facteurs sont le facteur de croissance insulinaire -I et -II (IGFs), le facteur de croissance épidermique (EGF) et le facteur de croissance fibroblastique basique (bFGF). Nous avons donc mesuré les niveaux d'ARN messager (ARNm) de chacun des facteurs et de leurs récepteurs (R) ainsi que les protéines liantes de IGF (IGFBPs) à partir du stade foetal jusqu'à l'âge de 180 jours. Dans le cas des IGF et de ses protéines liantes, les concentrations sériques et dans chacun des tissus ont aussi été mesurées.

Les concentrations sériques d'IGFs et d'IGFBPs croissent avec l'âge, l'IGFBP-3 étant la forme dominante lors de la période postnatale. Dans le tissu pancréatique, on observe des niveaux d'ARNm de l'IGF-I qui sont très élevés dans le pancréas foetal et à la naissance. Au début du sevrage (21^{ème} jour), la concentration d'un des deux types d'IGF, soit l'IGF-I, augmente de façon importante, y atteignant un maximum. Cette augmentation est concomitante avec un niveau élevé de son ARNm et des zymogènes pancréatiques. Quant aux niveaux pancréatiques des ARNm de l'IGF-II et du récepteur de l'IGF-I (IGF-IR), ils suivent un patron similaire à la concentration d'IGF-II, laquelle est élevée chez le fœtus de 90 jours, période qui correspond à une croissance rapide du pancréas. Les niveaux d'ARNm

de l'EGF, de son récepteur (EGFR) et du bFGF sont plus élevés durant la vie foetale qu'après la naissance. Ces observations suggèrent que les quatre facteurs de croissance étudiés sont impliqués dans le développement pancréatique foetal. À l'âge de 27 et 30 jours, on a constaté que les niveaux d'ARNm pancréatique de l'EGF sont plus élevés chez les porcelets sevrés que chez ceux qui sont encore allaités, ce qui suggère un rôle de l'EGF dans le développement pancréatique lors du sevrage.

Dans le foie, les niveaux d'ARNm de l'IGF-I sont parallèles à sa concentration dans le tissu. Les concentrations élevées de l'IGF-I et -II dans le tissu correspondent à des périodes de croissance accélérée de l'organe, soit entre le 1^{er} et le 21^{ème} jour. Par comparaison avec les autres tissus étudiés, c'est dans le foie que l'ARNm de l'IGFBP-I est le plus élevé. Bien que le niveau d'ARNm du récepteur de l'EGF soit élevé, l'ARNm de l'EGF lui-même n'a pu y être détecté. Quant au bFGF hépatique, ses niveaux d'ARNm sont élevés durant toute la période de développement.

Dans le rein, les niveaux d'ARNm des IGFs étaient élevés dans le fœtus tandis que les concentrations des IGFs atteignaient un maximum chez le nouveau-né, lesquelles étaient associées à une période de croissance rapide de cet organe. Comme dans le foie, les ARNm du bFGF sont abondants mais stables contrairement au niveau d'ARNm de l'EGF qui augmente durant cette période de développement.

Dans le muscle strié, les ARNm des deux espèces d'IGF (IGF-I et IGF-II), de son récepteur, de ses protéines liantes ainsi que le bFGF sont abondants durant toute la période foetale et les premiers jours de vie. Quant à l'EGF, son niveau d'ARNm y augmente tout

au cours du développement. Ces observations suggèrent donc que les IGF, l'EGF et les bFGF sont des régulateurs physiologiques de la croissance et de la maintenance du tissu musculaire strié.

On peut donc conclure que les niveaux d'ARNm et les concentrations dans les tissus des différents facteurs de croissance étudiés ici et ceux de leur protéines accessoires varient considérablement selon l'organe et l'âge de l'animal. Nous avons mis en évidence que les ARNm des IGF, de leurs récepteurs et de leurs protéines liantes sont parfois contrôlés de façon coordonnée dans les tissus comme le pancréas et le foie. Nous avons aussi mis en évidence que les périodes de croissance rapide du pancréas, du foie et du rein sont accompagnées par des niveaux élevés d'ARNm des IGF, de l'EGF et du bFGF, suggérant donc que ces facteurs de croissance sont d'importants régulateurs de la croissance et du développement de ces organes.

SUMMARY

In the present study, we have examined three growth factors which can be important for organ development of pancreas, liver, kidney and muscle. We believe that these growth factors are involved in the growth of these tissues. These growth factors are the insulin like growth factor-I and -II (IGFs), the epidermal growth factor (EGF) and the basic fibroblast growth factor (bFGF). We have measured the messenger RNA (mRNA) levels of these growth factors and those of their receptors (R) as well as IGF binding proteins (IGFBPs) from fetal life to 180 days of age. In the case of IGFs and IGFBPs, concentrations in the serum and in each tissue were also measured.

The IGFs and IGFBPs serum concentrations increased with advancing age, the IGFBP-3 being the major IGF binding protein in serum during postnatal life. In the pancreas, IGF-I mRNA levels were high during the fetal and early postnatal life. Around the weaning period (21 days of age), tissue concentration of IGF-I reached a maximal level which was concomitant with a high IGF-I mRNA level and an increased activity of pancreatic enzymes. Pancreatic IGF-II and IGFI-R mRNA levels as well as IGF-II tissue concentrations were high in fetuses and were accompanied by a rapid growth period of pancreas in fetuses of 90 days of age. Levels of EGF, EGFR and bFGF mRNAs were higher during the fetal life than after birth. These results imply that multiple growth factors are involved in fetal pancreatic development. At 27 and 30 days of age, EGF mRNA levels were higher in weaned than in suckling piglets, suggesting a possible involvement of EGF in pancreatic development during

the weaning period.

In the liver, IGF-I mRNA level paralleled its tissue concentration. High tissue concentration of both IGF-I and -II at 1 and 21 days of age corresponded to an accelerated growth period of the liver. The IGFBP-1 mRNA level was the most abundant in the liver when compared to that of other tissues. In the liver, abundant EGFR mRNA level was observed whereas EGF mRNA was undetected. The bFGF mRNA levels were high over the whole developmental period.

In the kidney, IGFs mRNA levels were high in fetuses while kidney IGFs concentrations peaked in newborns, which were associated with a fast growth period of this organ. As observed in the liver, the bFGF mRNA was abundant in the kidney during the whole developmental period, while EGF mRNA level increased with development.

In the skeletal muscle, IGF-I, IGF-II, IGF-IR, IGFBP-3 and bFGF mRNAs were all abundant during fetal and neonatal life. The EGF mRNA level increased during development. These data suggest that IGFs, EGF and bFGF are likely physiological regulators of growth and maintenance of the skeletal muscle.

In conclusion, mRNA levels and concentrations of growth factors and their binding proteins are tissue and developmentally regulated. Concentrations and mRNA levels of IGFs, IGFRs and IGFBPs are coordinately regulated in the pancreas and liver. Fast growth periods of pancreas, liver and kidney are accompanied by high concentrations of IGFs and abundant mRNA levels of IGFs, EGF and bFGF, suggesting that these growth factors are important regulators for growth and development of these organs.

ACKNOWLEDGEMENTS

I would like to express my appreciation to all who have contributed to the completion of this thesis. I am greatly indebted to professor G. Pelletier and professor D. LeBel, my supervisors, for their guidance, encouragement and financial assistance throughout the research program and preparation of this thesis.

Thanks are also given to professor C. Asselin, professor R. Bealouin and professor F. Pothier members of my Ph.D. program committee for discussion and helpful suggestion for thesis writing.

I also want to extend my sincere thanks to Dr. E. Calvo and Dr. M-F. Palin for their advice, useful discussions and technical support.

I would also like to thank all the members of our research group for their friendship, helpful discussion and technical support.

Finally, I would like to thank my husband, Xiaojun Li, my daughter Wenfei Li as well as my parents in China for their deepest love, encouragement and understanding throughout the whole period of my study here.

CONTENTS

RÉSUMÉ	i
SUMMARY.....	iv
ACKNOWLEDGMENT	vi
CONTENTS	vii
LIST OF ABBREVIATIONS.....	xi
LIST OF FIGURES	xv
LIST OF TABLES	xviii
LIST OF APPENDIX	xix
CHAPTER I INTRODUCTION	1
PART A: BASIC KNOWLEDGE	1
1.1 EMBRYONIC DEVELOPMENT OF PANCREAS, LIVER, KIDNEY AND SKELETAL MUSCLE IN HUMAN.....	1
Pancreas	1
Liver	2
Kidney	2
Muscle	3

1.2	SIGNAL TRANSDUCTION PATHWAYS AND CELL PROLIFERATION.....	6
	Signal transduction by receptors with ligand-depaendent tyrosine kinase activity	6
	Signal transduction through G protein-coupled receptors	9
	Signalling pathways from cell surface receptors to nuclei.....	11
1.3	REGULATION OF TRANSCRIPTION FACTOR EXPRESSION BY SIGNAL TRANSDUCTION PATHWAYS	13
	Altered DNA-binding and activation	13
	Signalling pathways regulating transcription factors by phosphorylation...	14
	Regulation of transcription initiation by RNA polymerase II (pol II)	16
	Regulation of mRNA stability	18
PART B:	GENERAL INTRODUCTION TO THE PROJECT	21
1.4	GENE EXPRESSION AND BIOLOGICAL ACTION OF INSULIN-LIKE GROWTH FACTORS (IGFs), EPIDERMAL GROWTH FACTOR (EGF) AND BASIC FIBROBLAST GROWTH FACTOR (bFGF) DURING DEVELOPMENT.....	21
1.4.1	Insulin-like growth factor-I and -II (IGF-I and -II)	22
	IGFs during development	26
	IGF receptors during development	28
	IGF binding proteins during development.....	30
	Biological action of IGF-I and IGF-II	32

	<i>IGFs and pancreas</i>	33
	<i>IGFs and liver</i>	33
	<i>IGFs and kidney</i>	34
	<i>IGFs and skeletal muscle</i>	35
1.4.2	Epidermal growth factor (EGF)	36
	EGFR during fetal development	37
	EGF during development	38
	Biological action of EGF	41
	<i>EGF and pancreas</i>	41
	<i>EGF and liver</i>	42
	<i>EGF and kidney</i>	42
1.4.3	Basic fibroblast growth factor (bFGF)	43
1.4.4	Nutritional regulation of IGFs, EGF and bFGF	45
1.5	HYPOTHESIS AND OBJECTIVES OF THE PROJECT	47
CHAPTER II	MATERIALS, METHODS AND RESULTS	49
2.1	ONTOGENY OF IGFs, IGFBPs AND IGFRs mRNA LEVELS IN PORCINE PANCREAS	49
2.1.1	Contributions to manuscript 2.1	49
2.1.2	Manuscript 2.1	50

2.2	ONTOGENY OF IGFs AND IGFBPs mRNA LEVELS AND TISSUE CONCENTRATIONS IN LIVER, KIDNEY AND SKELETAL MUSCLE OF PIG	90
2.2.1	Contributions to manuscript 2.2	90
2.2.2	Manuscript 2.2	91
2.3	ONTOGENY OF EPIDERMAL GROWTH FACTOR (EGF), EGF RECEPTOR (EGFR) AND BASIC FIBROBLAST GROWTH FACTOR (bFGF) mRNA LEVELS IN PANCREAS, LIVER, KIDNEY AND SKELETAL MUSCLE OF PIGS....	108
2.3.1	Contributions to manuscript 2.3	108
2.3.2	Manuscript 2.3	109
2.4	EFFECT OF WEANING ON EPIDERMAL GROWTH FACTOR AND ITS RECEPTOR MESSENGER RNA LEVELS IN VARIOUS TISSUES OF PIGLETS	134
2.4.1	Contributions to manuscript 2.4	134
2.4.2	Manuscript 2.4	135
CHAPTER III	GENERAL DISCUSSION.....	139
REFERENCES.....		146
ANNEX		166

LIST OF ABBREVIATIONS

AC:	adenylate cyclase
ALS:	acid-labile
bFGF:	basic fibroblast growth factor
BSA:	bovine serum albumin
cAMP:	cyclic adenosine monophosphate
CBP:	CREB-binding protein
CCK:	cholecystokinin
cDNA:	complementary DNA
CKII:	casein kinase II
CRE:	cAMP-response element
CREB:	cAMP-response element-binding protein
CRID:	coding region instability determinant
CTD:	C-terminal domain
DAG:	diacylglycerol
DNA:	deoxyribonucleic acid
EDTA:	disodium ethenediamine tetraacetic acid
EGF:	epidermal growth factor
EGFR:	EGF receptor
FRK:	Fos-regulating kinase

GH:	growth hormone
GHR:	GH receptor
GAP:	GTPase-activating protein
GDP:	guanosine diphosphate
GTP:	guanosine triphosphate
HGF:	hepatocyte growth factor
HLH:	helix-loop-helix
IGF:	insulin-like growth factor
IGFBP:	IGF binding protein
IGFR:	IGF receptor
I κ B:	inhibitor protein
IP3:	inositol 1,4,5-trisphosphate
IRS:	insulin-receptor substrate
JAK:	Janus kinase
JNK:	c-Jun NH ₂ -terminal kinase
MAPK:	mitogen activated protein kinase
MAPKK:	MAPK kinase
mRNA:	messenger RNA
NC:	negative cofactor
NF-I:	neurofibromatosis type I protein
ODC:	ornithine decarboxylase

PABP:	poly (A)-binding protein
PH:	pleckstrin homology
PI3-K:	phosphoinositide 3-kinase
PIP2:	phosphatidylinositol 4,5-bisphosphate
PKC:	protein kinase C
PL:	phospholipase
PLD:	phospholipase D
PLC:	phospholipase C
PLC- γ :	phospholipase C- γ
PLC- β :	phospholipase C- β
Pol II:	polymerase II
RIA:	radioimmunoassay
RNA:	ribonucleic acid
RTK:	receptor tyrosine kinase
RT-PCR:	reverse transcription polymerase chain reaction
SDS:	sodium dodecyl sulfate
SH2:	src homology 2 domains
SP1:	stimulated protein 1
SRE:	serum response element
SRF:	serum response factor
STAT:	signal transducer and activator of transcription

TBP:	TATA box binding protein
TBS:	tris buffer saline
TCF:	ternary complex factor
TPA:	12-0-tetradecanoyl-phorbol-13-acetate
TRE:	TPA response element
TF:	transcription factor
TTR:	transthyretin
USF:	upstream stimulatory factor

LIST OF FIGURES

Figure 1.1.1	Development of pancreas in human embryo during the fourth to sixth week of gestation.....	4
Figure 1.2.1	Signalling pathways from the cell surface receptors to the nuclei.....	12
Figure 1.2.2	Schematic model of transcription initiation complex assembly.....	20
Figure 1.4.1	Illustration of some growth factors involved in the cell cycle at different phases.....	22
Figure1.4.1.1	Structure and expression of the human IGF-I gene.....	24
Figure1.4.1.2	Structure of the human IGF-II gene organization and mRNAs species...	25
Figure1.4.2.1	Ontogeny of EGF receptors in the fetal mouse.....	40

Figures of manuscript 2.1: Peng, M. et al. J. Anim. Sci. (Submitted)

Figure 1	Effect of age on: a)pig pancreatic weight, b)total pancreatic DNA to body weight ratio, c)organ weight, d)total RNA and e)protein to DNA ratios ..	81
Figure 2	Effect of age on IGF-I mRNA level in pig pancreas	82
Figure 3	Effect of age on pig pancreatic IGFI-R mRNA level	83
Figure 4	Effect of age on IGF-II mRNA level in pig pancreas	84
Figure 5	Representitive Northern blot of IGFBP-1 mRNA in various pig tissues at fetal 90 days of age	85
Figure 6	Effect of age on pig pancreatic IGFBP-3 mRNA level	86

Figure 7	Effect of age on pig pancreatic GHR mRNA level	87
Figure 8	Effect of age on pig pancreatic IGF-I and -II concentrations	88
Figure 9	Effect of age on IGFBPs contents in pig pancreas	89

Figures of manuscript 2.2: Peng, M. et al. Growth Dev. Aging, 1996.
60:171-187.

Figure 1	Representative Northern blot of IGF-I, -II, IGFI-R, IGFI-R, IGFBP-1, IGFBP-3 and GHR mRNAs in various fetal tissues	93
Figure 2	Northern analysis of IGF-I mRNA levels in various tissues of pig during development	95
Figure 3	Northern analysis of IGF-II mRNA levels in various tissues of pig during development	95
Figure 4	Northern analysis of the IGFBP-1 mRNA levels in pig liver during development	97
Figure 5	Northern analysis of IGFBP-3 mRNA levels in various tissues of pig during development	97
Figure 6	Northern analysis of IGFI-R mRNA levels in various tissues of pig during development	98
Figure 7	Northern analysis of IGFI-R mRNA levels in various tissues of pig during development	98
Figure 8	Northern analysis of GHR mRNA levels in various tissues of pig during	

	development	99
Figure 9	Effect of age on serum IGF-I, -II and IGFBPs concentrations in pig.....	100
Figure 10	Effect of age on IGF-I, -II and IGFBPs concentrations in liver of pig ...	101
Figure 11	Effect of age on IGF-I, -II and IGFBPs concentrations in kidney of pig.	102

Figures of manuscript 2.3: Peng, M. et al. Domest. Anim. Endocrinol.
(Submitted)

Figure 1	Representative Northern blot of EGF, EGFR and bFGF mRNAs in pig various tissues at 90 days of age	130
Figure 2	Effect of age on EGF mRNA levels in various tissues of pig.....	131
Figure 3	Effect of age on EGFR mRNA levels in various tissues of pig.....	132
Figure 4	Effect of age on bFGF mRNA levels in various tissues of pig	133

Figures of manuscript 2.4: Peng, M. et al. Can. J. Anim. Sci. 1996. 76:621-
624.

Figure 1	Effect of weaning on EGF mRNA in pig pancreas	137
----------	---	-----

LIST OF TABLES

Table 1.1.1	Morphological development of human exocrine pancreas.....	5
Table 1.1.2	Functional development of human exocrine pancreas.....	5
<p>Tables of manuscript 2.2: Peng, M. et al. Growth Dev. Aging, 1996. 60: 171-187.</p>		
Table 1	Effect of age on liver weight and total DNA to body weight ratios and liver weight, total RNA and protein to DNA ratios in the liver of pig.....	103
Table 2	Effect of age on kidney weight and total DNA to body weight ratios and kidney weight, total RNA and protein to DNA ratios in the kidney of pig	103
<p>Tables of manuscript 2.4: Peng, M. et al. Can. J. Anim. Sci., 1996. 76:621-624.</p>		
Table 1	Effect of weaning on pancreas weight and total pancreatic DNA to body weight ratios and pancreas weight, total RNA and protein to DNA ratios in piglets (S:suckling, W: weaning).....	137

APPENDIX

Appendix I	Comparison of IGFs and IGFBPs mRNA levels in rat and pig during fetal and postnatal life	167
Appendix II	Body weight and food consumption of piglets around the weaning period	168
Appendix III	Structure of human IGF-I cDNA probe	169
Appendix IV	Structure of rat IGF-II cRNA probe	170
Appendix V	Structure of porcine IGFBP-3 cRNA probe	171
Appendix VI	Structure of human IGFI-R cDNA probe	172

CHAPTER I INTRODUCTION

PART A: BASIC KNOWLEDGE

1.1 EMBRYONIC DEVELOPMENT OF PANCREAS, LIVER, KIDNEY AND SKELETAL MUSCLE IN THE HUMAN

The first phase of human embryonic development lasts 8 weeks. From week 9 of gestation starts the fetal period which can be subdivided into the previable fetal period (9-18 weeks of development) and the viable fetal period (19-38 weeks of development). Development during the whole fetal period primarily concerns rapid body growth and further differentiation of organs and tissues (Kalousek et al., 1990).

Pancreas

The pancreatic exocrine and endocrine tissues arise from the dorsal and ventral pancreatic buds that originate from the endodermal lining of the foregut (Gray et al., 1987). The pancreas is first detectable during the fifth week of gestation. By the 17th week, as a consequence of rotation and fixation of the gut, the two buds fuse to form definitive ducts (Fig.1.1.1). The dorsal bud contributes to the tail and body of the mature gland, while the ventral bud contributes to the head. The main pancreatic duct is formed by the fusion of the distal part of the dorsal pancreatic duct and the entire ventral pancreatic duct. The accessory pancreatic duct is derived from the proximal dorsal pancreatic duct (Fig.1.1.1). By 12 to 14

weeks, tubules become a network of interconnected ductulus and separation of endocrine from exocrine tissue has occurred. Discrete lobules and acini can be identified by 14-16 weeks. By 20 weeks, the acinar cells are well polarized with many mature zymogen granules crowded in the apical cytoplasm (Table 1.1.1 and 1.1.2).

Liver

The liver bud is formed from outgrowth of the endodermal epithelial lining of the foregut early in the fourth week (Kalousek et al., 1990). The caudate lobe and the quadrate lobes develop as a subdivision of the right lobe. The hepatic volume consistently increases during embryonic life. At about 8 to 9 weeks, the liver represents 10% of the body weight due to rapid growth and erythroblast accumulation. By term, the weight of the liver is only 5% of the total body weight. During the early fetal stage, the basic glandular unit of the liver, seen through childhood and adulthood, is established. This unit, called the hepatic triad, consists of the bile ducts, hepatic artery, and portal vein. Differentiating biliary ducts can be seen in the connective tissue at 9 to 12 weeks. Bile formation by hepatic cells begins during the 12th week.

Kidney

The kidney begins to develop early in the 5th week and start to function about six weeks later (Kalousek et al., 1990). Kidney develops from the nephrogenic blastema and ureteric bud. The nephrogenic blastema gives rise to the nephrons each consisting of a glomerulus and a proximal convoluted tubule, a loop of Henle, and a distal convoluted tubule. The ureteric bud differentiates into collecting tubules, renal pelvis, calyces, and

ureter. Glomeruli are first formed in the region of the metanephric tissue that, in the definitive kidney, constitutes the juxtamedullary region. It has been estimated that approximately 20% of nephrons are morphologically formed and mature at 9 to 11 weeks of development, and another 10% is added at 14-18 weeks. By 12 weeks, the kidney is differentiated into a cortex and a medulla. By 16 weeks, development of the pyramids is advanced. Glomeruli continue to form from the metanephric blastemal cap until about 36 weeks of gestation.

Muscle

The muscle system develops from the mesoderm (Hauschka, 1994). Muscle tissue develops from primitive cells called myoblasts which are derived from mesenchyme. The first indication of muscle development is the elongation of the nuclei and cell bodies of the mesenchymal cells to form myoblasts. Soon, these cells begin to fuse with one another to form elongated, multinucleated, cylindrical structures called myotubes. Growth occurs by continued fusion of myoblasts and myotubes. The specialized myofilaments develop in the cytoplasm of the myotubes during or after fusion of the myoblasts. Then, the myofibrils and other organelle characteristics of striated muscle fibres (cells) develop. Most striated skeletal muscle fibres develop before birth, and almost all the remaining ones are formed by the end of the first year. After birth, muscle increases in length and width in order to grow with the skeleton.




Fig. 1.1.1 Development of pancreas in human embryo during the fourth to sixth week of gestation. A. Formation of the dorsal and ventral pancreatic primordia. B. Rotation of the ventral primordium. C. Fusion of the primordia and formation of the definitive ducts. The contribution of the ventral primordium is shaded. (From Gray, S.W., Skandalakis, J.E. and Skandalakis, L.J. In: Surgical diseases of the pancreas, pp. 37-45, 1987).

Table 1.1.1 Morphological development of human exocrine pancreas

Event	Developmental age (weeks)
Dorsal and ventral anlagen detectable	5
Fusion of anlagen	7
Differentiation of endocrine and exocrine tissue	12-14
Lobules and acini formed	14-16
Polarity of acinar cells established	20
Zymogen granules present	20-22
Adult appearance of gland (histological)	40

Table 1.1.2 Functional development of human exocrine pancreas

Event	developmental age
Zymogens detectable in pancreatic homogenates	20 weeks
Lipase detectable in pancreatic homogenates	24 weeks
Enterokinase detectable in intestinal content	26 weeks
Response to secretagogues	1 month (postnatal)
Amylase detectable in pancreatic homogenates	2 months (postnatal)

1.2 SIGNAL TRANSDUCTION PATHWAYS AND CELL PROLIFERATION

Cell proliferation is controlled by a large variety of stimulative or inhibitory signals mediated through specific receptors on the cell surface. One class of receptors consists of transmembrane surface receptors with intrinsic tyrosine kinase activity, some of which bind polypeptide growth factors such as IGF-I, EGF and FGF (Geer and Hunter, 1994). The second class of receptors consists of G protein-coupled receptors interacting with different intracellular signalling systems (e.g. phospholipid breakdown, adenylyl cyclase, ion channels) and bind different hormones, such as thrombin, serotonin and bombesin (Strader et al., 1994). These two classes of receptors are tightly interconnected.

Signal transduction by receptors with ligand-dependent tyrosine kinase activity

Polypeptide growth factors represent a group of extracellular signals that are critically important for influencing a diverse array of cellular responses including proliferation, differentiation and cell survival. The effects of many growth factors are mediated by high-affinity tyrosine kinase receptors (Geer and Hunter, 1994). Ligand binding to receptor tyrosine kinase results in dimerization of adjacent receptor monomers and activation of tyrosine kinase phosphorylation, a process termed autophosphorylation. Receptor autophosphorylation acts as a switch to induce the binding of cytoplasmic signal proteins to the receptor. These signalling molecules mediate the cellular responses to growth factors. Over the recent years, several tyrosine kinase substrates and cell mediators have been

identified, including phospholipase C- γ (PLC- γ), phosphoinositide-3-kinase (PI-3K), insulin-receptor substrate (IRS-1) and GTPase-activating protein (GAP) modulating c-ras proto-oncogene function (Pawson, 1992). All these tyrosine kinase substrates contain specific protein sequences Src homology 2 domains or Src homology 3-like region (SH2 or SH3 domains) which allow them to associate with specific tyrosine phosphorylated sites on receptor proteins.

PLC activation is a common feature in the mechanism of action of a wide variety of growth factors and mitogens. Several PLC isozymes can mediate this step. G-protein coupled receptors activate PLC- β , while tyrosine kinase receptors other than insulin and IGF-I receptors utilize PLC- γ as a substrate. Hydrolysis of the PLC substrate phosphatidylinositol 4,5-bisphosphate (PIP₂) produces two second messengers, diacylglycerol (DAG) which activates protein kinase C (PKC), and inositol 1,4,5-trisphosphate (IP₃) which mobilizes intracellular stored calcium.

PI-3-kinase is another tyrosine kinase receptor substrate involved in phosphoinositide metabolism. PI-3-kinase phosphorylates phosphatidylinositol at position 3 of the inositol ring to produce PI-3-P (which is not a substrate for PLC). PI-3-P is an important mediator of signal transduction, linked to several biological actions during growth factor stimulation.

IRS-1 is the principal substrate of insulin and IGF-I receptor tyrosine kinases (Myers et al., 1994). The activated receptor phosphorylates IRS-1 and SH2 containing proteins bind to IRS-1. IRS-1 contains a pleckstrin homology (PH) domain which mediates the interaction of IRS-1 with a common motif in the receptors for insulin and IGF-I. Removal of the PH

domain from IRS-1 impairs insulin signalling in a background of low insulin receptor expression. IRS-1 mediates cellular mitogenesis during stimulation with insulin and IGF-I. Overexpression of IRS-1 in Chinese hamster ovary cells, which contain only a few endogenous insulin receptors, doubles the maximal response of thymidine incorporation during insulin stimulation (Sun et al., 1992).

Many studies have suggested that ras plays a key role in signal transduction and control of cellular proliferation (Marshall, 1995). Ras is active in the GTP-bound form and inactive in the GDP-bound form. The GTPase activity of ras is enhanced by GTPase-activating protein (GAP) and neurofibromatosis type I protein (NF-I). Various growth factors stimulate the formation of GTP-ras, thus coupling the signals from the cell surface to the downstream kinase cascade. There are several ras target proteins such as Raf, MEKK1 and PI3-K. Active Raf phosphorylates the MEK protein kinase on serine, which results in its activation. MEK (also known as MAP kinase kinase MAPKK) is a dual specificity threonine/tyrosine kinase that phosphorylates and activates mitogen activated protein kinase (ERK/MAPK). Although the end results of ERK substrate phosphorylations are diverse, the most significant effects on cellular proliferation are probably caused by the increased transcriptional activity of the AP-1 complex, resulting from increased expression of fos (Marais et al., 1993). ERK/MAPKs activation through Raf is the predominant ras effector pathway. MAPK functions as a key molecule in signalling processes. Active MAPK may be responsible for triggering S6 kinase and casein kinase II and may also participate in the growth factor-mediated stimulation of ion transporters such as the Na/K/Cl cotransporter or

the Na/H antiporter.

Other cytokines and growth factors function by interacting with receptors that are members of the cytokine receptor superfamily (Schindler, 1995). These receptors share the same extracellular motifs and have limited similarity in their cytoplasmic domains. Although lacking catalytic domains, in contrast to tyrosine-kinase receptors, this family of receptors couples ligand binding with the induction of tyrosine phosphorylation. Recent studies have shown that this is mediated by members of the Janus kinase (JAK) family of cytoplasmic protein tyrosine kinases (Inglese et al., 1995). Binding of a cytokine induces receptor oligomerization and activation of JAKs. The activated JAK subsequently phosphorylates both receptor and cellular substrates, which include members of the signal transducers and activators of transcription (STATs) family of transcription factors. Following phosphorylation, the STATs form dimers through SH2 domain-dependent intermolecular association with carboxyl sites of tyrosine phosphorylation. Dimerization triggers dissociation from the receptor complex and translocation to the nucleus. In the nucleus, the STAT dimers bind response elements and are generally associated with the activation of gene expression.

Signal transduction through G protein-coupled receptors

Many hormones, neurotransmitters and vasoactive agents transmit signals by interacting with specific G protein-coupled receptors (Strader et al., 1994). A ligand-occupied receptor induces the exchange of GDP for GTP in specific G proteins. An active G protein is a heterotrimer containing α , β and γ chains. Upon activation by ligand binding,

this complex dissociates into a separate α subunit carrying the GTP and a $\beta\gamma$ complex. The α subunit will interact with effector enzymes, stimulating or inhibiting them. Several effector enzymes controlled by G proteins have been described, including adenylate cyclase (AC) and phospholipases C- β , D and A₂ (PLC- β , PLD and PLA₂). AC is the enzyme that synthesizes cAMP from ATP and is linked to G protein receptors. cAMP as a second messenger exerts its effect by activating cAMP-dependent protein kinase-A (PKA). Another effector enzyme, PLC- β , hydrolyses PIP₂ into two second messengers IP₃ and DAG, leading to transient rise in cytoplasmic Ca⁺⁺ levels and protein kinase C (PKC). In addition, receptor-mediated activation of PLD and PLA₂ leads to hydrolysis of phosphatidylcholine into DAG and free fatty acids. A growing body of evidence now supports the idea that the $\beta\gamma$ subunit can itself interact functionally with effector proteins. It has been reported that the $\beta\gamma$ subunit can stimulate PLC β , phospholipase A₂ (PLA₂) and PI3-kinase activities and participate in the inhibition of AC. Recent studies have shown that the $\beta\gamma$ subunit may even provide a way to link G proteins to receptor tyrosine kinase (RTK) initiated cascades (Inglese et al., 1995). This connection may be mediated by G $_{\beta\gamma}$ alone or by a PH domain-directed binding, leading to ras activation. RTK activation (for example, by epidermal growth factor, EGF) also activates ras through the recruitment (directed by the SH2 and SH3 domains) of the cytoplasmic proteins Grb2 and Sos1. The convergence of these two different surface-receptor signalling pathways on ras activation, in turn, leads to the sequential activation of the raf-1-MAPK cascade.

Signalling pathways from cell surface receptors to nuclei

Signalling pathways from cell surface receptors to nuclei is one of the central subject of modern biology. Fig. 1.2.1 outlines some of the early events commonly activated in all cell types by different promoting agents (Hill and Treisman, 1995; Pawson, 1993). Signals through tyrosine kinase receptors and G protein-coupled receptors could converge and /or synergise at the level of switch kinases such as serine/threonine MAP kinase and Raf kinase. These kinases receive the signal from various external messengers and pass on the signals by activating other specific protein kinases (e.g. S6 kinase) to increase protein synthesis, by activating antiporter Na/H or symporter Na/K/Cl to induce ionic change, or directly by initiating early gene transcription. This notion of switch kinases although still very hypothetical, could account for the integrated and synergistic aspects of various responses.




Fig. 1.2.1 Signalling pathways from the cell surface receptors to the nuclei (From Pouyssegur, J., Kahan, C., Magnaldo, I. and Seuwen, K. In: Transmembrane signalling intracellular messengers and implications for drug development, pp 119-132, 1992).

1.3 REGULATION OF TRANSCRIPTION FACTOR EXPRESSION BY SIGNAL TRANSDUCTION PATHWAYS

Signal transduction pathways regulate nuclear transcription factors expression by modulating their activity. The most studied members are the AP-1 (Jun/Fos) and cAMP-response element-binding (CREB) protein. Molecular cloning revealed that AP-1 consists of a variety of different transcription factors which belong to the Fos and Jun families (Sassone-Corsi, 1994). Serum response element (SRE) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA) response element (TRE) mediate c-Fos and c-Jun expression respectively, induction by growth factors, cytokines and other stimuli that activate MAPKs. CREB mediates transcription in response to the cAMP-dependent protein kinase A (PKA) signal transduction pathway and controls gene expression by binding to the cyclic AMP (cAMP) response element (CRE) (Brindle and Montminy, 1992).

Altered DNA-binding and activation

Many transcription factors bind DNA as dimers either of homodimeric or heterodimeric nature (Kerr et al., 1992). There are several different types of sequence-specific DNA-binding domains, such as zinc finger, leucine zipper/basic DNA-binding domains, helix-loop-helix (HLH) and helix-turn-helix. All members of the CREB and AP-1 families are leucine zipper containing proteins. Induction of Fos transcription results in increased synthesis of Fos proteins which combine with pre-existing Jun proteins to form

AP-1 heterodimers through leucine zipper motifs, in such a way that they bind DNA more stably and thereby increase the level of AP-1 activity.

Signalling pathways regulating transcription factors by phosphorylation

Regulation of transcription factor activity is mostly by phosphorylation events (Hunter, 1995). Three different types of MAPKs, the extracellular signal-regulated protein kinases (ERKs), the c-Jun NH₂-terminal kinases (JNKs) and the Fos-regulating kinases (FRKs) contribute to induction of AP-1 activity through phosphorylation of different substrates that potentiate their transcriptional activities. JNK-mediated phosphorylation of ATF2 and c-Jun bound to the c-Jun promoter (TRE) stimulates their transcriptional activities, leading to c-Jun production. Phosphorylation by ERK of the serum response factor (SRF) and its accessory ternary complex factor (TCF) Elk-1 bound to the c-Fos promoter serum response element (SRE) stimulates its transcriptional activity, thus leading to c-Fos induction. The newly synthesized c-Fos and c-Jun proteins combine to form stable AP-1. A further increase in AP-1 activity is brought about by the JNK and FRK which phosphorylate c-Jun and c-Fos, respectively, on sites that increase their transcriptional activities. As mentioned earlier, activation of PKA depends on increases in cAMP generated at the plasma membrane as a result of activation of adenylate cyclase by G protein-coupled receptors or other signal transduction pathways. One of the major nuclear PKA substrates is the transcription factor CREB. The PKA C subunit phosphorylates a single serine, Ser-133. This phosphorylation results in increased transactivation activity, without a significant effect on CREB DNA-

binding activity. Phosphorylation of Ser-133 promotes binding of the CREB-binding protein (CBP), a large protein with an activation domain that can interact with TFIIB (Chrivia et al., 1993).

Transcription factors can be sequestered in an inactive form in the cytoplasm. Phosphorylation of the factor itself or a cytoplasmic anchor protein allows translocation of the transcription factor into the nucleus. One example of phosphorylation-regulated nuclear translocation is provided by the Rel family of transcription factors which includes NF- κ B (Hunter and Karin, 1992). NF- κ B is activated in many different cell types following a stimuli. In unstimulated cells, the majority of the NF- κ B p50/p65 proteins is retained in the cytoplasm, through binding to I κ B inhibitor proteins. I κ B proteins mask the DNA-binding activity of NF- κ B and control the nuclear uptake of associated DNA binding proteins. Following stimulation with TPA, the NF- κ B complex translocates to the nucleus in an active form. External stimuli activate several protein kinases such as PKA or PKC which can induce the phosphorylation of I κ B. This phosphorylation leads to dissociation of I κ B from the NF- κ B complex and to the unmasking of the DNA-binding domain. This is followed by translocation to the nucleus where NF- κ B binds to κ B sites to activate transcription of target genes.

The DNA binding activity of nuclear transcription factors can be modulated by phosphorylation either positively or negatively (Lüscher et al., 1990). One example of negative regulation by phosphorylation is the c-myc protein. Phosphorylation of c-myc by casein kinase II (CKII) results in a large decrease in DNA binding activity. Another example

is c-Jun. In non-stimulated cells, c-Jun is present in a form that is phosphorylated on sites that inhibit DNA binding activity. In response to cell stimulation with growth factors, c-Jun undergoes dephosphorylation of these sites and its DNA binding activity increases (Boyle et al., 1991).

Phosphorylation can affect the interaction of transcription factor transactivation domains. Transcription factors are usually composed of separable DNA-binding and transcriptional activation domains. In most cases, phosphorylation effects on transactivation are of positive control. As shown earlier, PKA regulates CREB activity by phosphorylation of its activation domain at Ser-133. c-Myc is an example of a transcription factor whose transactivation function is stimulated by phosphorylation. Ser-62 is a MAP/ERK kinase phosphorylation site in human c-Myc and is stimulated by growth factors treatment.

Regulation of transcription initiation by RNA polymerase II (pol II)

Regulation of transcription initiation is by far the most widespread form of gene control in eukaryotes (Hernandez, 1993). Such control results in the response to extracellular signals, leading to changes in levels of specific mRNAs and their translation products. In eukaryotes, initiation is governed by DNA sequence elements comprising several functional classes. Core promoter elements contain binding sites for general transcription factors leading to recruitment of RNA pol II and control the location of transcription initiation sites. Upstream promoter elements and enhancers regulate the rate at which RNA pol II initiates new rounds of transcription from the core promoter. Seven general transcription factors have

been identified and extensively purified. Among these factors, only TFIID contains a DNA binding activity with specificity for the TATA box. The others and RNA pol II enter the transcription complex by protein-protein interactions. The largest subunit of RNA pol II contains a C-terminal domain (CTD). Hyperphosphorylation of the CTD blocks incorporation of pol II into the initiation complex.

Initiation of transcription by RNA pol II requires the formation of a complex containing the basal factors TFIID, TFIIA, TFIIB, TFII E/F, TFIIF, TFIIH, TFIIJ and RNA pol II (Buratowski, 1994) (Fig. 1.2.2). The first step in the assembly of the initiation complex is binding of TFIID (the TATA box binding protein (TBP) and associated factors) to the TATA element. It provides a recognition site for the association of the other general transcription factors and pol II. TFIIA promotes stable binding of TFIID to the core promoter and has been shown to bind stably to TATA box binding protein (TBP). TFIIB binds directly to the TFIID-DNA complex and serves as a bridge for the recruitment of RNA pol II linked to IIF into the initiation complex. However, with purified factors TFIIA appears not essential for basal transcription. It does function to establish and maintain the committed complex under more physiological conditions.

The formation of the DB-polF or DAB-polF complex leads to the association of the remaining factors (TFIIE, TFIIH, and TFIIJ) required for basal transcription. The function of TFIIE is not clear, but TFIIE incorporation appears necessary for subsequent recruitment of TFIIH. TFIIH possesses a kinase activity that is capable of phosphorylating the CTD of pol II. The CTD is in a non-phosphorylated (Pol IIA) form in the preinitiation complex

where it is engaged in an interaction with TFIID. RNA pol IIO is the phosphorylated form found in the elongation complex. Thus, each transcription cycle may be associated with the reversible phosphorylation of the CTD. The subsequent phosphorylation of the CTD is thought to be a key step in the progression from an initiation complex to an elongation complex. TBP interacts only with the nonphosphorylated form of RNA pol II which is the form known to enter the initiation complex. In addition to interacting with the general transcription factors, TBP interacts with several factors termed negative cofactors (NC)1, NC2, and Dr1. These factors have a negative effect on core promoter function and interfere with the binding of TFIIA. Thus, phosphorylated Dr1 can associate stably with TBP on a TATA box and displace TFIIA. Transcription of protein-coding genes can be stimulated by transcriptional activators, sequence-specific transcription factors such as stimulated protein 1 (SP1), upstream stimulator factor (USF), AP-1 and CREB. As stated earlier, these factors contain two principal domains (1) a sequence-specific DNA-binding domain and (2) an activation domain which allow them to stimulate transcription synergistically in combination with other activators. Transcription initiation is thought to be one of the targets of these regulatory proteins.

Regulation of mRNA stability

The control of mRNA stability is important in determining the levels of gene expression during cell growth (Ross, 1995; Beelman and Parker, 1995). Recent studies have defined several mechanisms of regulation of RNA stability.

The general mRNA decay pathway is initiated by shortening of the poly (A) tail followed by decapping and 5' to 3' exonucleolytic degradation of the transcripts. Messenger RNAs lacking the cap structure are rapidly degraded in many eukaryotic cells. A variation of this pathway has been observed in which transcripts undergo 3' to 5' decay after poly (A) shortening. Messenger RNA decay can also be initiated by decapping followed by 5' to 3' decay of the transcript independent of poly (A). Degradation of mRNAs containing nonsense codons is part of a process termed mRNA surveillance, that ensures the rapid degradation of aberrant transcripts.

Another possible pathway leads to decay of unstable mRNAs through a 3'-AU-rich instability determinant binding some cytoplasmic factors (Ross, 1996). Many transcription factors (c-fos, c-myc) and cytokines as well contain such elements regulated by different signal transduction pathways. The AU-rich elements (ARE)s and their associated proteins interact with poly (A)-binding protein (PABP), forming a bridge between the ARE and the poly (A) tail. It has been shown that PABP in association with the poly (A) tail protects the 3' end of mRNAs from nuclease attack. An association between PABP and the ARE might allow PABP to be released from the poly (A) tail. The poly (A) tail might then be susceptible to complete degradation. It is suggested that the AU-rich sequences may play a role in nuclear export or nuclear mRNA decay as well as in cytoplasmic mRNA decay. A family of ARE-binding proteins (AUBPs) has been described. Some are primarily cytoplasmic, while others are nuclear or shuttle between both compartments. Several observations suggest that AUBPs influence mRNA stability (Ross, 1996). AUBP abundance, or activity, increases

or decreases as mRNA decay rates change.

Some unstable mRNAs such as Fos and myc mRNAs contain a coding region instability determinant (CRID) (Schiavi et al., 1992). Ribosomes may carry associated factors involved in mRNA decay. The movement of ribosomes across the CRID sequence may alter the ribosome and /or associated factors. This alteration may lead to rapid and complete digestion of the poly (A) tail. Once the poly (A) tail is removed, the transcribed portion of the mRNA is rapidly degraded.




Fig.1.2.2 Schematic model of transcription initiation complex assembly (From Buratowski, S. Cell, 77: 1-3, 1994).

PART B: GENERAL INTRODUCTION TO THE PROJECT

1.4 GENE EXPRESSION AND BIOLOGICAL ACTION OF INSULIN-LIKE GROWTH FACTORS (IGFS), EPIDERMAL GROWTH FACTOR (EGF) AND BASIC FIBROBLAST GROWTH FACTOR (bFGF) DURING DEVELOPMENT

All cells in the body are derived from a fertilized egg. In order to reproduce and multiply, every cell must undergo an orderly series of events, generally called the cell cycle (Fig. 1.4.1). The full mature cell is said to be in Go phase (G stands for gap). At this stage, the cell is not committed to division. G is the decision phase in which cells either commit to undergo another round of DNA synthesis (S phase) and continue to cycle, or to exit the cell cycle to enter a quiescent stage, referred to as Go phase. When DNA synthesis is completed, cell normally proceed to G2 which is a short period where some protein synthesis occurs. During this time, cells prepare to enter into mitosis (M phase).

Control of cell proliferation is a result of coordinated regulation of multiple biochemical pathways that integrate both intracellular and extracellular signals. A number of hormones are essential to normal body growth such as somatotropin and insulin. During the last decade, it was found that some growth factors, such as insulin-like growth factor I and II (IGF-I and II), epidermal growth factor (EGF), and fibroblast growth factor (FGF) are mitogenic polypeptides. Although the ontogeny and targets of IGF, EGF and bFGF actions are largely unknown, these growth factors are considered important for cellular differentiation and growth.




Fig. 1.4.1 Illustration of some growth factors involved in the cell cycle at different phases (From Lowe, W. L. Jr. In: Insulin-like growth factors: Molecular and cellular aspects, pp. 49-85).

1.4.1 Insulin-like growth factor I and II (IGF-I and -II)

IGF-I and IGF-II are non glycosylated single-chain peptides with three intrachain disulfide bridges consisting of 70 (7.6kDa) and 67 (7.5kDa) amino acids, respectively (Daughaday and Rotwein, 1989). The mature molecule of IGF-I contains four domains, an N-terminal B region followed by C, A and D domains (Foyt and Roberts, 1991). The B, C and A domains are structural homolog of proinsulin. The IGF-I prohormone has an additional E domain which varies in length due to alternative splicing of the primary transcripts. A single gene encodes human IGF-I which consists of 6 exons distributed over

nearly 70 kb of chromosomal DNA (Kim et al., 1991; Fig. 1.4.1.1). Several transcription start sites were identified within IGF-I exons 1 and 2, adjacent to distinct promoters upstream of exons 1 and 2, respectively, and at least three polyadenylation sites were mapped to exon 6. Genomic DNA encoding the 5' region of the porcine IGF-I gene was cloned and sequenced and shown to be highly homologous to that of man, rats and sheep (Weller et al., 1993). The primary transcript of the IGF-I gene can be alternatively spliced to result in two mRNAs encoding either precursor proteins IGF-Ia or IGF-Ib differing in their carboxy-terminal amino acid extensions. Although the biological activities generated from these alternative precursors have yet to be determined, alternative RNA splicing may provide a mechanism for regulating IGF-I biosynthesis and subsequent function. A 40 kb single gene encoding human IGF-II contains 9 exons which are transcribed from four promoters. In addition there are two polyadenylation sites (Sussenbach et al., 1991; Fig. 1.4.1.2). The mature IGF-II polypeptide is encoded by exons 7, 8 and part of 9. Promoter 1 (P1) is thought mainly expressed in adult liver required for transcription of leader exons 1, 2 and 3, whereas homologue of P1 is absent in the rat and mouse gene (Ikejiri et al. 1990; Rotwein and Hall, 1990). Therefore, in contrast to the rodent liver, in which IGF-II expressed is repressed to zero after birth, expression of IGF-II in human liver persists postnatally. Initiation of transcription at these various sites and alternative RNA splicing can generate alternate mRNA species. For both IGFs genes, the use of different promoters contributes at least in part, to the observed developmental and tissue specific patterns of IGFs gene expression.




Fig. 1.4.1.1 Structure and expression of the human IGF-I gene. An overview of the human IGF-I gene organization and its different mRNAs is presented. Exons 1-6 are indicated by boxes, with coding regions in black and noncoding regions in white. Promoter 1 and putative promoter 2 are labelled on the gene. Not all transcription start sites have been drawn on the map. Since the 5'-end of exon 2 has not been established with certainty, it has been left open. Sites of pre-mRNA processing are indicated by thin lines. Polyadenylation sites are marked by vertical arrows in the gene and by box of varying length at the 3'-end of the mRNAs (From Kim, S.W., Rosemarie, L and Rotwein, P., *Mol. Endocrinol.*, 5: 1964-1972, 1991).




Fig. 1.4.1.2 Structure of the human IGF-II gene organization and mRNAs species. The gene consists of 9 numbered exons, 4 promoter sites indicated by the arrows (P1-4). The asterisks show two alternative polyadenylation sites. Initiation of transcription at P1, which is mainly active in adult liver, generates an IGF-II mRNA of 5.3 kb. The mature IGF-II polypeptide is encoded by exons 7, 8 and part of 9 (From Sussenbach, J.S., Steenbergh, P.H., Hansen, E., Meinsma, D., van Dijk, M.A., Holthuisen, P., de Moor, C.H., Jansen. M. and Van den Brande, J.L. In: Modern Concepts of Insulin-like Growth Factors, pp639-654, 1991).

IGFs during development

IGF-I and -II are potent mitogenic growth factors which are capable of inducing cell proliferation and differentiation (Lowe, 1991). Transgenic mice for IGF-I exhibited an increased level of IGF-I with an increase body weight (Mathrew et al., 1988). Conversely, embryonic mice with inactive IGF-I gene were significantly smaller than their normal litters (Powell-Braxton et al., 1993). They have severe muscle dystrophy and the majority of these mice die at birth. Mice lacking a functional IGF-II gene were viable but are 60 % of the size of wild-type litter mates (de Chiara et al., 1990). These observations suggest an important role for IGF-I and -II in promoting both pre- and postnatal growth.

Developmental and tissue specific pattern of IGFs expression has been characterized with the rat model (Hogg et al., 1994; Brown et al., 1986; Rotwein et al., 1987). Both IGF-I and -II mRNAs were detectable in rat embryos as early as 11 days (Rotwein et al., 1987). Over the gestation period, IGF-II transcripts were more abundant than IGF-I. Brown et al. (1986) found that IGF-II mRNAs were present in multiple tissues such as liver, kidney and muscle from the fetal to postnatal period. In the fetal rat, IGF-II mRNA was found to be abundant in most tissues including liver, intestine, lung and brain but decreased markedly at birth in all tissues except in the brain (Lund et al., 1986). During postnatal life, a decrease in IGF-II mRNA levels corresponded to a decrease in circulation levels of IGF-II (Moses et al., 1980). In the rat, IGF-I mRNA was higher in most fetal tissues, with the exception of liver where IGF-I mRNA level was higher in the adult (Lund et al., 1986), paralleling an increase in plasma IGF-I level (Donovan et al., 1989). Han et al. (1988) found that IGF-I

and II mRNAs were present in human fetal tissues such as pancreas, liver, kidney and muscle at 16 to 20 weeks of gestation. The same authors reported that IGF-II mRNA was present in greater quantities than that of IGF-I in most tissues during early fetal life. Similar to rat, human adult liver expressed higher IGF-I mRNA than fetal liver (Han et al., 1988). In ovine, the level of IGF-II mRNA was high in various tissues from early gestation and decreased with maturation (O'Mahoney et al., 1991). In the pig, IGFs mRNA levels were also detected in multiple tissues during the fetal life (Lee et al., 1993). Messenger RNA for IGF-I was most abundant in the skeletal muscle and least abundant in the liver, showing that expression of IGF-I and -II are tissue and developmentally regulated.

IGFs are released from many cell lines in culture and synthesized in various tissues (Rutanen and Pekonen, 1990). Tissue IGF-I has been detected in the rat (D'Ercole et al., 1980), the human (D'Ercole et al., 1986) and the pig (Hausman et al., 1991). Multiple tissues express IGF-I peptide including liver, kidney and muscle, suggesting an autocrine and/or paracrine role of IGF-I during development. Changes with age in circulating concentrations of IGFs have been characterized in humans (Ashton et al., 1985; Bala et al., 1981) rats (Donovan et al., 1989) and pigs (Lee et al. 1991). In humans and rats, IGF-I serum concentrations are low around birth, but rise postnatally (Ashton et al., 1985; Bala et al., 1981; Donovan et al., 1989). Concentration of IGF-II in rat was high prenatally and declined rapidly after birth (Moses et al., 1980), whereas, in humans, it was low prenatally and increased after birth (Enberg and Hall, 1984). Serum IGFs pattern in the pig is similar to human but different from that in the rat. In the pig, IGF-II concentration was higher than

IGF-I and both increased during development (Lee et al., 1991). All these findings suggest that IGFs produced by the tissues and present in the serum act as important regulators of animal growth and development.

IGF receptors during development

The biological effects of IGFs are mediated through binding to high affinity receptors on the cell surface (Werner et al., 1991). Targeted disruption of the IGF-I receptor gene resulted in growth-retarded mouse embryos (Liu et al., 1993). In fact, growth was retarded to about 70 % of that seen in normal mouse embryos, strongly suggesting that the IGF-I receptor plays a major role in embryonic growth. Receptors of IGF-I are distributed in the majority of tissues and cells (Rechler and Nissley, 1985). Two types of IGF receptors, based on their relative affinities for IGF-I, IGF-II and insulin, have been identified (Werner et al., 1991; Nissley et al., 1991). The type I receptor, like the insulin receptor, is a glycoprotein with a molecular weight between 300 kDa and 350 kDa which consists of two extracellular α -subunits (≈ 130 kDa) and two β -subunits (≈ 95 kDa) containing a transmembrane and a tyrosine kinase domain (Werner et al., 1991). In the mature receptor, two α and β chains are joined by disulfide bonds. The type I receptor shows both structural and functional similarities with the insulin receptor and has high affinity for IGF-I and IGF-II, but a much lower affinity for insulin. The signal transduction is thought to be mediated by activation of the tyrosine kinase domain. By contrast, the type II receptor is a monomeric, transmembrane 250 kDa protein with a short cytoplasmic domain that lacks kinase activity (Nissley et al., 1991). The type II receptor has no structural homology with insulin or type I receptor. It is

identical to the cation-independent mannose-6-phosphate receptor which directs mannose-6-phosphate-containing proteins to lysosomes. IGF-II binds with high affinity to type II receptor while IGF-I binds less avidly, and insulin does not bind at all to the type II receptor. It has become increasingly clear that type I receptor mediates most of the well known biological effects of both IGF-I and -II. The role of type II receptor in IGF-I or -II-mediated transmembrane signalling is still obscure. In addition to the above receptors, another receptor named IGFII-XR has been tentatively identified from placenta. Lack of this receptor results in reduced placental growth (Baker et al., 1993).

In the rat, levels of IGF-I and -II receptor mRNAs were determined in various tissues from late fetal to early postnatal development (Werner et al., 1989; Sklar et al., 1992). The IGF-I and -II receptor mRNA levels were high in multiple tissues of fetuses and decreased to much lower levels during postnatal life (Werner et al., 1989; Sklar et al., 1992). The IGF-II receptor is present and expressed in a variety of human tissues including pancreas, liver and stomach (Funk et al., 1992). The highest amount of IGF-II receptor was detected in kidney, heart and thymus and the lowest receptor content was measured in muscle and brain. In the pig, it was found that at day 20 of pregnancy, IGF-I receptors were present in the placenta, but only in endometrial cells (Chastant et al., 1994). In contrast, IGF-II receptors were detected on whole embryos from day 8 of pregnancy (Chastant et al., 1994). The variable amounts of IGF receptors present in different tissues make them likely candidates for regulatory processes that might be involved in organ and tissue growth and development.

IGF binding proteins during development

In the circulation and body fluids, IGFs are bound to specific proteins which are synthesized in the liver and in other tissues (Clemmons, 1991). To date, six forms of IGF binding proteins (IGFBPs) that range in size from 24-45 kDa have been identified. Their cDNAs have been cloned and designated IGFBP-1 to -6 (Shimasaki and Ling, 1991). The predominant binding protein in serum of adult rat and human is IGFBP-3, which binds 95 % of endogenous IGF-I (Jones and Clemmons, 1995). IGFBP-1 has a similar affinity for IGF-I and IGF-II, while IGFBP-2 and IGFBP-3 have greater affinity for IGF-II and IGF-I respectively. The function of these proteins is not completely understood. It is hypothesized that the IGFBPs (1) act as transport proteins in plasma to control the efflux of IGFs from the vascular space, (2) serve as reservoir for IGFs prolonging the biological half-life of the IGFs (3) provide a means of tissue- and cell type-specific localization (McCusker and Clemmons, 1992). In the extracellular fluids, IGFBPs can alter the IGF-I and II binding capacity to receptors on the surface of intact cells (Jones and Clemmons, 1995). It has also been suggested that the IGFBPs function as major modulators of IGF action either as inhibitors (Frost et al., 1993) or enhancers (Conover, 1992). Transgenic mice overexpressing human IGFBP-3 resulted in a liver, spleen and heart significantly heavier than that of normal mice (Murphy et al., 1995). Transgenic mice that overexpressed rat IGFBP-1 had a significant reduction of 83-92 % of the body weight (Rajkumar et al., 1995). The authors also found that the difference in body weight between transgenic and wild-type mice was most apparent around the time of weaning when the transgenic mice showed a more marked growth

retardation. In addition, the transgene was highly expressed in brain, uterus, lung, kidney and heart, but little expression was detected in the liver, thus showing that IGFBPs may function to inhibit IGFs action *in vivo* and this inhibition selectively impairs development of specific organs.

Messenger RNAs of IGFBPs and their proteins were detected in various tissues during development (Clemmons, 1991). During the postnatal life in rat, IGFBP-3 mRNA was expressed in a large number of tissues (Albiston and Herington, 1992). The kidney had the greatest amount of IGFBP-3 mRNA with moderate mRNA levels in liver, stomach and placenta. IGFBP-1 mRNA was present in many human fetal tissues, such as liver, gut, kidney and lung (Hill et al., 1990). Like IGFs, IGFBPs are also subject to different developmental and tissue-specific regulation. In rat, levels of both IGFBP-1 and -2 mRNAs were the highest in liver, with abundant IGFBP-2 mRNA present in fetal kidney, stomach and brain (Ooi et al., 1990). Similar to rat, IGFBP-2 mRNA levels in ovine tissues were high in early gestation and decreased with maturation thus following the same pattern of expression as IGF-II (Delhanty and Han, 1993). Multiple isolated human fetal tissues release IGFBPs *in vitro* including fibroblasts and myoblasts (Hill et al., 1989), liver explants (Lewitt and Baxter, 1989), and pancreas explants (Hill et al., 1987). The immunopositive staining for IGFBP-1, -2 and -3 was found in many human fetal tissues, being prominent in kidney, pancreatic endocrine tissue and skeletal muscle fibres (Hill and Clemmons, 1992), supporting the idea that IGFBPs might exert differential effects in various tissues during development and growth. In the pig, IGFBP-2 was more abundant in fetal than in postnatal serum. During

postnatal life, the liver IGFBP-3 mRNA expression and serum IGFBP-3 concentrations increased with serum IGF-I levels (Lee et al., 1991; Kampman et al., 1994). These data suggest that mRNA levels as well as tissue and serum concentrations of IGFBPs are influenced by age. The IGFBPs are present in multiple tissues and serum, implying that IGFBPs are important in regulating IGFs actions.

Biological action of IGF-I and IGF-II

The two main biological actions of the IGFs may be summarized as insulin-like metabolic and growth promoting actions. With the use of primary cell culture or organ explants, it has been demonstrated that both IGF-I and IGF-II stimulate glucose uptake, glycogen and lipid synthesis in adipose tissue and stimulate cell proliferation and differentiation (Froesch et al., 1985; Lowe et al., 1991). Anabolic effect of IGF-I in rats was reported by Tomas et al. (1993) who observed that administration of IGF-I over a 14 day period to growing rats led to an increased body weight gain, an improved nitrogen retention and a greater food conversion efficiency. IGF-I is thought to mediate many of the physiological actions of GH on somatic growth (Copeland et al., 1980). Transgenic mice expressing GH exhibited increased whole body growth rate after IGF-I gene expression was induced (Mathew et al., 1986). Targeted mutagenesis of the genes encoding IGF-I and -II demonstrated the importance of IGFs in the growth process (Baker et al., 1993). The authors conclude that IGF-I, a previously known mediator of postnatal GH action, is also involved in embryonic development. The essential growth-promoting function of IGF-II is believed

to be restricted to the period of embryogenesis in the mouse (de Chiara et al., 1990). However, Wolf et al. (1994) found that postnatally elevated IGF-II in transgenic mice displayed increased kidney, testicles and adrenal weight at the age of 4 to 12 weeks although body growth was not significantly changed.

IGFs and pancreas Specific receptors for IGF-I have been detected on rat pancreatic cells and murine acinar tissues (Williams et al., 1984; Miettinen et al., 1993). Messenger RNAs of IGFs and IGFBPs were detected in rat pancreas (Hogg et al., 1994). Other studies have shown that cultured fetal and neonatal rat islets and human fetal pancreatic explants release immunoreactive IGF-I (Scharfmann et al., 1989; Romanus et al., 1985; Hill et al., 1987) and IGF-II (Bryson et al., 1989) into the medium. By immunohistochemical localization, IGF-I was reported in A cells whereas IGF-II has been observed exclusively in B-cells in man, dog and rat (Maake and Reinecke, 1993). Recently, Hayakawa et al. (1996) reported that following 95 % pancreatectomy, gene expression of IGF-I and IGF-I peptide level was rapidly induced in the remnant pancreas. The authors suggested that the newly synthesized IGF-I may stimulate ornithine decarboxylase (ODC), which is an early event in cell proliferation, inducing DNA replication and tissue regeneration. These observations suggest that IGFs may be involved in pancreatic growth and development.

IGFs and liver The liver is believed to be the main producer of circulating IGF-I in adult rats and human (Daughaday and Rotwein, 1989; Scharf et al., 1995). It is also an important

source of circulating IGFbps in the rat (Daughaday and Rotwein, 1989). Both IGF-I and -II are expressed in liver of rat (Zarrilli et al., 1992; Streck and Pintar, 1992) and pig (Lee et al., 1993). It has also been observed that IGF-I receptors are present in the rat liver (Santos et al., 1994). During development, binding of IGF-I to liver membranes is 4.5 times higher in 20 day-old fetuses than in adult rats (Santos et al., 1994). It has been reported that IGFs are involved in liver regeneration (Caro et al., 1988; Burguera et al., 1990). In fact, the number of IGF-I, IGF-II/M-6-P receptors and the level of IGF-II receptor mRNAs are greater in regenerating hepatocytes than in normal liver cells. The [¹²⁵I] IGF-II binding to crude plasma membranes from regenerating liver was maximal 2 days after hepatectomy. This increase in binding in regenerating liver was associated with an increase in the concentration of IGF-II receptors (Burguera et al., 1990). It was also observed that gene encoding rat IGF-I and IGFbp-1 were induced in regenerating rat liver (Mohn et al., 1991). Thus, IGF-I and IGFbp-1 may interact with hepatocytes to promote liver regeneration. These studies also suggest that IGFs are important stimulators of liver growth and regeneration.

IGFs and kidney Several lines of evidence suggest that IGF-I can affect kidney growth and renal function. Overexpression of IGF-I in transgenic mice induced kidney growth (Mathrew et al., 1988). During development, high levels of IGFs and IGFbps mRNAs have been detected in fetal kidney of human (Han et al., 1988; Suikkari et al., 1992) and rodent (Stylianopoulou et al., 1988; Price et al., 1995). In rat, the renal IGF-II mRNA levels rapidly decreased after birth (Stylianopoulou et al., 1988) whereas the IGF-I mRNA

increased after birth (Albiston and Herington, 1992). It was observed that the collecting duct of the kidney is a major source of IGF-I which is also produced by glomerular mesangial cells in culture (Bortz et al., 1988; Aron et al., 1989). Both IGFBPs and IGF-I are synthesized in the kidney (Aron et al., 1991). It has been shown that IGF-II receptors are present in glomeruli and in both basolateral and brush border membranes of proximal tubular cells (Haskell et al., 1988). IGF-I mRNA level and peptide concentration as well as IGF-I binding increased in the generative zone of the post-ischemic regenerating rat kidney (Matejka and Jennische, 1992). In young male rat, unilateral nephrectomy resulted in a compensatory growth of the remaining kidney (Fagin and Melmed, 1987), where IGF-I mRNA level increased within 24 h, and remained at high level for at least 7 days. Levels of IGF-I and -II receptors and their mRNAs in whole kidney were also increased (Mulroney et al., 1992), suggesting that IGF-I has a trophic effect during kidney regeneration.

IGFs and skeletal muscle In the skeletal muscle, both IGF-I and -II exhibit a range of physiological effects that includes glucose uptake (Bevan et al., 1992), protein metabolism (Fryburg, 1994), acceleration of the rate of DNA synthesis, and enhancement of myoblast differentiation (Rosen et al., 1993). Transgenic mice overexpressing IGF-I have myofiber hypertrophy (Coleman et al., 1995). Messenger RNA for IGF-II has been detected in muscle of 12 day-old rat fetuses (Stylianopoulou et al., 1988). In the rat, mRNA of IGF-II receptor was in great abundance in fetal muscle and decreased after birth, but it was still more abundant than that of IGF-I in 4 week-old rats (Alexandrides et al., 1989). The number of

receptors for IGF-I is constant from birth to 4 weeks of age in the rat (Alexandrides et al., 1989). Using L6A rat myoblasts incubated with IGF-II, Bach et al. (1995) have demonstrated that IGF-II has a primary role in promoting the differentiation and growth of skeletal muscle predominately through the IGF-I receptor (Bach et al., 1995). In addition, IGFs are believed to be involved in muscle regeneration and growth (Levinovitz et al., 1992) since during the regeneration process, levels of both IGF-I and -II mRNA as well as IGFs proteins were transiently induced. This suggests that tissue IGFs could act locally to stimulate tissue growth and /or differentiation.

1.4.2 Epidermal growth factor (EGF)

Epidermal growth factor is a 53 amino acid polypeptide with three disulfide bonds. It is a powerful stimulator of proliferation and differentiation of a variety of cell types *in vitro* as well as *in vivo* (Fisher and Lakshmanan, 1990). The EGF is initially synthesized as a large (130 kDa) precursor molecule with the mature EGF sequence located near the C-terminus (Carpenter and Wahl, 1990). The sequence shows two hydrophobic domains, one representing a signal sequence and the other a transmembrane domain, indicating that the precursor is a transmembrane protein. The cytoplasmic domain of the precursor has no known function. The extracellular domain of the EGF precursor contains, in addition to the sequence for mature EGF, eight other EGF-like domains. The uncleaved precursor is capable of binding to the EGF receptor and shows biological activity. Thus, pro-EGF functions not only as a source for soluble EGF, but may also have a role in mediation of intercellular

communication between cells with pro-EGF on their surfaces and cells with EGF receptors (Carpenter and Wahl, 1990). Proteins of the EGF family act via a surface EGF receptor (EGFR) which is an approximately 170 kDa (1186 amino acids) transmembrane glycoprotein encoded by the c-erbB proto-oncogene (Velu, 1990). The EGF receptor consists of an extracellular domain with a high cysteine and N-linked glycosylation content, one transmembrane domain, and a cytoplasmic domain with tyrosine kinase activity. Targeted disruption of EGFR gene in mice reduced life span and resulted in abnormalities in skin, kidney, brain, liver and gastrointestinal tract (Threadgill et al., 1995), indicating that the receptor is involved in a wide variety of cells.

EGFR during fetal development

It has been shown that EGFR mRNA and protein are expressed from the very early stage of the mouse embryo (Wiley et al., 1992). Adamson and Meek (1984) have studied the ontogeny of the EGF receptor in several tissues of the fetal mouse, and observed its presence in the whole embryos and placenta with different patterns of expression among tissues (Fig.1.4.2.1). In fetal bovine, immunocytochemical studies revealed that EGFR was localized in the ductal and tubular epithelium of mesonephros and associated organs of the urogenital tract (Winters et al., 1993). In addition, in bovine mesonephric cells, EGF induced DNA synthesis and tyrosine phosphorylation, suggesting that EGFR detected in these cells was functional. Messenger RNA of EGF receptor was present in human fetal ovary and uterus during the first- and second-trimester of gestation (Yeh et al., 1994). Receptors for EGF

have also been found in human fetal kidney, liver and lung (Nexø et al., 1989) and sheep placenta (Lacroix and Kann, 1993). In the pig, mRNAs for EGF and EGFR were expressed in the conceptus at all stages of development, suggesting that EGF could be involved in regulating growth and development of early pig conceptus (Zhang et al., 1992). Thorburn et al. (1981) observed that infusion of recombinant EGF to ovine fetus for 3-14 days produced skin hypertrophy and increased liver, kidney, adrenal and thyroid weights. It has also been reported that the development of mouse embryos is improved by the addition of EGF in culture (Kuo et al., 1990). Taken together, all these studies suggest that EGF acts as a regulator of mammalian embryonic and fetal development.

EGF during development

It is thought that EGF plays pivotal roles as an autocrine and / or paracrine regulatory signal during development. Messenger RNAs of EGF and pro-EGF were identified in most adult rodent tissues. Levels of mRNA were the highest in the salivary gland and the kidney (Rall et al., 1985). In human, mRNA of EGF was expressed in the kidney, the salivary and the thyroid (Kajikawa et al., 1991). A wide range of pig tissues expressed EGF mRNA (Vaughan et al., 1991). The highest level of EGF mRNA was found in kidney and pancreas, with lower levels in submaxillary gland and seminal vesicle. EGF is present in multiple body fluids such as plasma, salivary, pancreatic and gastric fluids (Capenter and Wahl, 1990). The authors found that the concentration of EGF in tissue is generally low. Tissues with high level of pro-EGF mRNA and EGF protein are salivary gland, kidney, mammary gland and

pancreas. During the early neonatal period, EGF levels are low in most mouse tissues (Perheentupa et al., 1985; Laborde et al., 1988). Tissue concentration of EGF was shown to increase in the mouse during the first 2 months of postnatal life. Vaughan et al. (1992) reported that EGF was present in extracts of kidney and pancreas, as well as in urine, but was not detected in extracts of submaxillary gland or liver of the pig. Thus, many tissues appear to synthesize EGF indicating that EGF may be involved in various organs growth and development.




Fig.1.4.2.1 Ontogeny of EGF receptors in the fetal mouse (From Fisher, D.A. and Lakshmanan. Endocr. Rev., 11: 418-442, 1990).

Biological action of EGF

The best documented activity of EGF is its ability to induce DNA synthesis and to promote proliferation and differentiation of mesenchymal and epithelial cells (Carpenter and Wahl, 1990).

It has been reported that EGF stimulates gastrointestinal, liver, and pancreatic maturation (Marti et al., 1989; Logsdon, 1986). In addition, EGF has shown therapeutic potential as an accelerator of wound healing (Schultz et al., 1990). Recently, it was found that EGF exerted mitostimulatory action and stimulated protein synthesis in fetal bovine myoblasts (Blachowski et al., 1993). There is evidence that EGF is involved in animal growth and development since daily administration of EGF antiserum to neonatal mice reduced weight gain by 40% during the first postnatal 4 weeks (Zschiesche, 1989).

EGF and pancreas Several studies suggest a role for EGF in the growth and exocrine function of the pancreas. Relatively high levels of EGF (Hirata and Orth, 1979; Hirata et al., 1982) and EGFR (Hormi and Lehy, 1994) have been observed in human pancreatic tissue and juice. Korc et al. (1983) reported that pancreatic acinar cells express the EGF receptor. It was observed that EGF stimulates pancreatic acinar cell growth, increases the rate of DNA and protein synthesis and amylase release in cultured pancreatic acini (Logsdon, 1986; Brannon et al., 1988; Logsdon and Williams, 1983). Intraperitoneal administration of EGF in rats stimulated pancreatic DNA synthesis and increased pancreatic gland weight; the effect was similar to the maximal effect obtained with cholecystokinin (CCK) and secretin (Dimbinski et al., 1982).

EGF and liver Administration of EGF to neonatal rabbit increased liver weight, DNA and protein concentrations, bile flow and bile salt excretion (Opleta et al., 1987). Ishigami (1993) reported that in primary cultured hepatocytes, EGF stimulated DNA synthesis after 12 h and reached a peak at 48 h. The level of EGF receptor mRNA significantly increased above control level after 24 and 72 h of partial hepatectomy (Johnson et al., 1988). In addition, normal mice showed a rapid increase in plasma EGF levels 8 h after partial hepatectomy (Noguchi et al., 1990), suggesting a possible role of EGF in liver regeneration.

EGF and kidney In human, EGF was first purified from urine (Gregory, 1975). It was found that levels of EGF in urine were much higher than that in blood (Fisher et al., 1989), suggesting that in human, kidney is the source of urinary EGF. In fact, EGF was detected in human distal nephron (Nouwen and de Broe, 1994). Administration of EGF resulted in a number of renal responses, including decreased renal blood flow and glomerular filtration rate, increased urine flow, inhibition of Na⁺ reabsorption, and altered tubular transport function (Harris, 1991). The growth and differentiation of renal proximal tubular cells *in vivo* is under the control of a number of growth factors, including EGF (Hammerman et al., 1993). *In vitro*, EGF has been shown to regulate renal metabolism, filtration and transport processes (Harris and Daniel, 1989; Vehaskari et al., 1989). Exogenous EGF administration accelerated renal tubular regeneration following gentamicin induced nephrotoxicity (Morin et al., 1992), suggesting an involvement of EGF in renal tubular regulation. A role for EGF as a growth promoting agent in kidney was also suggested by an increased EGF content of hypertrophy kidney after unilateral nephrectomy (Miller et al., 1992).

1.4.3 Basic Fibroblast growth factor (bFGF)

Basic FGF is a single chain polypeptide, composed of 146 amino acids (Baird and Böhlen, 1990). The bFGF gene encodes 3 exons separated by two introns. In various cultured cells and tissues, the bFGF gene encodes two polyadenylated RNAs of approximately 3.7 and 7 kb. All cell types which respond to bFGF bear specific FGF cell surface tyrosine kinase receptors.

Basic FGF has been purified from many meso-, ecto- and neuroectodermal-derived tissues, which have been shown to be FGF sensitive either *in vitro* or *in vivo* (Gospodarowicz et al., 1987). *In vitro*, bFGF is a potent mitogen for meso-, and neuroectodermal derived cells such as fibroblasts, skeletal myoblasts and vascular endothelial cells. Addition of bFGF to rat cerebral cortical neurons markedly enhanced their survival (Morrison et al., 1986) and promoted the formation of new nerve fibre tracts (Thompson et al., 1989). In early embryos, bFGF can act as a primordial differentiation factor which induces the ectoderm to become mesoderm. Infusion of anti-bFGF has significantly retarded rat embryo growth and differentiation of all tissues of endodermal origin and decreased their protein and DNA content (Liu and Nicoll, 1988). The same authors found a pronounced increase in embryonic growth, protein and DNA content following infusion of bFGF. These results suggest that bFGF may be important for growth and differentiation of endodermal and some mesodermal tissues of mammalian embryos (Liu and Nicoll, 1988). Receptors for bFGF have been detected in fetal bovine ovaries, suggesting that bFGF is a potent mitogen

involved in regulation of granulosa cell function (Wandji et al., 1992). Basic FGF and its receptor have been detected in different adult tissues including pancreas, liver and kidney (Knee et al., 1994; Friess et al., 1992). It was shown that bFGF stimulated ODC activity which is an early event in cell proliferation and increased ODC mRNA levels in a pancreatic tumoral cell line (AR4-2J) (Sarfati et al., 1992). Hoshi and Logsdon (1993) observed that bFGF stimulated DNA synthesis in a dose-dependent fashion in pancreatic acinar cells, the maximum effect being 6-7 fold over control. Basic FGF induced a marked increase in the levels of inositol 1,4,5- trisphosphate and a rapid rise in cytosolic free calcium $[Ca^{2+}]_i$ levels in rat pancreas acini (Chandrasekar and Korc, 1991), indicating that bFGF may play an important role in regulation of exocrine pancreatic function. It was found that isolated mouse hepatic sinusoidal endothelial cell synthesized bFGF (Rosenbaum et al., 1989). As a potent mitogenic regulator, bFGF stimulated the proliferation of all cell types involved in the wound healing process both *in vitro* and *in vivo* (Buntrock et al., 1984; Gibran et al., 1994). Basic FGF uptake by the liver was increased after partial hepatectomy (Baruch et al., 1995), suggesting a role for bFGF in liver regeneration. Basic FGF is a known mitogen for skeletal muscle precursor cells and many other mesodermal cell types (Gospodarowicz et al., 1987) by the observation that bFGF present in muscle recovering from a crush injury revealed that bFGF plays a role in skeletal muscle regeneration (Anderson et al., 1995).

1.4.4 Nutritional regulation of IGFs, EGF and bFGF

Growth hormone and nutrition are two important regulators of IGF-I expression. This regulation of IGF-I may be a key control point for nutritional regulation of growth (Bass et al., 1991; Pell et al., 1993). Gene expression of IGF-I exhibits a profound sensitivity to nutritional alteration in young growing rats (Straus and Takemoto, 1990). Fasting results in a decrease in IGF-I and growth hormone receptor (GHR) mRNA levels and IGF-I gene transcription in rat liver (Straus and Takemoto, 1990). A decrease in circulating levels of IGF-I and abundance of hepatic and muscle IGF-I mRNA have been observed during periods of protein deprivation (VandeHaar et al., 1991). A RNase protection assay revealed that fasting reduced nuclear transcripts of IGF-I and another nutritionally sensitive gene, the gene encoding transthyretin (TTR) (Hayden et al., 1994). The decrease in IGF-I mRNA was matched by a similar decrease in IGF-I nuclear transcripts (Hayden et al., 1994), suggesting that fasting controls IGF-I gene expression primarily at the transcriptional level. In protein restricted rats, IGFBP-1 mRNA levels rose rapidly in the liver and kidney whereas hepatic IGF-I and IGFBP-3 mRNA decreased, thus paralleling the serum IGFBP-3 concentration (Lemozy et al., 1994). In contrast, an absence of change in IGFBP-3 mRNA and a slight increase in IGFBP-2 were observed in the kidney (Lemozy et al., 1994), suggesting that there is an organ specificity in the nutritional regulation of IGFBPs. Data about the effect of weaning on serum IGF are limited. White et al. (1991) reported that in the pig, serum IGF-I and IGFBP-3 levels decreased 36 h after weaning. Recently, Cymbaluk and Laarveld

(1996) found that in foals, weaning whether at 13 or 16 weeks of age, reduced growth rates and serum IGF-I concentrations. Serum IGF-I values recovered to preweaning values within 1 to 3 weeks postweaning concurrent to an improved weight gain.

Very little information is available about nutrition status effect on EGF and bFGF concentrations in tissue and serum during development. It was reported that nutrient intake may modulate EGF receptor number *in vivo* (Freidenberg et al., 1986). In fact, fasted rats had 40-50% less receptor binding affinity. Fasting also caused a significant decrease in gastrointestinal tissues of EGF levels in suckling rats but resulted in minimal changes in adults, suggesting that the contents of EGF in gastrointestinal tract are dependent on both age and dietary status (Schaudies et al., 1989). Levels of EGF decreased in gastrointestinal mucosa of rats fed with higher proportion of fibre (Schaudies et al., 1989), indicating that dietary fibre modulates the content of EGF. EGF receptors were widely distributed in the intestinal mucosa and submucosa of pigs. Levels of receptor tended to be higher in weaned than in newborn pigs (Kelly et al., 1992), suggesting a functional role for EGF during postnatal development.

One study showed that bFGF mRNA level was altered by diabetes in a tissue-specific fashion (Karpen et al., 1992). They found that in skeletal muscle, the bFGF mRNA level decreased, while it increased in the heart, lung and brain. As far as we know, there is no information about effect of weaning on IGFs, EGF and bFGF mRNA levels in various mammalian tissues.

1.5 HYPOTHESIS AND OBJECTIVES OF THE PROJECT

The above observations support the view that growth factors are regulators of fetal and postnatal growth and development. In the rat, liver is believed to be the major producer of circulating IGF-I (Daughaday and Rotwein, 1989) as well as an important endocrine source of IGFBPs (Ooi et al., 1990; Orlowski et al., 1990). The skeletal muscle represents the bulk of the body weight, which is a major target tissue for IGFs. Receptors for IGFs have indeed been found in muscle and cultured skeletal muscle cells (Beguinot et al., 1985). In the human, the kidney is the main source of urinary EGF (Gregory, 1975) and relatively high EGF concentration has been detected in the pig kidney (Vaughan et al., 1992). Pig is used in the present study because of its anatomical and physiological similarities with the human. In addition, pig pancreas is big enough to do all the planned measurements (radioimmunoassay, Western blot, Northern blot, RNA, DNA and protein concentration) simultaneously on the same animal. Although accumulating information suggests that IGFs, EGF and bFGF are involved in animal growth and development, about ontogenic IGFs mRNA levels in pig tissues studies are very limited. No information is available on the ontogeny of EGF and bFGF mRNA levels and tissue IGFs and IGFBPs concentrations in various tissues of mammals. The relationship between mRNAs and tissue concentrations of IGFs and IGFBPs has not been reported yet.

Therefore, the objectives of the present study in the pig are:

- (1) to examine the ontogeny of IGFs, IGFBPs, IGFRs, EGF, EGFR and bFGF mRNA

levels as well as tissue concentrations of IGFs and IGFBPs in the pancreas, liver, kidney and skeletal muscle

- (2) to examine the relationship between mRNA levels and tissue concentrations of these growth factors and organ growth during development
- (3) to determine the effect of weaning on levels of IGFs, IGFRs, IGFBPs, EGF, EGFR and bFGF mRNAs in pancreas, liver, stomach, duodenum and skeletal muscle

CHAPTER II MATERIALS, METHODS AND RESULTS

2.1 M. Peng, T. Abribat, E. Calvo, D. DeBel, M.-F. Palin, G. Bernatchez, J. Morisset and G. Pelletier. ONTOGENY OF IGFs, IGFBPs AND IGFRs mRNA LEVELS IN PORCINE PANCREAS. J. Anim. Sci. (Submitted).

2.1.1 Contribution to manuscript 2.1

My contribution to this manuscript was to (1) plan and write the project outline, (2) prepare and organize the sample collection, (3) extract total RNA and carry out Northern analysis, (4) provide data to the statistician, (5) prepare the figures and write the manuscript. Dr. T. Abribat's laboratory determined IGFs and IGFBPs concentrations by RIA and Western blot analysis respectively. We have also got the technical assistance of Drs. E. Calvo for RNA isolation, M-F. Palin for probe preparation. In addition, Mr. G. Bernatchez and the team of M. Morisset have contributed to samples collection. The project was directed by Drs. G. Pelletier and D. LeBel. Help in the manuscript preparation was provided by Drs. G. Pelletier, D. LeBel and J. Morisset.

2.1.2 Manuscript 2.1

Running head: Developmental IGFs mRNA in pig pancreas

Ontogeny of IGFs, IGFbps, IGFRs and GHR mRNA levels in porcine pancreas

M. PENG², T. ABRIBAT³, E. CALVO⁴, D. LeBEL², M.-F. PALIN¹, G.

BERNATCHEZ², J. MORISSET⁴ AND G. PELLETIER¹

¹Agriculture and Agri-Food Canada, Dairy and Swine Research Centre, P.O. Box 90, Lennoxville, Québec J1M 1Z3, CANADA

Mailing address: M.-F. Palin, Agriculture and Agri-Food Canada, Dairy and Swine Research and Development Centre, P.O. Box 90, Lennoxville, Québec J1M 1Z3, CANADA

Tel.: (819) 565-9174 ext. 207

Fax: (819) 564-5507

Email: palinmf@em.agr.ca

² Department of Biology, Faculty of Science, University of Sherbrooke, Sherbrooke QC J1K 2R1, CANADA

³ Montréal University, Notre-Dame Hospital Research Centre, P.O. Box 90, Montréal QC H2L 4M1, CANADA

⁴ Service de gastroentérologie, Faculty of Medicine, University of Sherbrooke, Sherbrooke QC J1H 5N4, CANADA

Abstract

The ontogeny of mRNA levels of insulin-like growth factor-I and -II (IGF-I and -II, or IGFs), IGF type 1 (IGFI-R) and type II receptors (IGFII-R), IGF binding protein-1 and -3 (IGFBP-1 and -3 or IGFBPs), growth hormone receptor (GHR) and tissue concentrations of IGFs and IGFBPs were examined in the pancreas of pigs. Tissues were collected from fetuses at 90 and 110 d of gestation and pigs at 1, 21, 90 and 180 d of age. Northern blots were performed using total RNA hybridized with ³²P labelled cDNA probes (human IGF-I and human IGFI-R) and cRNA probes (rat IGF-II, human IGFII-R, human IGFBP-1, pig IGFBP-3 and pig GHR). There were two accelerated growth periods of pancreas: the first one at 90 d of fetal life, which is characterized by cell hyperplasia (high ratio of DNA to body weight) and the second one at postnatal 90 d which is attributed to cell hypertrophy (high ratios of pancreatic weight, RNA and protein to DNA). The level of IGF-II mRNA and its tissue concentration were predominant during fetal life and low thereafter. The IGF-I mRNA level was high during fetal and early postnatal life and decreased thereafter. Messenger RNA levels of IGFI-R, IGFBP-3 and GHR and concentrations of IGFBP-1 and -2 were abundant during fetal and early postnatal life. In conclusion, IGFs may be involved in various physiological periods of pancreatic development in pig.

Key Words: Pigs, Pancreas, Age, mRNA, IGF

Introduction

It is well accepted that growth and secretion of the exocrine pancreas are dietarily and hormonally regulated. Insulin-like growth factor -I and -II (IGF-I and -II or IGFs) are ubiquitous mitogenic peptides that are present in serum and various tissues and stimulate the proliferation and differentiation of a variety of somatic cell types (Froesch et al., 1985). So far, the information on IGFs in regulating pancreatic development have been derived largely from rodents. It was reported that IGFs stimulate DNA synthesis in isolated fetal rat islets of Langerhans (Hogg et al., 1993). However, no data is available on tissue concentration and mRNA content of IGFs in pancreas of large mammals during development.

The physiological effects of IGFs are mediated predominantly by the type I IGF receptor (IGFI-R) which binds IGF-I with greater affinity than IGF-II (Nissley and Lopaczynski, 1991). IGF-II also binds to the IGF-II/Mannose-6-phosphate receptor (Type II IGF receptor or IGFII-R). Both IGF receptor subtypes are widely distributed into the different organisms of the body (Nissley and Lopaczynski, 1991; Werner et al., 1991). IGFI-R was also found on rat pancreatic A and B cells (Van Schravendijk et al., 1987).

Messenger RNAs for IGF-I and -II were found in various tissues of rat (Murphy et al., 1987) and pig (Lee et al., 1993; Peng et al., 1996a). Tissue mRNA levels of IGF-I and -II were developmentally regulated in both rat and pig.

In serum and other extracellular fluids, IGFs are associated with specific IGF binding proteins (IGFBPs) which are thought to prolong their half-life, serve as their carrier in the

circulation, provide a storage pool for IGFs or act as regulator of their biological actions by regulating their availability to cell surface receptors (Clemmons, 1991). Various forms of IGFBPs have been identified from pig serum (Lee et al., 1991a). In human, IGFBP-1, -2 and -3 were found in various fetal tissues, including the pancreatic endocrine tissue (Hill and Clemmons, 1992). Exogenous IGFBP-1 and -2 can potentiate the ability of IGF-1 or IGF-II to stimulate DNA synthesis by isolated fetal rat islets of Langerhans (Hogg et al., 1993). In rat, pancreatic IGFBP-1 and -2 mRNAs increased from late fetal to early postnatal life, whereas mRNAs for IGFBP-3 and -4 were predominant after birth (Hogg et al., 1994).

Growth hormone (GH) plays an important role in postnatal development. The GH acts via its membrane-bound receptor and mRNA of GH receptor (GHR) has been found in fetal rat tissues (Walker et al., 1992) and in liver and muscle of pig (Brameld et al., 1996).

The objectives of the present study were (1) to characterize the developmental pattern of pancreatic growth, (2) to determine mRNA levels of IGFs, IGFBPs, IGFRs and GHR and tissue concentrations of IGFs and IGFBPs in the pancreas during fetal and postnatal development and (3) to investigate potential relationship that might exist between pancreas growth, mRNA levels and tissue concentrations of IGFs and IGFBPs in pig.

Materials and Methods

Tissue Preparation. Yorkshire purebred fetuses from 90 (F90) and 110 (F110) d of gestation and pigs of postnatal 1 (P1), 21 (P21), 90 (P90) and 180 (P180) d of age were used. Ages of the fetuses were determined according to the sows mating date. For each age, two males and two females were obtained from the same litter and this was replicated three times. Pigs including sows, with the exception of fetuses were fasted for 16 h. Animals were slaughtered (stunning and exsanguination) according to recommended code of practice for the care and handling of farm animals, pigs (Agriculture and Agri-Food Canada, 1993). After laparotomy, the uterus was gradually opened and the fetuses were removed. The body weights (mean \pm SE) at slaughter were $.61 \pm .01$, $1.15 \pm .05$, $1.48 \pm .03$, $6.08 \pm .46$, 28.9 ± 2.12 and 95.4 ± 3.48 kg for F90, F110, P1, P21, P90 and P180 respectively. Immediately after exsanguination, the pancreas was removed by dissection and weighted. Tissue samples used for Northern blot analysis and radioimmunoassay (RIA) measurements were frozen in liquid nitrogen and stored at -80°C until analyzed. Fresh tissue samples were used for DNA, RNA, protein determination and enzyme activity assays.

Measurement of DNA, RNA and Protein. Tissues (150 mg) were homogenized and precipitated in .7 N perchloric acid (PCA) for DNA, RNA and protein determinations. Protein was analyzed by the method of Lowry et al. (1951) with bovine serum albumin (BSA) as a standard. DNA and RNA were extracted and measured according to the methods previously described (de Passillé et al., 1989).

RIA. Pancreas IGF-I and -II were quantified by RIA using methodologies previously described (Abribat et al., 1990; Lee et al., 1991b). The pancreatic tissue was homogenized in freshly prepared 3.3 M formic acid containing .5% Tween 20 (1:4 wt vol) at pH 2 and centrifuged at $40,000 \times g$ for 15 min at 4°C to dissociate the IGF-IGFBPs complex. A 150 μ L aliquot of each sample was heated at 90°C for 30 min, 350 μ L acetone were then added and the mixture was thoroughly vortexed followed by centrifugation at $3,500 \times g$ for 15 min at 4°C. The supernatant was neutralized with the RIA buffer and used directly for IGFs measurement.

Recombinant human IGF-I and II (Bachem California, Torrance, CA) were used for iodination and standards. Anti hIGF-I antibodies were kindly provided by Drs E. Underwood and J.J. Van Wyk (University of North Carolina, by the National Institute of Diabetes, Digestive and Kidney Disease through the National Hormone and Pituitary Program). Monoclonal anti-hIGF-II was purchased from Amano International Enzyme Co (Troy, VA). The RIAs were carried out under equilibrium condition using IGF-I or -II radioiodinated by conventional chloramine T method. The RIA buffer consisted of 30 mM phosphate buffer, pH 7.4, containing .02% protamine sulphate (Grade II), 10 mM EDTA, .02% sodium azide and .25% bovine serum albumin (BSA) RIA grade (all buffer components from Sigma Chemical Co, St Louis, MO). One hundred μ L of diluted sample extract or standard were incubated at 4°C for 24 h with 100 μ L of specific antibody (final dilution 1/20,000 and 1/50,000 for the anti IGF-I and IGF-II antisera, respectively, 100 μ L 125 I-IGF-I or -II tracer (10,000 cpm) and 200 μ L of RIA buffer. The binding reaction was stopped by precipitation

(24 h at 4°C) with 100 μ L of the second antibody (goat antirabbit IgF for IGF-I and goat antimouse IgG for IGF-II purchased from Linco Research Inc., St. Louis, Mo) and pellets were counted in a gamma counter (Beckman LS 580, Beckman Instruments Inc., Scientific Instruments Division, Irvine, CA) after centrifugation. In our assay conditions, ED50s from standard curves were 60 ± 8 pg/tube and 86 ± 10 pg/tube for IGF-I and -II, respectively (means \pm SD of 10 replications). Intra and inter assay coefficients of variation were 4 and 13% and 3 and 12% for IGF-I and IGF-II, respectively.

Western Ligand Blotting for IGF-BPs. Pancreatic acid extracts were subjected to Western ligand blot analysis as described by Hossenlopp et al. (1986). Initial experiments showed that neutralized acid extracts gave similar results to extracts performed in neutral conditions. Therefore, the 40,000 \times g supernatants of the formic acid extracts (described in the previous section) were neutralized with an equal volume of 2 M Tris buffer, pH 8.5, then diluted in SDS non reducing sample buffer, and loaded onto a 12% SDS polyacrylamide gel and electrophoresed. Proteins were then transferred to nitrocellulose (BioRad, Richmond, CA) at 15 V overnight in a Transblot Cell (BioRad, Richmond, CA). The blotted membranes were washed with Tris buffer saline (TBS) (.1 M Tris, pH 7.4, .15 M NaCl, .05% sodium azide), containing sequentially 3% NP 40 for 30 min, 1% BSA for 2 h, .1% Tween 20 for 10 min and then incubated with 125 I-IGF-I (1.4×10^5 cpm/ml) in 30 ml TBS, .1% BSA overnight at 4°C. Membranes were washed twice for 15 min in TBS, .1% Tween 20, three times for 15 min in TBS, dried and exposed to X ray films in the presence of intensifying screen for 3 days at -80°C. For quantitative analysis, bands of the membrane corresponding

to those on autoradiograms were cut and counted in a gamma counter. For each individual IGFBP, data were expressed as cpm.

RNA Preparation. Total RNA from the pancreas were extracted by the method described by Chirgwin et al. (1979). Tissues were homogenized in 4 M guanidinium thiocyanate using a polytron homogenizer. Supernatants were used for precipitation of RNA in 100% ethanol and 2 M potassium acetate at -20°C. After centrifugation, the RNA pellets were dissolved in 7 M guanidine hydrochloride. Then, RNA was precipitated again and quantified by measuring its absorbance at 260 nm.

Preparation of Probes. A human IGF-I cDNA which corresponds to a 659 bp cDNA *EcoR*I fragment (Jansen et al., 1983) and a human IGF-IR cDNA (Ullrich et al., 1986) corresponding to a 700 bp cDNA *EcoR*I fragment were used. The cDNA probes were labelled with [³²P]dCTP (3000 Ci/mmol; Amersham Canada Limited, Oakville, Ont., Canada) by random priming using a commercial kit (Megaprime DNA labelling System, Amersham Canada Limited, Oakville, Ont., Canada).

A rat IGF-II, human IGFBP-1, porcine IGFBP-3 and human IGFII-R complementary RNA (cRNA) probes were transcribed from a 720 base pairs (bp) *Bam*H1 cDNA fragment (Ueno et al., 1988), a 1443 bp *EcoR*I cDNA fragment (Julkunen et al., 1988), a 595 bp *EcoR*I-*Sma*I cDNA fragment (Shimasaki et al., 1990) and a 695 bp *Kpn*I-*Hind* III (Morgan et al., 1987) fragment, respectively. The cDNA fragments were inserted into the pBluescript KSII+ plasmid vector. The inserts were sequenced using a T⁷Sequencing™ Kit (Pharmacia Biotech Inc, Piscataway, NJ) in order to check the orientation of the cDNAs. The templates

were linearized with *Eco*R1 for IGF-II, *Hind*III for IGFBP-1, *Sam*I for IGFBP-3 and *Kpn*I for IGFII-R and then used in a T7 transcription Riboprobe System (Promega, Madison, WI).

The GHR probe was prepared by RT-PCR. The GHR primers were designed according to known regions of the pig GHR cDNA sequence (Cioffi et al., 1990). The upstream primer (5'-ATCCCGCGGAACACCTCCCAATGCAGATGTTC-3') is identical to nucleotide 545-568, while the downstream primer (5'-ATCTCTAGATGGCGCTAGACGTGATTCAACCTC-3') represents the reverse complement of nucleotides 1669-1692. An *Eco*RV site for upstream primer and a *Xba*I site for downstream primer were created by addition of nine nucleotides. This primer pair predicts a 1166 bp fragment. First-strand cDNA was synthesized from total RNA (6 µg) using a "SuperScript™ Preamplification System for First Strand cDNA Synthesis" kit (Gibco BRL, Life Technologies, Burlington, ON) and 500 ng of oligo(dT)₁₂₋₁₈ primer in a total reaction volume of 30 µL. An aliquot of 3 µL was subjected to PCR amplification using a PTC-100™ Programmable Thermal Controller (MJ Research Inc., Watertown, Mass.). The reaction mix contained 3 µL of reverse transcription mixture, 30 pmol of each primer, 1x PCR buffer (Pharmacia Biotech Inc., Piscataway, NJ), .35 mM dNTPs and water to 100 µL. After overlaying with 3 drops of light mineral oil (Sigma ST. Louis, MO), the reactions were heated to 94°C for 2 min prior to the addition of 4 U of the *Taq* polymerase (Pharmacia Biotech Inc., Piscataway, NJ). The amplification profile comprised 35 cycles: at 94°C for .75 min (dissociation), 55°C for 1.25 min (annealing) and 72°C for 2.5 min (extension). The final cycle included a further 5 min at 72°C for complete strand extension. A PCR amplified

cDNA fragment of the predicted length was inserted into the pBluescript KSII+ plasmid vector. The authenticity of the cDNA clone was verified by sequencing using a ³²P-Sequencing™ kit (Pharmacia Biotech Inc., Piscataway, NJ). The template was linearized with *EcoRV* and then used in a T7 transcription Riboprobe System (Promega, Madison, WI) to synthesis the cRNA probe.

Northern Blot Analysis. The procedure for Northern blot was described by Lehrach et al. (1977) with some modifications. Briefly, 20 µg of total RNA was fractionated in a 1% agarose gel containing 2.2 M formaldehyde before transfer to nylon membranes (Nytran, Schleicher and Schuell, Keene, NH). For RNA probes, membranes were prehybridized for 4 h in a solution of 50% formamide, 5 × SSC, 50 mM Hepes pH 6.8, 2 mM EDTA pH 8.0, 5 × Denhardt's, 1% SDS and 200 µg/ml of salmon sperm DNA at 65°C. They were then hybridized in the same solution overnight at 65°C with cRNA riboprobes (rat IGF-II, human IGFII-R, human IGFBP-1, porcine IGFBP-3 and pig GHR) which were labelled with [³²P]-labelled dUTP.

For DNA probes, membranes were prehybridized for 15 min in a solution (Rapid-hyb buffer, Amersham Canada Limited, Oakville, Ont., Canada) at 65°C, and then hybridized in the same solution for 2 h at 65°C with cDNA probes labelled with [³²P]-labelled dCTP (human IGF-I and human IGF-I receptor). Membranes were then washed with .1 × SSC/.1% SDS twice, 30 min at 85°C for RNA probes and at 60°C for cDNA probes and exposed to Kodak films (Eastman Kodak Company, Rochester, NY) with an intensifying screen at -80°C. The blots were reprobbed with 18S ribosomal ³²P-labelled cDNA probe as a control to

quantitate RNA loading and transfer. The size of RNA transcript was evaluated according to the position of 18S and 28S rRNAs or RNA ladder.

Autoradiograms were scanned using a densitometer (BIO-RAD Imaging Densitometer Model GS-670, Biorad Laboratories Ltd., Mississauga, Ont., Canada). The relative density of the transcript is expressed as arbitrary optical units. To correct for the possible difference in loading of total RNA in Northern blot, a ratio of the relative density of each specific transcript of growth factors with the relative density of the 18S ribosomal RNA band was calculated before statistical analysis was performed.

Statistical Analysis. We ran an analysis of variance for the following parameters: body weight, organ weight, tissue content of RNA, DNA and protein. We used the age of pig as main effect, sow within each age as first error term, sex of piglets as a split effect and age \times sex interaction. The different ages were compared using a *priori test* comparisons. The following comparison were used: (1) fetuses (F90 + F110) vs suckling piglets (P1 + P21), (2) suckling vs postweaning pigs (P90 + P180), (3) within fetal ages: F90 vs F110, (4) within suckling ages: P1 vs P21, (5) within postweaning ages: P90 vs P180. For the Northern blot analysis, the same model as the previous one was used, except that the membrane effect was tested instead of the sow effect. All variables were submitted to an analysis of variance using the general linear model procedure of Statistical Analysis System software (SAS, 1985). Data were considered significantly different if probability value (P) $\leq .05$.

Results

Development of the Pancreas

Two fast growing periods of the pancreas in terms of organ weight to body weight were observed at fetal F90 and P90 respectively (Figure 1a). The highest ratio of total pancreatic DNA to body weight was observed at F90 and decreased ($P < .001$) to a lower level thereafter (Figure 1b). The ratios of pancreatic weight to DNA, RNA to DNA and protein to DNA were the lowest ($P < .001$) during the fetal life and increased thereafter (Figure 1c, d and e).

Pancreatic IGFs, IGFBPs, IGFRs and GHR mRNA Levels

One major IGF-I mRNA transcript of approximately 7.8 kb was detected in the pancreas (Figure 2, top panel). High levels of IGF-I mRNA were observed during fetal and suckling periods (P1 and P21) and decreased ($P = .001$) after weaning (P90 and P180) (Figure 2, bottom panel). Messenger RNA for IGFI-R was present as a single 11 kb transcript (Figure 3, top panel) while IGFI-R mRNA was undetectable in the pancreas (data not shown). Pancreatic mRNA of IGFI-R was relatively abundant during the fetal and neonatal life and was low from P21 to P180 ($P = .05$, Figure 3, bottom panel). A single IGF-II mRNA transcript of approximately 2.2 kb was found in the pancreas (Figure 4, top panel). The highest level of IGF-II mRNA was observed during the fetal life and decreased ($P < .05$) at birth (Figure 4, bottom panel). A 1.8 kb IGFBP-1 mRNA transcript was found abundant

in the fetal liver while it is low in the pancreas (Figure 5). A single 2.8 kb mRNA transcript for IGFBP-3 was detected in the pancreas (Figure 6, top panel). A high level of IGFBP-3 mRNA occurred from fetal to early postnatal life and declined ($P = .003$) thereafter (Figure 6, bottom panel). One major transcript of 4.6 kb for GHR was found in the pancreas (Figure 7, top panel) at a relatively high level in fetuses and newborns and was low ($P < .05$) from P21 to P180 (Figure 7, bottom panel).

Pancreatic IGFs and IGFBPs Concentrations

The pancreatic concentration of IGF-I was low in fetuses and newborns then peaked in piglets of 21 days of age (17 fold higher in P21 compared to F90, $P < .001$) followed by a relatively low level thereafter (Figure 8). On the other hand, IGF-II concentration was high during fetal life and decreased ($P < .001$) with advancing age (Figure 8).

Western blotting of IGFBPs in pancreas homogenates showed two major bands (Figure 9, top panel). One band was present at 32.5 kDa corresponding to IGFBP-2 and another at 27.5 kDa corresponding to IGFBP-1 which was the predominant one in the pig pancreas. Contents of IGFBP-1 and 2 shared a similar pattern with the highest levels ($P < .001$) present in fetuses then followed by a marked decrease (IGFBP-1, $P < .001$; IGFBP-2, $P = .001$) during the postnatal period (Figure 9, bottom panel). The concentrations of IGFBP-3 and 4 were barely detected (data not shown).

Discussion

This is the first report on the development of IGFs, IGFRs, IGFBP-1 and -3 mRNA levels and tissue concentrations of IGFs and IGFBPs in the pancreas of pig. A fast fetal pancreatic growth at F90 is characterized by cell hyperplasia (high DNA / body weight) and a fast postnatal growth at P90 can be attributed to cell hypertrophy (high RNA / DNA and protein / DNA). The rapid growth of the pancreas during fetal life was accompanied by high levels of IGF-II and IGFI-R mRNAs and high tissue IGF-II concentration in the pancreas. It was reported that mouse embryos carrying null mutations of the genes encoding IGF-I, -II and IGFI-R lead to growth deficiency (Baker et al., 1993). Furthermore, using *in-situ* hybridization, IGF-II mRNA was found more abundant than that of IGF-I in human fetal exocrine and endocrine pancreas (Miettinen et al., 1993). However, in the current study, IGFI-R mRNA was undetected. Baker et al. (1993) reported that in 11 and 12.5 day-old mouse embryo, IGFI-R mediates only mitogenic signalling of IGF-II. After 13.5 days of age, IGFI-R interacts with both IGF-I and -II while IGF-II recognizes an additional unknown receptor which is different from IGFI-R. This suggests that IGF-II regulates pancreatic growth mainly through IGFI-R.

The pancreas IGF-I concentration was the highest at 21 days of age which is preceded by a fast growth period of pancreas at P90. In the present study, we did not evaluate changes of pancreas weight between 21 to 90 days of age, although another fast growth period of this organ occurred at 90 days of age. However, it is possible that pancreatic weight increased

before 90 days of age. This assumption is supported by the fact that pancreatic weight (Peng et al., 1996b) and pancreatic enzyme activities increased during the weaning period (Kelly et al., 1991; Lainé et al., 1996). A role of IGF-I on pancreatic growth was suggested since IGF-I is present in pancreatic A cells while IGF-II was observed exclusively in B-cells in man, and the pancreas of dog and rat (Maake and Reinecke, 1993). It was also observed that IGF-I mRNA increased fourfold above control value 3 days after 90% of rat pancreatectomy (Smith et al., 1991) and high affinity receptors for IGF-I were present on rat pancreatic A and B cells (Van Schravendijk et al., 1987). We have observed that IGF-I and IGF-I-R mRNAs were more abundant in the pancreas during the fetal life than during the postnatal life. However, IGF-I mRNA is much less abundant in pancreas compared to the other studied tissues (unpublished observations). This is consistent with a study on human (Bergmann et al., 1995), where IGF-I mRNA was low in normal pancreas. Therefore, during postnatal life, pancreatic growth of the pig might also be regulated by other growth factors. The cholecystokinin (CCK) is a gastrointestinal hormone that plays an important role in regulation of pancreatic function and stimulate pancreatic growth (Williams and Blevins, 1993). However, a previous study indicated that pig pancreatic acinar cells express few CCK_A receptors and possess a large majority of the CCK_B receptors responsible for their relatively low sensitivity to CCK (Morisset et al., 1996). On the other hand, Vilá et al. (1995) using [³H]-thymine uptake assay, found that hepatocyte growth factor (HGF) was the most potent mitogen for normal human pancreas cultures compared to IGF-I and EGF. The HGF receptor has been identified as *c-met* which was located to the apical membrane of

ductal cells in normal pancreas tissue (Vilá et al., 1995), suggesting that HGF and *c-met* may be involved in pancreatic growth. In the present study, IGF-I mRNA was abundant in fetal and early postnatal life and decreased with advancing age which is in agreement with our recent observations in rats (Calvo et al., 1996). However, these observations are not in agreement with the study reported earlier by Hogg et al. (1994), who showed that pancreatic IGF-I mRNA was predominant during late postnatal development in rats. The reason for such a discrepancy is unknown, beside the fact that different breeds of rat were used in these studies.

The levels of IGF-I and IGFBP-3 mRNA were high during the fetal and neonatal life while IGF-I concentration was low during the same period and IGFBP-3 was barely detectable over the whole developmental period examined. These results suggest that tissue content of IGF-I and IGFBP-3 may be regulated by posttranscriptional and(or) translational rate of protein synthesis. The levels of IGFs, IGFI-R, IGFBP-3 and GHR mRNAs presented a similar pattern which was high during the fetal and early postnatal life and declined thereafter, suggesting that accumulation of these mRNAs is coordinated in the pancreas. The IGFBP-3 is believed to be the major carrier of IGFs in the serum of adult pig (Lee et al., 1991a). In cell culture, intact IGFBP-3 has been shown to directly alter the interaction between IGF-I and its receptor (McCusker et al., 1991). Furthermore, it was reported that during rat pregnancy, IGFBP-3 decreased in serum, fetus and reproductive tissues. The decreased in IGFBP-3 was temporally related to the appearance of IGFBP-3 protease activity (Davenport et al., 1992). The undetected IGFBP-3 level in fetal pancreas may also be due

to protein degradation and(or) proteolysis of IGFBP-3 which likely makes more IGF-I and -II available for binding to cell surface receptors.

In the present study, pancreatic GHR mRNA was abundant in fetuses and newborns and decreased thereafter. Messenger RNA for GH receptor/binding protein (GHR/BP) (Edmondson et al., 1995) and GH receptors (Walker et al., 1992) have been identified in rat fetal tissues including the pancreas. In the fetal rat pancreas, GHR/BP mRNA was expressed mainly in the epithelium cells of the pancreatic acini which is adjacent to the connective tissue expressing high level of IGF-I mRNA, thus suggesting a role for GH acting both directly and indirectly via IGF-I (Edmondson et al., 1995). In addition, it was reported that GH stimulates DNA replication of fetal rat islet cell directly by inducing the local production of IGF-I (Swenne et al., 1987), an indication that GHRs detected *in vivo* are functional. Together these findings and data of the present study suggest that IGF-I may act as a mediator of GH involved in fetal pancreatic growth.

We observed that pancreatic IGFBP-1 and -2 contents were high during fetal and early postnatal life, thus paralleling the high levels of pig serum IGFBP-1 and -2 (Lee et al., 1991a). However, IGFBP-1 mRNA was very low in the pancreas during the whole developmental period, suggesting that pancreatic accumulation of IGFBP-1 is regulated at the posttranscriptional level. It is also possible that high pancreatic IGFBP-1 and -2 concentrations come from serum, since these proteins can cross the capillary boundaries (Bar et al., 1990). Exogenous IGFBP-1 and -2 could both potentiate the ability of IGF-I or -II to stimulate DNA synthesis by isolated fetal rat islets of Langerhans, and that IGFBPs were

themselves released by islets *in vitro* (Hogg et al., 1993). These results suggest that IGFs and IGFBPs may interact to promote cell hyperplasia in fetuses during late gestation.

In summary, pancreatic IGFs and IGFBPs concentrations and IGFs, IGFBPs and IGFI-R mRNAs levels are developmentally regulated. Pancreatic mRNA and tissue concentration of IGF-II were abundant in fetuses and neonatal piglets. The IGF-I mRNA level was high during the fetal and early postnatal life. A peak of IGF-I concentration was found at 21 days of age corresponding to high IGF-I mRNA level and an increase of digestive enzyme activities, suggesting that IGF-I may be involved in pancreatic development.

Implication

Our study shows for the first time a relationship between mRNA levels and concentrations of IGFs and growth of pancreas in pig. High concentrations of IGF-II and IGF-I occurred in fetal and early postnatal period respectively, which are related to a fast growth period of the pancreas and an increased enzyme activities. In addition, IGFs, IGFI-R, IGFBP-3 and GHR mRNA levels were abundant during fetal and early postnatal periods, implicating that these hormonal factors might be involved in early pancreatic growth and development in pig. Any treatment that would increase IGF production may accelerate pancreas development and pig performance around the weaning period.

The authors acknowledge L. St-James for her technical assistance, Y. Lachance for probe preparation, J. P. Charuest for statistical analysis and M. Morissette and his team for animal care and tissue sampling at slaughtering.

This work was financially supported by the Natural Sciences and Engineering Research Council of Canada grant No. GP 0002887.

Address for reprint requests: M.-F. PALIN, Agriculture and Agri-Food Canada, Dairy and Swine Research and Development Centre, P.O. Box 90, Lennoxville, Québec J1M 1Z3, CANADA

Literature Cited

- Abribat, T., H. Lapierre, P. Dubreuil, G. Pelletier, P. Gaudreau, P. Brazeau and D. Petitclerc. 1990. Insulin-like growth factor-I concentration in Holstein female cattle: variations with age, stage of lactation and growth hormone-releasing factor administration. *Domest. Anim. Endocrinol.* 7:93.
- Agriculture and Agri-Food Canada. 1993. Recommended code of practice for the care and handling of farm animals, pigs. Communications Branch, Agriculture Canada, Ottawa, ON Publication no. 1898/E, p. 43.
- Baker, J., J.P. Liu, E.J. Robertson and A. Efstratiadis. 1993. Role of insulin-like growth factors in embryonic and postnatal growth. *Cell* 75:73.
- Bar, R.S., M. Boes, D.R. Clemmons, W.H. Busby, A. Sandra, B.L. Dake and B.A. Booth. 1990. Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF binding proteins in the rat heart. *Endocrinology* 127:497.
- Bergmann, U., H. Funatomi, M. Yokoyama, H.C. Beger and M. Korc. 1995. Insulin-like growth factor overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. *Cancer Res.* 55:2007.
- Brameld, J.M., J.L. Atkinson, J.C. Saunders, M.M. Pell, P.J. Buttery and R.S. Gilmour. 1996. Effects of growth hormone administration and dietary protein intake on insulin-like growth factor I and growth hormone receptor mRNA expression in porcine liver,

- skeletal muscle, and adipose tissue. *J. Anim. Sci.* 74:1832.
- Calvo, E.L., G. Bernatchez, G. Pelletier, J.L. Iovanna and J. Morisset. 1996. Down regulation of the IGF-I mRNA expression during postnatal pancreatic development and overexpression after subtotal pancreatectomy and acute pancreatitis in the rat pancreas. *J. Mol. Biol.* (In press).
- Chirgwin, J.J., A.E. Przbyla, R.J. MacDonald and W.J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry* 18:5294.
- Cioffi, J.A., X. Wang and J.J. Kopchick. 1990. Porcine growth hormone receptor cDNA sequence. *Nucleic Acids Res.* 18:6451.
- Clemmons, D.R. 1991. Insulin-like growth factor binding proteins. (Insulin-like growth factor: molecular and cellular aspects, (ed. LeRoith, D.) CRC press, Boca Raton), p.152. Ann Arbor, Boston, London
- Davenport, M.L., J. Pucilowska, D.R. Clemmons, R. Lundblad, J.A. Spencer and L.E. Underwood. 1992. Tissue-specific expression of insulin-like growth factor binding protein-3 protease activity during rat pregnancy. *Endocrinology* 130:2505.
- de Passillé, A-M.B., G. Pelletier, J. Ménard and J. Morisset. 1989. Relationship of weight gain and behaviour to digestive organ weight and enzyme activities in piglets. *J. Anim. Sci.* 67: 2921.
- Edmondson, S.R., G.A. Werther, A. Russell, S, LeRoith, C.T. Jr. Roberts and F. Beck. 1995. Localization of growth hormone receptor/binding protein messenger ribonucleic

- acid (mRNA) during rat fetal development: Relationship to insulin-like growth factor-I mRNA. *Endocrinology* 136:4602.
- Froesch, E.R., Chr. Schmid, J. Schwander and J. Zapf. 1985. Actions of insulin-like growth factors. *Ann. Rev. Physiol.* 47: 443.
- Hill, D.J. and D.R. Clemmons. 1992. Similar distribution of insulin-like growth factor binding proteins-1, -2, -3 in human fetal tissues. *Growth Factors* 6:315.
- Hogg, J., D.J. Hill and V.K.M. Han. 1994. The ontogeny of insulin-like growth factor (IGF) and IGF-binding protein gene expression in the rat pancreas. *J. Mol. Endocrinol.* 13:49.
- Hogg, J., V.K.M. Han, D.R. Clemmons and D.J. Hill. 1993. Interactions of nutrients, insulin-like growth factors (IGFs) and IGF-binding proteins in the regulation of DNA synthesis by isolated fetal rat islets of Langerhans. *J. Endocrinol.* 138:401.
- Hossenlopp, P., D. Seurin, B. Segovia-Quinson, S. Hardouin and M. Binoux. 1986. Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. *Anal. Biochem.* 154:138.
- Jansen, M., F.M.A. Van Schaik, A.T. Ricker, B. Bullock, D.E. Woods, K.H. Gabbay, A.L. Nussbaum, J.S. Sussenbach and J.L. Van den Brande. 1983. Sequence of cDNA encoding human insulin-like growth factor I precursor. *Nature* 306:609
- Julkunen, M., R. Koistinen, K. Aalto-Setälä, M. Seppälä, O.A. Jänne and K. Kontula. 1988. Primary structure of human insulin-like growth factor-binding protein/placental

- protein 12 and tissue-specific expression of its mRNA. *FEBS Lett.* 236:295.
- Kelly, D., J.A. Smyth and K.J. McCracken. 1991. Digestive development of the early-weaning pig. *Br. J. Nutr.* 65:169.
- Lainé, J., G. Pelletier, G. Grondin, M. Peng and D. LeBel. 1996. Development of GP-2 and five zymogens in the fetal and young pig: Biochemical and immunocytochemical evidence of an atypical zymogen granule composition in the fetus. *J. Histochem. Cystochem.* 44:481.
- Lee, C.Y., C.S. Chung and F.A. Simmen. 1993. Ontogeny of the porcine insulin-like growth factor system. *Mol. Cell. Endocrinol.* 93:71-80.
- Lee, C.Y., F.W. Bazer, T.D. Etherton and F.A. Simmen. 1991a. Ontogeny of insulin-like growth factors (IGF-I and IGF-II) and IGF-binding proteins in porcine serum during fetal and postnatal development. *Endocrinology* 128:2336.
- Lee, W.H., R.R. Bowsher, J.M. Apathy, M.C. Smith and D.P. Henry. 1991b. Measurement of insulin-like growth factor-II in physiological fluids and tissues. II. Extraction and quantification in rat tissues. *Endocrinology* 128:815.
- Lehrach, H., D. Diamond, J.M. Wozney and H. Boedtker. 1977. RNA molecular weight determinations by gel electrophoresis under denaturing conditions: A critical reexamination. *Biochemistry* 16:4743.
- Lowry, O.H., N.J. Rosenbrough, A.L. Farr and R.J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 193:265.
- Maake, C. and M. Reinecke. 1993. Immunohistochemical localization of insulin-like growth

- factor 1 and 2 in the endocrine pancreas of rat, dog and man, and their coexistence with classical islet hormones. *Cell tissue Res.* 273:249.
- McCusker, R.H., W.H. Busby, M.H. Dehoff, C. Camacho-Hubner and D.R. Clemmons. 1991. Insulin-like growth factor (IGF) binding to cell monolayers is directly modulated by the addition of IGF binding proteins. *Endocrinology* 129:939.
- Miettinen, P.J., T. Otonkoski and R. Voutilainen. 1993. Insulin-like growth factorII and transforming growth factor- α in developing human fetal pancreatic islets. *J. Endocrinol.* 138:127.
- Morgan, M.D., J.C. Edman, D.N. Standring, V.A. Fried, M.C. Smith, R.A. Roth and W.J. Rutter. 1987. Insulin-like growth factor II receptor as a multifunctional binding protein. *Nature* 329:301.
- Morisset, J., F. Levenez, T. Corring, O. Benrezzak, G. Pelletier and E. Calvo. 1996. Is there a place for cholecystokinin in pig pancreatic physiology? *Am. J. Physiol. (Endocrinol. Metab.)* 34:E397.
- Murphy, L.J., G.I. Bell and H.G. Friesen. 1987. Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. *Endocrinology* 120:1279.
- Nissley, P. and W. Lopaczynski. 1991. Insulin-like growth factor receptors. *Growth Factors* 5: 29.
- Peng, M., G. Pelletier, M.-F. Palin, S. Véronneau, D. LeBel and T. Aribat. 1996a. Ontogeny of IGFs and IGFBPs mRNA levels and tissue concentrations in liver, kidney and skeletal muscle of pig. *Growth Dev. Aging* 60:171.

- Peng, M., M.-F. Palin, D. LeBel and G. Pelletier. 1996b. Effect of weaning on epidermal growth factor and its receptor messenger RNA levels in various tissues of piglets. *Can. J. Anim. Sci.* 76:621.
- Shimasaki, S., M. Shimonaka, M. Ui, S. Inouye, F. Shibata and N. Ling. 1990. Structural characterization of a follicle-stimulating hormone action inhibitor in porcine ovarian follicular fluid. *J. Biol. Chem.* 265:2198.
- Smith, F.E., K.M. Rosen, L. Villa-Komaroff, G.C. Weir and S. Bonner-Weir. 1991. Enhanced insulin-like growth factor I gene expression in regenerating rat pancreas. *Proc. Natl. Acad. Sci. USA* 88:6152.
- Statistical Analysis System Institute Inc. 1985. SAS user's guide. Statistics, Version 5 edition. SAS Institute Inc, Cary, NC.
- Swenne, I., D.J. Hill, A.J. Strain and R.D.G. Milner. 1987. Growth hormone regulation of somatomedin C / insulin-like growth factor I production and DNA replication in fetal rat islets in tissue culture. *Diabetes* 36:288.
- Ueno, T., K. Takahashi, T. Matsuguchi, H. Endo and M. Yamamoto. 1988. Transcriptional deviation of the rat insulin-like growth factor II gene initiated at three alternative leader-exons between neonatal tissues and ascites hepatomas. *Biochem. Biophys. Acta* 950:411.
- Ullrich, A., A. Gray, A.W. Tam, T. Yang-Feng, M. Tsubokawa, C. Collins, W. Henzel, T. Le Bon, S. Kathuria, E. Chen, S. Jacobs, U. Francke, J. Ramachandran and Y. Fujita-Yamaguchi. 1986. Insulin-like growth factor I receptor primary structure:

comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5:2503.

Van Schravendijk, C.F.H., A. Foriers, J.L. Van den Brande and D.G. Pipeleers. 1987.

Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells. Endocrinology 121:1784.

Vilá, M.R., T. Nakamura and F.X. Real. 1995. Hepatocyte growth factor is a potent mitogen for normal human pancreas cells *in vitro*. Lab. Invest. 73:409.

Walker, J.L., B.M. Moats-Staats, A.D. Stiles and L.E. Underwood. 1992. Tissue-specific developmental regulation of the messenger ribonucleic acids encoding the growth hormone receptor and the growth hormone binding protein in rat fetal and postnatal tissues. Pediatr. Res. 31:335.

Werner, H., M. Woloschak, B. Stannard, Z. Shen-Orr, C.T.Jr. Roberts and D. LeRoith. 1991. The insulin-like growth factor I receptor: molecular biology, heterogeneity and regulation. (Insulin-like growth factor:molecular and cellular aspects, (ed. LeRoith, D.) CRC press, Boca Raton), p. 17. Ann Arbor, Boston, London.

Williams, J.A. and G.T. Jr. Blevins. 1993. Cholecystokinin and regulation of pancreatic acinar cell function. Physiol. Rev. 73:701.

Figure 1. Effect of age on: a) pig pancreatic weight, b) total pig pancreatic DNA to body weight ratio, c) organ weight, d) total RNA, and e) protein to DNA ratios (F: fetus, P: postnatal). Values are means \pm SE of 6 to 12 observations at each age (at least one male and one female per litter from three different litters were used).

Figure 2. Effect of age on IGF-I mRNA level in pig pancreas (F: fetus, P: postnatal). TOP PANEL: Representative Northern blot of IGF-I mRNA in pig pancreas during development. Total RNA (20 μ g) was applied to a 1% agarose-formaldehyde gel followed by blot hybridization at 65°C using a human IGF-I cDNA probe and washed twice at 60°C with .1 \times SSC/ .1% SDS for 30 min. Autoradiography proceeded for two weeks at -80°C. The size of the IGF-I mRNA transcript was estimated according to the position of 18S and 28S. Blots were reprobed with an 18S ribosomal ³²P-labelled probe as a control to quantitate RNA loading and transfer. BOTTOM PANEL: IGF-I mRNA level was evaluated by densitometric scanning of the autoradiography and was expressed in arbitrary optical unit as a ratio of the 18S ribosomal RNA signal. One unit is attributed to the maximum ratio and the other values are reported relative to this maximum ratio. Data at each age represent means \pm SE obtained from four observations (one male and one female per litter from two different litters).

Figure 3. Effect of age on pig pancreatic IGFI-R mRNA level (F: fetus, P: postnatal). TOP PANEL: Representative Northern blot of IGFI-R mRNA in pig pancreas during development. Total RNA (20 μ g) was applied to a 1% agarose-formaldehyde gel followed

by blot hybridization at 65°C using a human IGFI-R cDNA probe and washed twice at 60°C with $.1 \times \text{SSC} / .1\% \text{ SDS}$ for 30 min. Autoradiography proceeded for two weeks at -80°C. The size of the IGFI-R mRNA transcript was estimated according to the position of 18S and 28S. The blots were reprobbed with a 18S ribosomal ^{32}P -labelled probe as a control to quantitate RNA loading and transfer. BOTTOM PANEL: IGFI-R mRNA level was evaluated by densitometric scanning of the autoradiography and was expressed in arbitrary optical unit as a ratio of the 18S ribosomal RNA signal. One unit is attributed to the maximum ratio and the other values are reported relative to this maximum ratio. Data at each age represent means \pm SE obtained from four observations (one male and one female per litter from two different litters).

Figure 4. Effect of age on IGF-II mRNA level in pig pancreas (F: fetus, P: postnatal). TOP PANEL: Representative Northern blot of IGF-II mRNA in pig pancreas during development. Total RNA (20 μg) was applied to a 1% agarose-formaldehyde gel followed by blot hybridization at 65°C using a rat IGF-II cRNA probe and washed twice at 85°C with $0.1 \times \text{SSC} / .1\% \text{ SDS}$ for 30 min. Autoradiography proceeded for one day at -80°C. The size of the IGF-II mRNA transcript was estimated according to the position of 18S and 28S. The blots were reprobbed with a 18S ribosomal ^{32}P -labelled probe as a control to quantitate RNA loading and transfer. BOTTOM PANEL: Relative tissue level of IGF-II mRNA was evaluated by densitometric scanning of the autoradiography and was expressed in arbitrary optical unit as a ratio of the 18S ribosomal RNA signal. One unit is attributed to the

maximum ratio and the other values are reported relative to this maximum ratio. Data at each age represent means \pm SE values obtained from four observations (one male and one female per litter from two different litters).

Figure 5. Representative Northern blot of IGFBP-1 mRNA in various pig tissues at fetal 90 days of age (P: pancreas, L: liver, K: kidney, M: muscle). Total RNA was applied to 1 % agarose-formaldehyde gel followed by blot hybridization using a human IGFBP-1 RNA probe (at 65°C). The filter was washed twice at 85°C with .1 \times SSC/.1% SDS for 30 min. Autoradiography proceeded approximately for two weeks at -80°C. The size of the transcript was estimated according to a RNA ladder. The blot was reprobed with a 18S ribosomal ³²P-labelled probe as a control to quantitate RNA loading and transfer.

Figure 6. Effect of age on pig pancreatic IGFBP-3 mRNA level (F: fetus, P: postnatal). TOP PANEL: Representative Northern blot of IGFBP-3 mRNA in pig pancreas during development. Total RNA (20 μ g) was applied to a 1 % agarose-formaldehyde gel followed by blot hybridization at 65°C using a porcine IGFBP-3 cRNA probe and washed twice at 85°C with .1 \times SSC/ .1% SDS for 30 min. Autoradiography proceeded for one week at -80°C. The size of the IGFBP-3 mRNA transcript was estimated according to the position of 18S and 28S. The blots were reprobed with a 18S ribosomal ³²P-labelled probe as a control to quantitate RNA loading and transfer. BOTTOM PANEL: IGFBP-3 mRNA level was evaluated by densitometric scanning of the autoradiography and was expressed in arbitrary

optical unit as a ratio of the 18S ribosomal RNA signal. One unit is attributed to the maximum ratio and the other values are reported relative to this maximum ratio. Data at each age represent means \pm SE obtained from four observations (one male and one female per litter from two different litters).

Figure 7. Effect of age on pig pancreatic GHR mRNA level (F: fetus, P: postnatal). TOP PANEL: Representative Northern blot of GHR mRNA in pig pancreas during development. Total RNA (20 μ g) was applied to a 1% agarose-formaldehyde gel followed by blot hybridization at 65°C using a pig GHR cRNA probe and washed twice at 85°C with .1 \times SSC/ .1% SDS for 30 min. Autoradiography proceeded for two weeks at -80°C. The size of the GHR mRNA transcript was estimated according to a RNA ladder. The blots were reprobed with a 18S ribosomal ³²P-labelled probe as a control to quantitate RNA loading and transfer. BOTTOM PANEL: GHR mRNA level was evaluated by densitometric scanning of the autoradiography and was expressed in arbitrary optical unit as a ratio of the 18S ribosomal RNA signal. One unit is attributed to the maximum ratio and the other values are reported relative to this maximum ratio. Data at each age represent means \pm SE obtained from four observations (one male and one female per litter from two different litters).

Figure 8. Effect of age on pig pancreatic IGF-I and -II concentrations (ng/g of tissue) (F: fetus, P: postnatal). Values are means of 6 to 12 observations at each age (at least one male and one female per litter from three different litters were used). IGF-I and IGF-II

concentrations were determined by RIA from pancreas homogenates prepared by homogenization of 500 mg to 1 g of tissue in a 1 g to 4 ml ratio wt/vol of 3.3 M formic acid solution to dissociate the IGF-IGFBPs complex.

Figure 9. Effect of age on IGFBPs contents in pig pancreas (F: fetus, P: postnatal). TOP PANEL: Representative Western blotting of IGFBPs in pancreas homogenates prepared as described in Figure 8. Pancreas homogenates were separated on a 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis under non-reducing conditions and transferred onto nitrocellulose membrane. Blots were probed with ^{125}I -labelled IGF-I and autoradiographed at -80°C for 72 h. Bands of the membrane corresponding to those on the autoradiograms were counted in a gamma counter and expressed in cpm. BOTTOM PANEL: Average values of IGFBPs from three Western blots are described in top panel (IGFBP-1=27.5 kDa; IGFBP-2=32.5 kDa; IGFBP-3=39.0 kDa; IGFBP-4=26.0 kDa).




Figure 1.




Figure 2.




Figure 3.

28 S -

2.2 kb -
18 S -

18 S -




Figure 4.




Figure 5.





Figure 6.





Figure 7.




Figure 8.





Figure 9.

2.2 M. Peng, G. Pelletier, M.-F. Palin, S. Véronneau, D. LeBel and T. Abribat.
ONTOGENY OF IGFs AND IGFBPs mRNA LEVELS AND TISSUE
CONCENTRATIONS IN LIVER, KIDNEY AND SKELETAL MUSCLE OF PIG.
Growth Dev. Aging, 1996. 60:171-187.

2.2.1 Contribution to manuscript 2.2

My contribution to this manuscript was to (1) plan and write the project outline, (2) prepare and organize sample collection, (3) extract total RNA and carry out Northern analysis, (4) provide data to the statistician, (5) prepare figures and tables and write manuscript. Dr. T. Abribat's laboratory determined IGFs and IGFBPs concentrations by RIA and Western blot analysis respectively. We have also got technical assistance from Dr. M-F. Palin and Mr. S. Véronneau for probe preparation. The research project and the manuscript preparation were directed by Drs. G. Pelletier and D. LeBel.

2.2.2 Manuscript of 2.2

Growth, Development & Aging, 1996, 60, 171-187

171

Ontogeny of IGFs and IGFBPs mRNA Levels and Tissue Concentrations in Liver, Kidney and Skeletal Muscle of Pig

M. Peng², G. Pelletier^{1,4}, M.-F. Palin¹, S. Véronneau¹, D. LeBel² and T. Abribat³

¹ Agriculture and Agri-Food Canada
Dairy and Swine Research and Development Centre
P.O. Box 90, Lennoxville,
Québec, CANADA J1M 1Z3
Contribution No. 522

² Department of Biology
Faculty of Science
University of Sherbrooke,
Sherbrooke, Québec, CANADA J1K 2R1

³ Montréal University
Notre-Dame Hospital Research Centre
P.O. Box 90, Montréal,
Québec, CANADA H2L 4M1

⁴ *Corresponding Author*

Pour l'article complet voir la copie papier à la Bibliothèque du Frère-Théode
Section Monographie QP 552 G76P46 1996

- 2.3 M. Peng, M.-F. Palin, S. Véronneau, D. LeBel and G. Pelletier. ONTOGENY OF EPIDERMAL GROWTH FACTOR (EGF), EGF RECEPTOR (EGFR) AND BASIC FIBROBLAST GROWTH FACTOR (bFGF) mRNA LEVELS IN PANCREAS, LIVER, KIDNEY AND SKELETAL MUSCLE IN PIG. *Domest. Anim. Endocrinol.* (Submitted).

2.3.1 Contributions to manuscript 2.3

My contribution to this manuscript was to (1) plan and write the project outline, (2) prepare and organize the sample collection (3) extract total RNA and carry out Northern analysis, (4) provide data to the statistician, (5) prepare figures and write manuscript. We have got technical assistance from Dr. M.-F. Palin and Mr. S. Véronneau for probe preparation. The project and the manuscript preparation were under the direction of Drs. G. Pelletier and D. LeBel.

2.3.2 Manuscript 2.3

Ontogeny of epidermal growth factor (EGF), EGF receptor (EGFR) and basic fibroblast growth factor (bFGF) mRNA levels in pancreas, liver, kidney and skeletal muscle of pig

M Peng**, M-F Palin*, S Véronneau*, D LeBel** and G Pelletier*¹

*Agriculture and Agri-Food Canada, Dairy and Swine Research and Development Centre,
P.O.Box 90 Lennoxville, Québec, CANADA, J1M 1Z3

**Department of Biology, Faculty of Science, University of Sherbrooke, Sherbrooke,
Québec, CANADA, J1K 2R1

Running head: Developmental EGF, EGFR and bFGF mRNA levels in pig tissues

Key words: EGF, EGFR, bFGF, mRNA, age, pig

Abstract

Epidermal growth factor (EGF), EGF receptor (EGFR) and basic fibroblast growth factor (bFGF) mRNA levels were examined by Northern blot analysis in four tissues (pancreas, liver, kidney and skeletal muscle) of pig from fetal 90 days to postnatal 180 days of age. The present study shows for the first time that EGF mRNA increased with advancing age in the kidney and skeletal muscle of pig. A high level of EGF mRNA were observed in the kidney compared to the liver and skeletal muscle. In the pancreas, high levels of EGF mRNA were found in fetuses and newborns and were low in older pigs. Pancreatic EGFR mRNA level paralleled its EGF mRNA whereas in the kidney and skeletal muscle, patterns of EGFR mRNA were reversed to their EGF mRNA levels. In the liver, EGFR mRNA was abundant but EGF mRNA was undetected. In the pancreas and skeletal muscle, the highest levels of bFGF mRNA were found in fetuses of 90 days of age and then decreased with advancing age. In the liver and kidney, there were no major changes in bFGF mRNA levels during the examined developmental periods. These results show that EGF, EGFR and bFGF mRNA levels are developmentally and tissue specifically regulated in pig. In the pancreas, mRNA levels of EGF, EGFR and bFGF were high in fetal and neonatal life and low thereafter. In the kidney and skeletal muscle, EGF mRNA increased with advancing age. EGF may play a role in muscle growth and maintenance in growing pigs during the later stage of development.

Introduction

In the pig, a wide range of tissues express EGF mRNA including pancreas, liver and kidney, with the highest level in pancreas and kidney with no reference to the age of the animal (1). EGF is known as a regulator in a wide variety of physiological processes including embryogenesis (2), growth (3) tissue repair and regeneration (4). We have shown recently (5) that the level of EGF mRNA is increased in the pancreas of weaning piglets while the organ undergoes rapid growth. EGF receptor (EGFR) is a transmembrane glycoprotein of 170-180 kDa (6). Its tyrosine kinase activity induced by EGF binding is directly implicated in the regulation of cell proliferation (7). High affinity EGF receptors are present in rat pancreatic acini (8) and in human fetal kidney and liver (9). In the regenerating rat liver, the level of EGFR mRNA increases after 1 and 3 days of partial hepatectomy (10). These observations suggest an autocrine action of EGF in various organs.

It was suggested that bFGF may function as “wound hormone”, both in the routine maintenance of tissue integrity and during repair after injury (11). Ku *et al.* (12) have shown that following scraping subconfluent bovine aortic endothelial cells, there was a 4- to 10-fold increase in steady state level of bFGF mRNA and protein. Nuclear run-on assay and mRNA stability studies indicate that the increase in steady state bFGF mRNA following scraping is due to the transcriptional activation of the bFGF gene. Also the increase in bFGF mRNA following scraping is dependent on new protein synthesis. Taken together these observations have led to the hypothesis that bFGF may be involved in tissue growth. In our laboratory,

we also observed that other growth factors such as the IGFs and their binding proteins are associated to the organ growth in pig (13).

Despite the importance of EGF and bFGF in regulating proliferation and differentiation of a wide variety of cell types, there is little information on ontogeny of EGF, EGFR and bFGF mRNA levels in tissues of large mammals. The objective of the present study was to examine the levels of mRNA for EGF, EGFR and bFGF in pancreas, liver, kidney and skeletal muscle during development in pig.

Material and Methods

Animal and tissue preparation

Yorkshire purebred fetuses of 90 (F90) and 110 (F110) days of gestation (Normal gestation age is 114 day-old) and pigs of 1 (P1), 21 (P21), 90 (P90) and 180 (P180) days of age were used. For each age two males and two females were obtained from one litter of two different sows. The ages of the fetuses were determined according to the sow's mating date. Pigs, including the sows (with the exception of fetuses), were fasted for 16 h before slaughtering. Animals were slaughtered (stunning and exsanguination) according to recommended code of practice for the care and handling of farm animals, pigs (14). After laparotomy, the uterus was gradually opened and the fetuses were removed and sampled. Immediately after exsanguination, pancreas, liver and kidney were removed by dissection, weighed and

sampled. A sample of the skeletal muscle from the biceps femoris was also taken. Tissue samples of pancreas, liver, kidney and skeletal muscle were frozen in liquid nitrogen and stored at -80°C until analyzed by Northern blot.

RNA preparation

Total RNA was extracted according to the method described by Chirgwin *et al.* (15). Tissues were homogenized in 4 M guanidinium thiocyanate using a polytron homogenizer. Supernatants were used for precipitation of RNA in 100 % ethanol and 2 M potassium acetate at -20°C. After centrifugation, the RNA pellets were dissolved in 7 M guanidine hydrochloride. Then, RNA was precipitated again and quantitated by measuring its absorbance at 260 nm.

Preparation of probes

A human EGFR complementary RNA (cRNA) probe was transcribed from a 1401 base pairs (bp) *Sma*1-*Eco*R1 cDNA fragment (16), inserted into the pBluescript SK+ plasmid vector. The insert was sequenced using a ³²PSequencing™ Kit (Pharmacia Biotech Inc, Piscataway, NJ) in order to check the orientation of the cDNA. The template was linearized with *Sma*1 then used in a T7 transcription Riboprobe System (Promega, Madison, WI).

EGF and bFGF probes were prepared by RT-PCR. EGF downstream primer (nt 186-209) 5'-ATCTCTAGAGCGCAGCTCCCACCATTTCAGTC-3' was designed according to a known region of the pig EGF cDNA sequence (17). The upstream primer 5'-

ATCGGTACCGCATGCTGAAGCCCTCATCACTGG-3' is identical to nucleotide 2607-2630 of the human EGF cDNA (18), a region where sequence is 96% homology for human, rat (19) and mouse EGF (20). A *KpnI* restriction site for upstream primer and a *XbaI* site for downstream primer were created by addition of nine nucleotides. This primer pair predicts a 917 bp fragment. The bFGF upstream primer 5'-ATCGGTACCTTCAAGGACCCCAAGCGGCTGTAC-3' is identical to nucleotide 107-130 of the marsupial bFGF cDNA sequence (21), while the downstream primer was 5'-ATCTCTAGACCCGTGCCAGTCAGCTCTTAGCAG-3' represents the reverse complement of nucleotides 486-509 of the marsupial cDNA sequence. These primers predict a 421 bp fragment. First-strand cDNA was synthesized from total RNA (6 μ g) using a "SuperScript™ Preamplification System for First Strand cDNA Synthesis" kit (Gibco BRL Life Technologies, Burlington, Ont., Canada) and 500 ng of oligo(dT)₁₂₋₁₈ primer in a total reaction volume of 30 μ L. An aliquot of 3 μ L was subjected to PCR amplification using a PTC-100™ Programmable Thermal Controller (MJ Research Inc., Watertown, Mass.). The reaction mix contained 3 μ L of reverse transcription mixture, 30 pmol of each primer, 1x PCR buffer (Pharmacia Biotech Inc., Piscataway, NJ), 0.35 mM dNTPs and water to 100 μ L. After overlaying with 3 drops of light mineral oil (Sigma ST. Louis, MO), the reactions were heated to 94°C for 2 min prior to the addition of 4 U of the *Taq* polymerase (Pharmacia Biotech Inc., Piscataway, NJ). The amplification profile comprised 35 cycles: at 94°C for 0.75 min (dissociation), 55°C for 1.25 min (annealing) and 72°C for 2.5 min (extension). The final cycle included a further 5 min at 72°C for complete strand extension.

The PCR amplified cDNA fragments of EGF and bFGF of the predicted length were inserted into the pBluescript KSII+ plasmid vector. The authenticity of the cDNA clones were verified by sequencing using a ^{T7}Sequencing™ kit (Pharmacia Biotech Inc., Piscataway, NJ). The templates were linearized with *EcoRV* and then used in a T7 transcription Riboprobe System (Promega, Madison, WI) to synthesis the cRNA probes.

Northern blot analysis

The procedure for Northern blot was described by Lehrach *et al.* (22) with some modifications. Briefly, 20 µg of total RNA was fractionated in a 1 % agarose gel containing 2.2 M formaldehyde before transfer to nylon membranes (Nytran, Schleicher and Schuell, Keene, NH). Membranes were prehybridized for 4 h in a solution of 50 % formamide, 5 × SSC, 50 mM Hepes pH 6.8, 2 mM EDTA pH 8.0, 5 × Denhardt's, 1 % SDS and 200 µg/ml salmon sperm DNA at 65°C. They were then hybridized in the same solution overnight at 65°C with cRNA riboprobes which were labelled with [³²P]-labelled dUTP. Membranes were then washed with 0.1 × SSC/ 0.1% SDS twice, 30 min at 85°C and exposed to Kodak films (Eastman Kodak Company, Rochester, NY) with an intensifying screen at -80°C. The size of RNA transcripts was evaluated according to a RNA ladder.

Autoradiograms were scanned using a densitometer (BIO-RAD Imaging Densitometer Model GS-670 Bio-Rad Laboratories Ltd., Mississauga, Ont., Canada). The relative density of the transcript was expressed as arbitrary optical units. The membranes were reprobed with a 18S ribosomal ³²P-labelled cDNA probe as a control to correct for the possible differences

in RNA loading and transfer in Northern blots. A ratio of the relative density of each specific transcript of growth factors with the relative density of the 18S ribosomal RNA band was calculated before statistical analysis was performed.

Statistical analysis

All variables were submitted to an analysis of variance with age, blot and age x blot interaction as main effects in a split plot design using the general linear model procedure of Statistical Analysis System software (23). The different ages were compared using *a priori test* comparisons. The following comparisons were used: (1) fetuses (F90 + F110) vs suckling piglets (P1 + P21) (2) suckling (P1 + P21) vs postweaning (P90 + P180) piglets (3) within fetal ages: F90 vs F110 (4) within suckling ages: P1 vs P21 (5) within postweaning ages: P90 vs P180. Data were considered significantly different if probability value (P) ≤ 0.05 .

Results

A single EGF mRNA transcript of approximately 4.9 kb was detected in pancreas, kidney and skeletal muscle, with the highest level in the kidney and an undetectable signal in the liver (Fig.1). In the pancreas, EGF mRNA levels were high in fetuses and newborns and relatively low (suckling vs postweaning: $P < 0.05$) from P21 to P180 (Fig.2). In kidney and skeletal muscle EGF mRNA levels exhibited an opposite pattern to that of the pancreas (Fig.2). In fact, EGF mRNA was relatively low during the fetal and neonatal life and increased (suckling vs postweaning: $P < 0.01$) markedly from 21 and 90 days of age in kidney and skeletal muscle respectively.

A major EGFR mRNA transcript of approximately 10.3 kb was detected in the four studied tissues (Fig. 1). High levels of EGFR mRNA were detected in the fetal and newborn pancreas and decreased ($P < 0.001$) abruptly thereafter (Fig. 3) thus paralleling its EGF mRNA levels. In the liver, EGFR mRNA was abundant without any significant change during development (Fig. 3). The kidney and skeletal muscle exhibited relatively high EGFR mRNA levels in fetuses and newborns, then the levels decreased (suckling vs postweaning: $P = 0.03$) with advancing age, showing an opposite pattern to their EGF mRNA levels (Fig. 3). A mRNA transcript of 7.0 kb for bFGF was found in the four studied tissues (Fig. 1). In the pancreas and skeletal muscle, the highest bFGF mRNA levels were found in fetuses of 90 days and decreased ($P < 0.05$) with advancing age (Fig. 4). In liver and kidney, no effect of age on bFGF mRNA level was observed. There was no effect of blot and age x blot interaction for any growth factors in the studied tissues.

Discussion

The present study shows, for the first time, that EGF mRNA in the kidney and skeletal muscle increased between three and six months in pig. Messenger RNAs of other growth factors such as IGF-I and -II (24,13) and bFGF in the muscle decreased with advancing age. This suggests that EGF might be an important growth factor regulating growth and maintenance of the skeletal muscle in the later stage of development in pig. It was reported (25) that EGF stimulates protein synthesis in fetal bovine myoblasts. However, in the skeletal muscle and kidney EGFR mRNA decreased with advancing age. Similar observations were made by Aharonov *et al.* (26) who found that EGF and its receptor are regulated in an opposite direction in 3T3 cells. The authors suggested that reduction of EGF receptors by down regulation may be to adjust the cell's subsequent sensitivity to EGF since EGF is still required continuously for mitogenic activity.

The EGF mRNA was more abundant in the pancreas and skeletal muscle than that of the liver which is in agreement with observations that, in pig, EGF mRNA (1) and immunoreactive EGF (27) were mainly present in the kidney and pancreas with no reference to the age of animals. We found that EGF and EGFR mRNA levels present a similar pattern in pig pancreas, suggesting that accumulation of both of them are regulated in a same fashion. High affinity EGF receptors have been detected in isolated rat pancreatic acinar cells (8) and in human pancreatic tissue (28). Combining these data with those of the present study, it appears that EGF may be involved in the regulation of early pancreatic development at the time the pancreas undergoes a rapid growth period in pig (29).

In the pig liver, EGF mRNA was undetected. This is consistent with earlier reports on pig (1) and mouse (30). However, liver EGFR mRNA was relatively abundant during development. It has been reported that EGF has an important developmental effect on liver growth and maintenance (10). The presence of EGF receptors has been shown in human fetal liver and some other tissues (9). It was also found that after 1 and 3 days of partial hepatectomy, EGFR mRNA increased in regenerating rat liver (10). In addition, the concentration of EGF increased in the plasma of rat following partial hepatectomy (31). In mouse, EGF originating from submandibular glands plays a role in promoting early stage of liver regeneration (32). However, in pig, EGF concentration in submaxillary gland has been shown to be very low (27). It was reported that isolated hepatocytes of rat have a great capacity to take up EGF from portal blood (33). Moreover, EGF injected into the portal vein was cleared from the blood through the liver (34), indicating that liver appears to be an important organ which regulates the circulating level of EGF. The presence of EGFR mRNA and the absence of EGF mRNA in the liver, in the present study, suggests that EGF may be involved in liver development through an endocrine action.

The high level of EGF mRNA found in the kidney is in agreement with another study in human (35). A low EGF concentration in plasma compared with the one of urine suggests that urinary EGF could originate from the kidney (36). Immunoreactive EGF in human kidney increased with age (37) in a similar pattern to the EGF mRNA level in pig. Although EGFR mRNA level decreased with advancing age in the kidney, its signal is still higher than pancreas and skeletal muscle during the postnatal life.

Messenger RNA levels for bFGF presented a similar pattern in pancreas and skeletal

muscle, which were high during the fetal life and declined after birth. Basic FGF and its receptors were expressed in human pancreatic cells (38). Messenger RNA of bFGF was also found in mouse skeletal myoblasts (39). In addition, bFGF was shown to be a potent stimulator of DNA synthesis of rat pancreatic acinar cell (40) and of mouse myoblast cells (41). Furthermore, it was suggested that bFGF plays a direct role in promoting skeletal muscle growth, since mechanical loading (stretching) induces bFGF release in the medium of differentiated skeletal muscle culture (42). These findings and the one of the present study, suggest that bFGF might be involved in the pancreas and skeletal muscle development during fetal and early postnatal life of pig.

In summary, our results show that mRNA levels of EGF, EGFR and bFGF in four studied tissues of pig exhibited distinct ontogenic patterns. In the pancreas, EGF, EGFR and bFGF mRNA levels were high in the fetal and neonatal life and low thereafter. In the liver, a high level of EGFR mRNA was observed whereas EGF mRNA was undetected in this organ. In the kidney and skeletal muscle, EGF mRNA levels increased with advancing age. Therefore, EGF may play a role in muscle growth and maintenance in growing pigs during the later stage of development.

Fig. 1. Representative Northern blot of EGF, EGFR and bFGF mRNAs in pig various tissues at 90 days of age (P: pancreas, L: liver, K: kidney, M: muscle). Total RNA was applied to 1% agarose-formaldehyde gel followed by blot hybridization using EGF, EGFR and bFGF RNA probes (at 65°C). Filters were washed twice at 85°C for EGF and EGFR and 65°C for bFGF with $0.1\times$ SSC/0.1% SDS for 30 min. Autoradiographs were proceeded approximately for 1 week for EGF and EGFR and 2 weeks for bFGF respectively at -80°C. The sizes of the transcripts were estimated according to a RNA ladder. The blots were reprobed with a 18S ribosomal ^{32}P -labelled probe as a control to quantitate RNA loading and transfer.

Fig. 2. Effect of age on EGF mRNA levels in various tissues of pig (F: fetus, P: postnatal). Relative tissue levels of EGF mRNA were evaluated by densitometric scanning of the autoradiograms and were expressed in relative optical units as a ratio of 18S ribosomal RNA signal. One unit is attributed to the maximum ratio and the other values are reported relative to this maximum ratio. Data at each age represented the mean values \pm SE obtained from four observations (one male and one female per litter obtained from two different litters).

Fig. 3. Effect of age on EGFR mRNA level in various tissues of pig (F: fetus, P: postnatal). Relative tissue levels of EGFR mRNA were evaluated by densitometric scanning of the autoradiograms and were expressed in relative optical units as a ratio of 18S ribosomal RNA signal. One unit is attributed to the maximum ratio and the other values are reported relative to this maximum ratio. Data at each age represented the mean values \pm SE obtained from four observations (one male and one female per litter obtained from two different litters).

Fig. 4. Effect of age on bFGF mRNA levels in various tissues of pig (F: fetus, P: postnatal). Relative tissue levels of bFGF mRNA were evaluated by densitometric scanning of the autoradiograms and were expressed in relative optical units as a ratio of 18S ribosomal RNA signal. One unit is attributed to the maximum ratio and the other values are reported relative to this maximum ratio. Data at each age represented the mean values \pm SE obtained from four observations (one male and one female per litter obtained from two different litters).

Acknowledgements

The authors acknowledge J. P. Charuest for statistical analysis and M. Morissette and his team for animal care and tissue sampling at slaughtering.

This work was financially supported by the Natural Sciences and Engineering Research Council of Canada grant No. GP 0002887.

¹Corresponding author: G Pelletier, Agriculture and Agri-Food Canada, Dairy and Swine Research and Development Centre, P.O. Box 90, Lennoxville, Québec, CANADA, J1M 1Z3

References

1. Vaughan TJ, Pascall JC, James PS, Brown KD. Expression of epidermal growth factor and its mRNA in pig kidney, pancreas and other tissues. *Biochem J* 279:315-318, 1991.
2. Vaughan TJ, James PS, Passcall JC, Brown KD. Expression of the genes for TGF α , EGF and the EGF receptor during early pig development. *Development* 116:663-669, 1992.
3. Zschiesche W. Retardation of growth and epithelial differentiation in suckling mice by anti-EGF antisera. *Biomed Biochem Acta* 48:103-109, 1989.
4. Morin NJ, Laurent G, Nonclercq D, Toubeau G, Heuson-Stiennon J-A, Bergeron MG, Beauchamp D. Epidermal growth factor accelerates renal tissue repair in a model of gentamicin nephrotoxicity in rats. *Am J Physiol* 263:(Renal Fluid Electrolyte Physiol. 32): F806-F811, 1992.
5. Peng M, Palin M-F, LeBel D, Pelletier G. Effect of weaning on epidermal growth factor and its receptor messenger RNA levels in various tissues of piglets. *Can J Anim Sci* 76:621-624, 1996.
6. Carpenter G, Wahl MI. The epidermal growth factor family. In: *Peptide growth factors and their receptors I*. pp.69-171. Eds by Sporn MB and Roberts AB, Springer-Verlag, Berlin Heidelberg New York London Paris Tokyo Hong Kong, 1990.

7. Carpenter G, Cohen S. Epidermal growth factor. *J Biol Chem* 265:7709-7712, 1990.
8. Korc M, Matrisian LM, Planck SR, Magun BE. Binding of epidermal growth factor in rat pancreatic acini. *Biochem Biophys Res Commun* 111:1066-1073, 1983.
9. Nexø E, Kryger-Baggesen N. The receptor for epidermal growth factor is present in human fetal kidney, liver and lung. *Reg Pep* 26:1-8, 1989.
10. Johnson AC, Garfield SH, Merlino GT, Pastan I. Expression of epidermal growth factor receptor proto-oncogene mRNA in regenerating rat liver. *Biochem Biophys Res Commun* 150:412-418, 1988.
11. Muthukrishnan L, Warder E, McNeil PL. Basic fibroblast growth factor is efficiently released from a cytosolic storage site through plasma membrane disruption of endothelial cells. *J Cell Physiol* 148:1-16, 1991.
12. Ku P-T, D'Amore PA. Regulation of basic fibroblast growth factor (bFGF) gene and protein expression following its release from sublethally injured endothelial cells. *J Cell Biochem* 58:328-343, 1995.
13. Peng M, Pelletier G, Palin M-F, Véronneau S, LeBel D, Abribat T. Ontogeny of IGFs and IGFBPs mRNA levels and tissue concentrations in liver, kidney and skeletal muscle of pig. *Growth Dev Aging* 60:171-187, 1996.
14. Agriculture and Agri-Food Canada. Recommended code of practice for the care and handling of farm animals, pigs. Communications branch, Agriculture Canada, Ottawa, ON. Publication NO. 1898/E. p. 43, 1993.
15. Chirgwin JJ, Przybyla AE, MacDonald RJ, Rutter, WJ. Isolation of biologically

active ribonucleic acid from sources enriched in ribonuclease. *Biochem* 18:5294-5299, 1979.

16. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD, Seeburg PH. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A 431 epidermoid carcinoma cells. *Nature* 309:418-425, 1984.
17. Pascall JC, Jones DSC, Doel SM, Clements JM, Hunter M, Fallon T, Edwards M, Brown KD. Cloning and characterization of a gene encoding pig epidermal growth factor. *J Mol Endocrinol* 6:63-70, 1991.
18. Bell GI, Fong NM, Stempien MM, Wormsted MA, Caput D, Ku L, Urdea MS, Rall LB, Sanchez-Pescador R. Human epidermal growth factor precursor: cDNA sequence, expression *in vitro* and gene organization. *Nucleic Acids Res* 14:8427-8446, 1986.
19. Saggi SJ, Safirstein R, Price PM. Cloning and sequencing of the rat preproepidermal growth factor cDNA: Comparison with mouse and human sequences. *DNA Cell Biol* 11:481-487, 1992.
20. Gray A, Dull TJ, Ullrich A. Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor. *Nature* 303:722-725, 1983.
21. Kusewitt DF, Sabourin CLK, Budge CL, Sherburn TE, Ley RD. Characterization of cDNA encoding basic fibroblast growth factor of the marsupial *monodelphis*

- domestica*. DNA Cell Biol 13:549-554, 1994.
22. Lehrach H, Diamond D, Wozney JM, Boedtker H. RNA molecular weight determinations by gel electrophoresis under denaturing conditions: A critical reexamination. Biochem 16:4743-4751, 1977.
 23. Statistical Analysis System Institute, Inc. SAS user's guide. Statistics, Version 5 edition. SAS Institute Inc, Cary, NC, 1985.
 24. Lee CY, Chung CS, Simmen FA. Ontogeny of the porcine insulin-like growth factor system. Mol Cell Endocrinol 93:71-80, 1993.
 25. Blachowski S, Motyl T, Orzechowski A, Grzelkowska K, Interewicz B. Comparison of metabolic effects of EGF, TGF- α , and TGF- β 1 in primary culture of fetal bovine myoblasts and rat L6 myoblasts. Int J Biochem 25:1571-1577, 1993.
 26. Aharonov A, Pruss R and Herschman H R. Epidermal growth factor. J Biol Chem 253: 3970-3977, 1978.
 27. Vaughan TJ, Littlewood CJ, Pascall JC, Brown KD. Epidermal growth factor concentrations in pig tissues and body fluids measured using a homologous radioimmunoassay. J Endocrinol 135:77-83, 1992.
 28. Hormi K, Lehy T. Developmental expression of transforming growth factor- α and epidermal growth factor receptor proteins in the human pancreas and digestive tract. Cell Tissue Res 278:439-450, 1994.
 29. Lainé J, Pelletier G, Grondin G, Peng M, LeBel D. Development of GP-2 and five zymogens in the fetal and young pig. Biochemical and immunocytochemical evidence

- of an atypical zymogen granule composition in the fetus. *J Histochem Cytochem* 44:481-499, 1996.
30. Rall LB, Scott J, Bell GI, Grawford RJ, Penschow JD, Niall HD, Coghlan JP. Mouse prepro-epidermal growth factor synthesis by the kidney and other tissues. *Nature* 313:228-231, 1985.
 31. Cornell RP. Gut-derived endotoxin elicits hepatotrophic factor secretion for liver regeneration. *Am J Physiol* 249 (Regulatory Integrative Comp. Physiol. 18): R551-R562, 1985.
 32. Noguchi S, Ohba Y, Oka T. Influence of epidermal growth factor on liver regeneration after partial hepatectomy in mice. *J Endocrinol* 128:425-431, 1991.
 33. Dunn WA, Connolly TP, Hubbard AL. Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes: receptor pathway. *J Cell Biol* 102:24-36, 1986.
 34. St. Hilaire RJ, Hradek GT, Jones AL. Hepatic sequestration and biliary secretion of epidermal growth factor: evidence for a high-capacity uptake system. *Proc Natl Acad Sci USA* 80:3797-3801, 1983.
 35. Kajikawa K, Yasui W, Sumiyoshi H, Yoshida K, Nakayama H, Ayhan A, Yokozaki H, Ito H, Tahara E. Expression of epidermal growth factor in human tissues. *Virchows Arch A Pathol Anat Histopathol* 418:27-32, 1991.
 36. Dailey GE, Kraus JW, Orth DN. Homologous radioimmunoassay for human epidermal growth factor (urogastrone). *J Clin Endocrinol Metab* 46:929-936, 1978.
 37. Kasselberg AG, Orth DN, Gray ME, Stahlman MT. Immunocytochemical

- localization of human epidermal growth factor/urogastrone in several human tissues. J Histochem Cytochem 33:315-322, 1985.
38. Friess H, Kobrin M, Korc M. Acidic and basic fibroblast growth factors and their receptors are expressed in the human pancreas. Pancreas 7:737, 1992.
 39. Olwin BB, Hauschka SD. Identification of the fibroblast growth factor receptor of Swiss 3T3 cells and mouse skeletal muscle myoblasts. Biochem 25:3487-3492, 1986.
 40. Hoshi H, Logsdon CD. Direct trophic effects of fibroblast growth factors on rat pancreatic acinar cells in *vitro*. Biochem Biophys Res Commun 196:1202-1207, 1993.
 41. Campbell JS, Wenderoth MP, Hauschka SD, Krebs EG. Differential activation of mitogen-activated protein kinase in response to basic fibroblast growth factor in skeletal muscle cells. Proc Natl Acad Sci USA 92:870-874, 1995.
 42. Clarke MSF, Feedback PL. Mechanical load induces saroplasmic wounding and FGF release in differential human skeletal muscle cultures. FASEB J 10:502-509, 1996.




Figure 1.




Figure 2.




Figure 3.




Figure 4.

2.4 M. Peng, M.-F. Palin, D. LeBel and G. Pelletier. EFFECT OF WEANING ON EPIDERMAL GROWTH FACTOR AND ITS RECEPTOR MESSENGER RNA LEVELS IN VARIOUS TISSUES OF PIGLETS. Can. J. Anim. Sci., 1996. 76:621-624.

2.4.1 Contributions to manuscript 2.4

My contribution to this manuscript was to (1) plan and write the project outline, (2) prepare and organize the sample collection, (3) extract total RNA and carry out Northern analysis, (4) determine tissue RNA, DNA and protein concentration, (5) provide data to the statistician, (6) prepare figures and tables and write manuscript. We got technical assistance from Dr. M.-F. Palin for probe preparation. The research project and the manuscript preparation were under the direction of Drs. G. pelletier and D. LeBel.

SHORT COMMUNICATION

**Effect of weaning on epidermal growth factor
and its receptor messenger RNA levels in
various tissues of piglets**

M. Peng,¹ M-F. Palin,² D. LeBel¹, and G. Pelletier²

¹*Department of Biology, Faculty of Science, University of Sherbrooke, Sherbrooke, Québec, Canada J1K 2R1;*

²*Agriculture and Agri-Food Canada, Dairy and Swine Research and Development Centre, Lennoxville, Québec, Canada J1M 1Z3. Contribution no. 523, received 13 February 1996, accepted 28 July 1996.*

Pour l'article complet voir la copie papier à la Bibliothèque du Frère-Théode
Section Monographie QP 552 G76P46 1996

CHAPTER III

GENERAL DISCUSSION

In the present study, mRNA levels and tissue concentrations of IGFs and IGFBPs were monitored simultaneously at various developmental stages of the pancreas, liver, kidney and skeletal muscle in pigs. Pig was chosen as a model because of its anatomical and physiological similarities with human. In addition, pig pancreas is big enough to allow all determinations with the same animal. This study shows for the first time that mRNA levels of IGFs, IGFBPs, EGF and bFGF and tissue concentrations of IGFs and IGFBPs are influenced by developmental stages and are sometimes coordinately regulated. It is also the first attempt to make the relationship between mRNA levels, tissue concentrations of IGFs and IGFBPs and organ growth at different physiological developmental stages in mammals. Ontogeny of IGFs mRNA levels have been studied in rat pancreas (Hogg et al., 1993). However, there is no such information reported in pig and no information with regard to IGFs and IGFBPs tissue concentrations either in pig or rat during development. A fast growth period was observed in fetuses of 90 days of age. This growth period was accompanied with high IGF-II mRNA and tissue concentration of the protein. It has been shown that disruption of one of the alleles for the mouse IGF-II gene resulted in a growth-deficient phenotype, implicating a crucial function for IGF-II in fetal growth (de Chiara et al., 1990). More specifically, IGF-II may be important for pancreatic growth since Miettinen et al. (1993) reported that IGF-II mRNA was abundant in both the exocrine and endocrine

human fetal pancreas, exceeding the amount of insulin mRNA. They have also reported that mRNA of IGF-II is under cAMP regulation. Furthermore, blocking the IGF-IR with a monoclonal receptor antibody markedly reduced insulin expression (87 %) and additionally down regulated IGF-II mRNA level (49 %), suggesting that IGF-II is involved in the regulation of pancreatic differentiation and growth through IGF-IR. In the present study, abundant IGF-IIR mRNA was found in the pancreas during fetal life, while IGF-IR mRNA was undetectable. It is assumed that in pig, IGF-II involvement in pancreatic development is mediated through IGF-IR. We have noticed that the IGF-I mRNA levels in pancreas were high during fetal and early postnatal life, which is in agreement with our recent observations in rat (Calvo et al., 1996). However, it displayed an opposite pattern to the one previously reported by Hogg et al. (1993) (Appendix I). The reason for such a discrepancy is unknown, beside the fact that different breeds of rat were used in these studies. These authors have found that both IGF-I and -II stimulate islet cell DNA synthesis, IGF-I being five-fold more potent than IGF-II. The IGF-I receptors were detected in mouse pancreatic acini (Williams et al., 1984) and rat islets (Van Schravendijk et al., 1987), indicating that postnatal pancreas development may be regulated by IGF-I. We found that a high IGF-I tissue concentration at 21 days of age (around weaning period) corresponded to abundant IGF-I mRNA and preceded another fast growth period at 90 days of age. It was reported that during the suckling period, the ratio of pancreas weight to body weight was relatively low in pig (Corring et al., 1978). After weaning (around three to four weeks of age), pancreatic growth and its protein content as well as digestive enzyme activities increased rapidly (Corring et

al., 1978; Kelly et al., 1991), which is in agreement with our observations. In the present study, we did not evaluate changes of the pancreatic weight between 21 to 90 days of age. According to the observations made by Corring et al. (1978) and Kelly et al. (1991), it is possible that a rapid growth of the pancreas occurs before 90 days of age. The high level of IGF-I at 21 days of age indicates its involvement in pancreatic development during the weaning period. This is one of the reasons why we studied the effect of weaning on mRNA levels of IGFs and some other growth factors in gastrointestinal tract development. It has been reported that IGF-I plasma concentrations and mRNA levels in various tissues are regulated by nutritional status (Thissen et al., 1994). Kanamoto et al. (1994) found that expression of c-myc mRNA was greatly enhanced whereas the IGF-I mRNA levels were reduced by consumption of a protein-free diet or by starvation, suggesting that nutrition not only supplies material for body components but also affects signal transduction for growth. During weaning, the diet switches from milk to solid food which might influence growth factors mRNA levels in gastrointestinal organs. However, there is no information about growth factors regulation of organ growth during this period. In order to check whether IGFs and some other growth factors were involved in pancreatic development during the weaning period, we have studied the effect of weaning on mRNA levels of IGFs, IGFRs, IGFBPs, EGF, EGFR and bFGF in pancreas, liver, stomach, duodenum and skeletal muscle of piglets. This study for the first time showed that in the pancreas, EGF mRNA levels increased markedly six and nine days following weaning at 21 days of age. There was no effect of weaning on EGF mRNA levels in any other tissues. In addition, IGFs, IGFRs,

IGFBPs, EGFR and bFGF mRNA levels in all analyzed tissues did not show any change during the weaning period. We have found that the weight of the pancreas and EGF mRNA levels were higher in weaned than that of the suckling piglets at 27 and 30 days of age. The role of EGF on pancreatic development was studied by Logsdon (1986), who found that EGF directly increase DNA synthesis in pancreatic acinar cells in mouse. In addition, high affinity EGF receptors were detected in pancreatic acinar cells (Hormi and Lehy, 1994). Together all these observations support the hypothesis that EGF may participate in the regulation of pancreatic growth during weaning. Further study would be necessary to know whether EGF protein level in the pancreas is altered by weaning. Results of the present study is helpful to understand the relationship between growth factors mRNA expression and organ development during weaning in order to improve piglet performance at weaning. Although IGF-I concentration was high at 21 days of age, there was no effect of weaning on the IGF-I mRNA level in the pancreas. It is possible that an interaction exists between IGF-I and EGF to regulate organ growth during the weaning period. In fact, such an interaction between IGF-I and EGF was observed in 3T3 fibroblasts (Leof et al., 1982). The authors reported that a physiological dose of IGF-I is required for EGF to stimulate 3T3 fibroblasts cells into S phase. Our study shows that in the pancreas, IGFs, IGF-IR, EGF, EGFR and bFGF mRNA levels were all predominant during fetal and early postnatal life, suggesting that multiple growth factors might be involved in pancreatic development.

In the liver, IGF-I mRNA and hepatic IGF-I concentration peaked at 21 days of age which is different from the observation in rat (Appendix I) where IGF-I mRNA increased

postnatally paralleling the plasma IGF-I concentration (Donovan et al., 1989). On the other hand, concentration of IGF-II was predominant during the suckling period (1 day to 21 days of age). The high IGF-I and -II concentrations were accompanied by relatively high ratio of DNA to body weight, an indication of cell hyperplasia and high organ weight to DNA and RNA to DNA, an indication of cell hypertrophy. In addition, serum IGF-I and -II concentrations all increased postnatally, suggesting IGF-II is not only important in fetal growth but also involved in postnatal development. Furthermore, IGF-IIR mRNA was abundant while IGF-IR mRNA was undetected in the liver, which is consistent with the observation in rat (Werner et al., 1989) (Appendix I). Lee et al. (1993) reported that in pig, IGF-I binding capacity was the lowest in liver compared with lung and brain, while IGF-II receptors were identified in all studied tissues. These observations suggest that the action of IGF-II is mediated through IGF-IIR while IGF-I action may be mediated by the insulin receptor in the liver. In the liver, EGF mRNA was undetected whereas EGFR mRNA was abundant during the whole developmental period. It is possible that EGF is involved in liver development through an endocrine action, since rat hepatocytes have a great capacity to take up EGF from the portal blood (Dunn et al., 1986) and that EGF injected into the portal vein is cleared from the blood by the liver (St. Hilaire et al., 1983). Taken together, the literature and our results support the idea that liver development is regulated by the interaction among various growth factors.

In the kidney, IGF-I and -II concentrations peaked at birth and were associated with relatively high rate of kidney growth in terms of organ weight to body weight and total DNA

to body weight. In addition, relatively high levels of IGF-IR and IGF-IIR mRNAs were detected, suggesting that IGFs may regulate kidney growth. Epidermal growth factor is a potent mitogen for cell proliferation (Prigent and Lemoine, 1992). Treatment with EGF of confluent renal proximal tubular cells for 6 consecutive days increases monolayer DNA content 3.3-fold (Nowak and Schnellmann, 1995). In the present study, EGF mRNA levels in the kidney and skeletal muscle increased with age. However, developmental pattern of EGFR mRNA level in these organs was the opposite to that of EGF. Although EGFR mRNA in the kidney decreased with age during the postnatal life, renal EGFR mRNA level was still relatively high compared to the pancreas and skeletal muscle. The high IGFs concentrations and EGF and EGFR mRNA levels in the kidney leads to the hypothesis that these growth factors are involved in kidney development.

In the muscle, EGF mRNA increased with advancing age. Although EGFR mRNA decreased postnatally, the number of EGF receptors might still be significant since skeletal muscle represents the bulk of the body weight. We postulate that EGF may be important for skeletal muscle growth and maintenance in animals of 90 and 180 days of age. In this study, we found that IGF-I mRNA was more abundant in the skeletal muscle compared to the other examined tissues, whereas, in rat, IGF-I mRNA is more abundant in the liver compared to other tissues during the postnatal life (Murphy et al., 1987). It was suggested that developmental and tissue specific expression of IGF-I mRNA is caused by variation in the 5'-untranslated region (5'-UTR) which could result from the use of different promoters and transcription start sites in the rat IGF-I gene (Hoyt et al., 1988). The different developmental

pattern of IGF-I mRNA between rat and pig in pancreas and liver may be due to gene expression regulated differently in pig and rat. We have also observed that IGFs, IGF-IR and bFGF mRNAs were high in fetal skeletal muscle and decreased with advancing age. These results suggest that IGFs, EGF and bFGF are likely physiological regulators of skeletal muscle growth and maintenance in mammals. In our laboratory, we have found that GHR and lipoprotein lipase DNA polymorphism is associated with muscle growth in different lines of landrace purebred pigs. Since EGF mRNA level increased with advancing age in muscle, it is a good candidate to look for DNA polymorphism in order to develop a genetic marker to assist genetic selection of swine for improvement of carcass quality.

In summary, our results indicate that ontogeny of IGFs, IGFBPs, IGFRs, EGF, EGFR and bFGF mRNA patterns are developmentally and tissues specifically regulated in the studied tissues. The fast growth period of pancreas during fetal life may be influenced by IGFs, EGF and bFGF. Pancreatic development during postnatal life may be also regulated by IGF-I. In addition, EGF is an important mitogenic factor involved in pancreatic growth during the weaning period. In the liver and kidney, IGFs concentrations were predominant between 1 and 21 days of age and were associated with rapid growth periods of these organs. In the kidney and skeletal muscle, mRNAs for IGF-I, IGF-IR and IGF-II were high during fetal and early postnatal life, suggesting that these growth factors may participate in organ growth and development. Messenger RNA of EGF in the kidney and skeletal muscle increases with advancing age, supporting the idea that EGF may be involved in growth and maintenance of these organs in pigs.

REFERENCES

- ADAMSON, E.D., and J. MEEK. 1984. Epidermal growth factor receptors during mouse development. *Dev. Biol.* 103: 62-70.
- ANDERSON, J.E., C.M. MITCHELL, J.K. MCGEACHIE, and M.D. GROUND. 1995. The time course of basic fibroblast growth factor expression in crush-injured skeletal muscle of SJL/J and BALB/c mice. *Exp. Cell Res.* 216: 325-334.
- ALBISTON, A.L., and A.C. HERINGTON. 1992. Tissue distribution and regulation of insulin-like growth factor(IGF)-binding protein-3 messenger ribonucleic acid (mRNA) in the rat: Comparison with IGF-I mRNA expression. *Endocrinology* 133: 497-502.
- ALEXANDRIDES, T., A.C. MOSES, and R.J. SMITH. 1989. Developmental expression of receptors for insulin-like growth factor-I(IGF-I) and IGF-II in rat skeletal muscle. *Endocrinology* 124: 1064-1076.
- ARON, D.C., J.L. ROSENZWEIG, and H.E. ABBOND. 1989. Synthesis and binding of insulin-like growth factor I by human mesangial cells. *J. Clin. Endocrinol.* 68: 585-591.
- ARON, D.C., F. HUSSEIN, F. SAADE, N.N. CHRISTINA, and J.G. DOUGLAS. 1991. Secretion of insulin-like growth factor I and its binding proteins by collecting cells. *Kidney Int.* 39: 27-32.
- ASHTON, I.K., J. ZAPF, I. EINSCHENK, and I.Z. MACKANZIE. 1985. Insulin-like growth factor (IGF) I and II in human foetal plasma and relationship to gestational age and foetal size during midpregnancy. *Acta Endocrinol.* 110: 558-563.
- BACH, L.A, R. SALEMI, and K.S. LEEDING. 1995 Roles of insulin-like growth factor (IGF) receptors and IGF-binding proteins in IGF-II-induced proliferation and differentiation of L6A1 rat myoblasts. *Endocrinology* 136: 5061-5069.
- BAIRD, A., and P. BÖHLEN. 1990. Fibroblast growth factors. In: *Peptide growth factors and their receptors I*, pp.369-418. Eds by Sporn, M.B., and Roberts, A.B., Springer-Verlag, Berlin Heidelberg New York London Paris Tokyo Hong Kong
- BAKER, J., J.P. LIU, E.J. ROBERTSON, and A. EFSTRATIADIS. 1993. Role of insulin-like growth factors in embryonic postnatal growth. *Cell* 75:73-82.

- BALA, R.M., J. LOPATKA, A. LEUNG, E. MCCOY, and R.G. MCARTHUR. 1981. Serum immunoreactive somatomedin levels in normal adults, pregnant women at term, children at various ages, and children with constitutionally delayed growth. *J. Clin. Endocrinol. Metab.* 52: 508-512.
- BARUCH, Y., G. SHOSHANY, G. NEUFELD, and R. ENAT. 1995. Basic fibroblast growth factor is hepatotropic for rat liver in regeneration. *J. Hepatol.* 23: 328-332.
- BASS, J.J., M. OLDHAM, S.C. HODGKINSON, P.J. FOWKE, H. SAUERWEIN, P. MOLAN, B.H. BREIER, and P.D. GLUCKMAN. 1991. Influence of nutrition and bovine growth hormone (GH) on hepatic GH binding, insulin-like growth factor-I and growth of lambs. *J. Endocrinol.* 128: 181-186.
- BEELMAN, C.A., and R. PARKER. 1995. Degradation of mRNA in eukaryotes. *Cell* 81: 179-183.
- BEGUINOT, F., C.R. KAHN, A.C. MOSES, and R.J. SMITH. 1985. Distinct biologically active receptor for insulin-like growth factor I, and insulin-like growth factor -II in cultured skeletal muscle cells. *J. Biol. Chem.* 260: 15892-15898.
- BEVAN, S.J., M. PARRY-BILLINGS, C.T. LIU, D.B. DUNGER, and E.A. NEWSHOLME. 1992. The effect of insulin-like growth factor II on glucose uptake and metabolism in rat skeletal muscle *in vitro*. *Biochem. J.* 286: 561-565.
- BLACHOWSKI, S., T. MOTYL, A. ORZECOWSKI, K. GRZELKOWSKA, and B. INTEREWICZ. 1993. Comparison of metabolic effects of EGF, TGF- α , and TGF- β in primary culture of fetal bovine myoblasts and rat L6 myoblasts. *Int. J. Biochem.* 25: 1571-1577.
- BORTZ, J.D., P. ROTWEIN, D. DEVOL, P.J. BECHTEL, and V.A. HANSEN. 1988. Focal expression of insulin-like growth factor I in rat kidney collecting duct. *J. Cell Biol.* 107: 811-819.
- BOYLE, W.J., T. SMEAL, L.H.K. DEFIZE, P. ANGLE, J.R. WOODGETT, M. KARIN, and HUNTER. 1991. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. *Cell* 64: 573-584.
- BRANNON, P.M., K. HIRSCHI, and M. KORC. 1988. Effects of epidermal growth factor, insulin and insulin-like growth factor I on rat pancreatic acinar cells cultured in serum-free medium. *Pancreas* 3: 41-48.

BRINDLE, P.K., and R. MONTMINY. 1992. The CREB family of transcription activators. *Curr. Opin. Gene. Dev.* 2: 199-204.

BROWN, A.L., D.E. GRAHAM, S.P. NISSLEY, D.J. HILL, A.J. STRAIN, and M.M. RECHLER. 1986. Developmental regulation of insulin-like growth factor-II mRNA in different rat tissues. *J. Biol. Chem.* 261: 13144-13150.

BRYSON, J.M., B.E. TUCH, and R.C. BAXTER. 1989. Production of insulin-like growth factor-II by human fetal pancreas in culture. *J. Endocrinol.* 121: 367-373.

BUNTROCK, P., M. BUNTROCK, I. MARX, D. KRANZ, K.D. JENTZSCH, and G. HEDER. 1984. Stimulation of wound healing using brain extract with fibroblast growth factor (FGF) activity. *Exp. Pathol.* 26: 247-254.

BURATOWSKI, S. 1994. The basic of basal transcription by RNA polymerase II. *Cell* 77: 1-3.

BURGUERA, B., H. WERNER, M. SKLAR, Z. SHEN-ORR, B. STANNARD, C.T. JR. ROBERT, S.P. NISSLY, S.J. VORE, J.F. CARO, and D. LEROITH. 1990. Liver regeneration is associated with increased expression of IGF-II/Mannose-6-phosphate receptor. *Mol. Endocrinol.* 4: 1539-1545.

CALVO, E.L., G. BERNATECHEZ, G. PELLETIER, J.L. IOVANNA, and J. MORISSET. 1996. Down regulation of the IGF-I mRNA expression during postnatal pancreatic development and overexpression after subtotal pancreatectomy and acute pancreatitis in the rat pancreas. *J. Mol. Biol.* (In press)

CARO, J.F., J. POULOS, O. ITTOOP, W.J. PORIES, E.G. FLICKINGER, and M.K. SINHA. 1988. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma and normal, regenerating and fetal rat liver. *J. Clin. Invest.* 81: 976-981.

CARPENTER, G., and M.I. WAHL. 1990. The epidermal growth factor family. In: *Peptide growth factors and their receptors I*. pp.69-171. Eds by Sporn M.B. and Roberts A.B., Springer-Verlag, Berlin Heidelberg New York London Paris Tokyo Hong Kong

CHANDRASEKAR, B., and M. KORC. 1991. Basic fibroblast growth factor is a calcium-mobilizing secretagogue in rat pancreatic acini. *Biochem. Biophys. Res. Commun.* 177: 166-170.

CHASTANT, S., P. MONGET, and M. TERQUI. 1994. Localization and quantification of insulin-like growth factor-I (IGF-I) and IGF-II/mannose-6-phosphate (IGF-II/M6P) receptors

in pig embryos during early pregnancy. *Biol. Reprod.* 51: 588-596.

CHRIVIA, J.C., R. P. S. KWOK, N. LAMB, M. HAGIWARA, M. R. MONTMINY, and R.H. GOODMAN. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. *Nature* 365:855-859.

CLEMMONS, D.R. 1991. Insulin-like growth factor binding proteins. In: *Insulin-like growth factor: molecular and cellular aspects*, pp.152-179, Ed.by LeRoith D., CRC press, Boca Raton Ann Arbor Boston, London

COLEMAN, M.E., F. DEMAYO, K.C. YIN, H.M. LEE, R. GESKE, C. MONTOMERY, and R.J. SEHWARTZ. 1995. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. *J. Biol. Chem.* 270: 12109-12116.

CONOVER, C.A. 1992. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: Studies of underlying mechanism. *Endocrinology* 130: 3191-3192.

COPELAND, K.C., L.E. UNDERWOOD, and J.J. VAN WYK. 1980. Induction of immunoreactive somatomedin-C in human serum by growth hormone: does response relationships and effect on chromatographic profiles. *J. Clin. Endocrinol. Metab.* 50: 690-697.

CORRING, T. A., AUMAITRE, and G. DURAND. 1978. Development of digestive enzymes in the piglet from birth to 8 weeks. *Nutr. Metab.* 22: 231-234.

CYMBALUK, N.F., and B. LAARVELD. 1996. The ontogeny of serum insulin-like growth factor-I concentration in foals: effects of dam parity, diet, and age at weaning. *Domest. Anim. Endocrinol.* 13: 197-209.

DAUGHADAY, W.H., and P. ROTWEIN. 1989. Insulin-like growth factors I and II. peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. *Endocr. Rev.* 10: 68-91.

DE CHIARA, T.M., A. EFSTRATIADIS, and E.J. ROBERTSON. 1990. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. *Nature* 345: 78-80.

DELHANTY, P.J.D., and V.K.M. HAN. 1993. The expression of insulin-like growth factor(IGF)-binding protein-2 and IGF-II genes in the tissues of the developing ovine fetus. *Endocrinology* 132: 41-52.

D'ERCOLE, A.J., G.T. APPLEWHITE, and L.E. UNDERWOOD. 1980. Evidence that somatomedin is synthesized by multiple tissues in the fetus. *Dev. Biol.* 75: 315-328.

D'ERCOLE, A.J., D.J. HILL, A.J. STRAIN, and L.E. UNDERWOOD. 1986. Tissue and plasma somatomedin-C/insulin-like growth factor I (Sm-C/IGF-I) concentrations in the human fetus during the first of gestation. *Pediatr. Res.* 20: 253-255.

DIMBINSKI, A., H. GREGORY, S.J. KONTUREK, and M. POLANSKI. 1982. Trophic action of epidermal growth factor on the pancreas and gastroduodenal mucosa on rats. *J. Physiol.* 325: 35-42.

DONOVAN, S.M., O.H. YOUNGMAN, P. HUNG, and R.G. ROSENFELD. 1989. Ontogeny of serum insulin-like growth factor binding proteins in the rat. *Endocrinology* 125: 2621-2727.

DUNN, W.A., T.P. CONNOLLY, and A.L. HUBBARD. 1986. Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes: receptor pathway. *J. Cell Biol.* 102: 24-36.

ENBERG, G., and K. HALL. 1984. Immunoreactive IGF-II in serum of healthy subjects and patients with growth hormone disturbances and uraemia. *Acta Endocrinol.* 107: 164-170.

FAGIN, J., and S. MELMED. 1987. Relative increase in insulin-like growth factor I messenger ribonucleic acid levels in compensatory renal hypertrophy. *Endocrinology* 120: 718-724.

FISHER, D.A., and J. LAKSHMANAN. 1990. Metabolism and effects of epidermal growth factor and related growth factors in mammals. *Endocr. Rev.* 11: 418-442.

FISHER, D.A., E.C. SALIDO, and L. BARAJAS. 1989. Epidermal growth factor and the kidney. *Annu. Rev. Physiol.* 51: 67-80.

FOYT, H.L., and C.T. ROBERT, JR. 1991. The IGF-I gene: structure, expression, and gene products. In: *Insulin-like growth factor: Molecular and cellular aspects*. pp. 1-47, Ed. By D. LeRoith. CRC press Boca Raton Ann Arbor Boston London.

FREIDENBERG, G.R., H.H. KLEIN, M.P. KLABDE, M.P. CORDERA, K.R. CORDERA, and J.M. OLEFSKY. 1986. Regulation of epidermal growth factor receptor number and phosphorylation by fasting in rat liver. *J. Biol. Biochem.* 15: 752-757.

FRIESS, H., M. KOBRIN, and M. KORC. 1992. Acidic and basic fibroblast growth factors

and their receptors are expressed in the human pancreas. *Pancreas* 7: 737.

FROESCH, E.R., C. SCHMID, J. SCHWANDER, and J. ZAPF. 1985. Action of insulin-like growth factors. *Ann. Rev. Physiol.* 47: 443-467.

FROST, R.A., J. MAZELLA, and L. TSENG. 1993. Insulin-like growth factor binding protein-1 inhibits the mitogenic effect of insulin-like growth factors and progestins in human endometrial stromal cell. *Biol. Reprod.* 49: 104-111.

FRYBURG, D.A. 1994. Insulin-like growth factor I exerts growth hormone and insulin-like actions on human muscle protein metabolism. *Endocrinol. Metab.* 30: E331-E336.

FUNK, B., U. KESSLER, W. EISENMENGER, A. HANSMANN, H.J. KOLB, and W. KIESS. 1992. Expression of insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy. *J. Clin. Endocrinol. Metab.* 75: 424-431.

GEER, P. VAN, D., and T. HUNTER. 1994. Receptor- tyrosine kinase and their signal transduction pathways. *Annu. Rev. Cell Biol.* 10: 251-337.

GIBRAN, N.S., F.F. ISIK, D.M. HEIMBACH, and D. GORDON. 1994. Basic fibroblast growth factor in the early human burn wound. *J. Surg. Res.* 56: 226-234.

GOSPODAROWICZ, D., N. FERRARA, L. SCHWEIGER, and G. NEUFELD. 1987. Structure characterization and biological functions of fibroblast growth factor. *Endocr. Rev.* 8: 1-20.

GRAY, S.W., J.E. SKANDALAKIS, and L.J. SKANDALAKIS. 1987. Embryology and congenital anomalies of the pancreas. In: *Surgical diseases of the pancreas*. pp. 37-45. Eds by Howard, J.M., Jordan, G.L.Jr., and Reber, H.A. LEA & FEBIGER Philadelphia.

GREGORY, H. 1975. Isolation and structure of urogastrone and its relationship to epidermal growth factor. *Nature* 257: 325-327.

HAMMERMAN, M.R., R. O'SHEA, and S.B. MILLER. 1993. Role of growth factors in regulation of renal growth. *Annu. Rev. Physiol.* 55: 305-321.

HAN, V.K.M., P.K. LUND, D.C. LEE, and A.J. D'ERCOLE. 1988. Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization and tissue distribution. *J. Clin. Endocrinol. Metab.* 66: 422-429.

HARRIS, R.C., and T.O. DANIEL. 1989. Epidermal growth factor binding, stimulation of phosphorylation and inhibition of gluconeogenesis in rat proximal tubule. *J. Cell Physiol.* 139: 383-391.

HARRIS, R.C. 1991. Potential physiological roles for epidermal growth factor in the kidney. *Am. J. Kidney Dis.* 17: 627-630.

HASKELL, J.F., D.J. PILLION, and E. MEEZAN. 1988. Specific, high affinity receptor for insulin-like growth factor II in rat kidney glomerulus. *Endocrinology* 123: 774-780.

HAUSCHKA, D. 1994. The scientific basis of myology. In: *Myology*, pp.3-73. Eds by Engle, A.G., and Franzini-Armstrong, C., McGraw-Hill, Inc. Health Professions Division. New York, St. Louis San Francisco Auckland Bogotá Caracas Lisbon London Madrid Mexico City Milan Montreal New Delhi Paris San Juan Singapore Sydney Tokyo Toronto.

HAUSMAN, G.J., D.R. CAMPION, and F.C. BUONOMO. 1991. Concentration of insulin-like growth factors (IGF-I and IGF-II) in tissues of developing lean and obese pig fetuses. *Growth, Dev. Aging* 55: 43-52.

HAYAKAWA, H., Y. KAWARADA, R. MIZUMOTO, H. HIBASAMI, M. TANAKA, and K. NAKASHIMA. 1996. Induction and involvement of endogenous IGF-I in pancreas regeneration after partial pancreatectomy in the dog. *J. Endocrinol.* 149: 259-267.

HAYDEN, J.M., N.W. MARTEN, E.J. BURKE, and S. STRAUS. 1994. The effect of fasting on insulin-like growth factor-I nuclear transcript abundance in rat liver. *Endocrinology* 134: 760-768.

HERNANDEZ, N. 1993. TAP, a universal eukaryotic transcription factor? *Gene. Dev.* 7: 1291-1308.

HILL, D.J., A. FRAZER, I. SWENNE, P.K. WIRDNAM, and R.D.G. MILNER. 1987. Somatomedin-C in human fetal pancreas. Cellular localization and release during organ culture. *Diabetes* 36: 345-352.

HILL, D.J., C. CAMACHO-HUBNER, P. RASHID, A.J. STRAIN, and D.R. CLEMMONS. 1989. Insulin-like growth factor (IGF) binding protein release by human fetal fibroblasts; dependency on cell density and IGF peptides. *J. Endocrinol.* 122: 87-98.

HILL, D.J., V.K.M. HAN, D.R.C. CLEMMONS, C. AMACHO-HUBNER, and J.F. WANG. 1990. Expression, distribution and biological of insulin-like growth factor binding proteins during development. In: *Insulin-like growth factor binding protein*, pp.55-61.

Excerpta Medica International Congress Series. Elsevier, Amsterdam.

HILL, D.J., and D.R. CLEMMONS. 1992. Similar distribution of insulin-like growth factor binding proteins-1, -2, -3 in human fetal tissues. *Growth Factors* 6: 315-326.

HILL, C.S. and R. TREISMAN. 1995. Transcriptional regulation by extracellular signals: mechanisms and specificity. *Cell* 80: 199-211.

HIRATA, Y. and D.N. ORTH. 1979. Epidermal growth factor(urogastrone) in human tissues. *J. Clin. Endocrinol. Metab.* 48: 667-672.

HIRATA, Y., M. UCHIIHASHI, M. NAKAJIMA, T. FUJITA, and S. MATSUKURA. 1982. Immunoreactive human epidermal growth factor in human pancreatic juice. *J. Clin. Endocrinol. Metab.* 54: 1242-1245.

HOGG, J., V.K.M. HAN, D.R. CLEMMONS, and D.J. HILL. 1993. Interactions of nutrients, insulin-like growth factors (IGFs) and IGF-binding proteins in the regulation of DNA synthesis by isolated fetal rat islets of Langerhans. *J. Endocrinol.* 138: 401-412.

HOGG, J., D.J. HILL, and V.K.M. HAN. 1994. The ontogeny of insulin-like growth factor (IGF) and IGF-binding protein gene expression in the rat pancreas. *J. Mol. Endocrinol.* 13: 49-58.

HORMI, K., and T. LEHY. 1994. Developmental expression of transforming growth factor- α and epidermal growth factor receptor proteins in the human pancreas and digestive tract. *Cell Tissue Res.* 278: 439-450.

HOSHI, H., and C.D. LOGSDON. 1993. Direct trophic effects of fibroblast growth factors on rat pancreatic acinar cells in vitro. *Biochem. Biophys. Res. Commun.* 196: 1202-1207.

HOYT, E.C., J.J. VAN, WYK, and P.K. LUND. 1988. Tissue and development specific regulation of a complex family of rat insulin-like growth factor I messenger ribonucleic acids. *Mol. Endocrinol.* 2: 1077-1086.

HUNTER, T., and M. KARIN. 1992. The regulation of transcription by phosphorylation. *Cell* 70: 375-387.

HUNTER, T. 1995. Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signalling. *Cell* 80: 225-236.

- IKEJIRI, K., T. UENO, T. MATSUGUCHI, K. TAKAHASHI, H. ENDO, and M. YAMAMOTO. 1990. The primary structure of the rat insulin-like growth factor II gene region. *Biochim. Biophys. Acta.* 1049: 350-353.
- INGLESE, J., W.J. KOCH, K. TOUHARA, and R.J. LEFKOWITZ. 1995. G₆ interactions with PH domains and Ras-MAPK signalling pathways. *TIBS* 20:151-156.
- ISHIGAMI, A., T.D. REED, and G.S. ROTH. 1993. Effect of aging on EGF stimulated DNA synthesis and EGF receptor levels in primary cultured rat hepatocytes. *Biochem. Biophys. Res. Commun.* 196: 181-186.
- JOHNSON, A.C., S.H. GARFIEL, G.T. MERLINO, and I. PASTAN. 1988. Expression of epidermal growth factor proto-oncogene mRNA in regenerating rat liver. *Biochem. Biophys. Res. Commun.* 150: 412-418.
- JONES, J. and CLEMMONS, D.R. 1995. Insulin-like growth factors and their binding proteins: Biological actions. *Endocr. Rev.* 16: 3-34.
- KAJIKAWA, K., W. YASUI, H. SUMIYOSHI, K. YOSHIDA, H. NAKAYAMA, A. AYHAN, H. YOKZAKI, H. ITO, and E. TAHARA. 1991. Expression of epidermal growth factor in human tissues. *Virchows Arch. A Pathol. Anat. Histopathol.* 418: 27-32.
- KALOUSEK, D.K., N. FITCH, and B.A. PARADICE. 1990. Pathology of the human embryo and previable fetus. An atlas, pp3-28. Spring-Verlag, New York Berlin Heidelberg London Paris Tokyo Hong Kong
- KAMPMAN, K.A., T.G. RAMSAY, and M.E. WHITE. 1994. Developmental changes in serum IGF-I and IGFBP levels and liver IGFBP-3 mRNA expression in intrauterine growth-retarded and control swine. *Comp. Biochem. Physiol.* 108B: 337-347.
- KANAMOTO, R., T. YOKOTA, and H. SHIN-ICHI. 1994. Expressions of c-myc and insulin-like growth factor -I mRNA in the liver of growing rats vary reciprocally in response to changes in dietary protein. *J. Nutr.* 124: 2329-2334.
- KARPEN, C.W., R.G. SPANHEIMER, A. RANDOLPH, and W.L. LOWE. 1992. Tissue-specific regulation of basic fibroblast growth factor mRNA levels by diabetes. *Diabetes* 41: 222-226.
- KELLY, D., J.A. SMYTH, and K.J. MCCracken. 1991. Digestive development of the early-weaning pig. *British J. Nutr.* 65: 169-180.

KELLY, D., M. MCFADYEN, T.P. KING, and P.J. MORGAN. 1992. Characterization and autoradiographic localization of the epidermal growth factor receptor in the jejunum of neonatal and weaned pigs. *Reprod. Fertil. Dev.* 4:183-191.

KERR, L.D., J.-I. INOUE, and I.M. VERMA. 1992. Signal transduction: the nuclear target. *Curr. Opin. Cell Biol.* 4: 496-501.

KIM, S.-W., R. LAJARA, and P. ROTWEIN. 1991. Structure and function of a human insulin-like growth factor-I gene promoter. *Mol. Endocrinol.* 5: 1964-1972.

KNEE, R.S., S.E. PITCHER, and P.R. MURPHY. 1994. Basic fibroblast growth factor sense (FGF) and antisense (GFG) RNA transcripts are expressed in unfertilized human oocytes and in differentiated adult tissues. *Biochem. Biophys. Res. Commun.* 205: 577-583.

KORC, M., L.M. MARTISIAN, S.R. PLANCK, and B.E. MAGUN. 1983. Binding of epidermal growth factor in rat pancreatic acini. *Biochem. Biophys. Res. Commun.* 111: 1066-1073.

KUO, T.M., Y. TAKETANI, T. AYABE, O. TSUTSUMI, and M. MIZUNO. 1990. Stimulatory effect of epidermal growth factor on the development of mouse early embryos *in vitro*. *Endocrinol. Jpn.* 38: 485-490.

LABORDE, N.P., M. GRODIN, G. BUENAFLORE, P. BROWN, and D.A. FISHER. 1988. Ontogenesis of epidermal growth factor in liver of BALB mice. *Am. J. Physiol.* 255 (Endocrinol. Metab. 18): E28-32.

LACROIX, M.C., and G. KANN. 1993. Ontogeny and characterization of epidermal growth factor receptors on the fetal serum of the sheep placenta. *J. Endocrinol.* 136: 43-50.

LEE, C.Y., F.W. BAZER, T.D. ETHERTON, and A.S. FRANK. 1991. Ontogeny of insulin-like growth factors (IGF-I and IGF-II) and IGF-binding proteins in porcine serum during fetal and postnatal development. *Endocrinology* 128: 2336-2344.

LEE, C.Y., C.S. CHUNG, and F.A. SIMMEN. 1993. Ontogeny of the porcine insulin-like growth factor system. *Mol. Cell. Endocrinol.* 93: 71-80.

LEMOZY, S., J.B. PUCILOWSKA, and L.E. UNDERWOOD. 1994. Reduction of insulin-like growth factor-I (IGF-I) in protein-restricted rats is associated with differential regulation of IGF-binding protein messenger ribonucleic acids in liver and kidney, and peptides in liver and serum. *Endocrinology* 135: 617-623.

- LEOF, E.B., W. WHARTON, VAN, J.J. WYK, and W.J. PLEDGER. 1982. Epidermal growth factor (EGF) and somatomedin-C regulate G1 progression in competent BALB/c-3T3 cells. *Exp. Cell Res.* 141: 107-115.
- LEVINOVITZ, A., E. JENNISCHE, A. OLDFORS, D. EDWALL, and G. NORSTEDT. 1992. Activation of insulin-like growth factor II expression during skeletal muscle generation in the rat: correlation with myotube formation. *Mol. Endocrinol.* 6: 1227-1234.
- LEWITT, M.S., and R.C. BAXTER. 1989. Regulation of growth hormone independent insulin-like growth factor-binding protein (BP-2) in cultured human fetal liver explants. *J. Clin. Endocrinol. Metab.* 69: 246-252.
- LIU, L., and C.S. NICOLL. 1988. Evidence for a role of BFGF in rat embryonic growth and differentiation. *Endocrinology* 123: 2027-2031.
- LIU, J.P., J. BAKER, A. PERKINS, E.J. ROBERTSON, and A. EFSTRATIADIS. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (IGF-) and type I IGF receptor (IGFI-R). *Cell* 75: 59-72.
- LOGSDON, C.D., and J.A. WILLIAMS. 1983. Epidermal growth factor binding and biological effects on mouse pancreatic acini. *Gastroenterology* 85: 339-494.
- LOGSDON, C.D. 1986. Stimulation of pancreatic acinar cell growth by CCK, epidermal growth factor and insulin. *Am. J. Physiol.* 251 (Gastroint. Liver Physiol.14): G487-494.
- LOWE, W.L. JR. 1991. Biological actions of the insulin-like growth factors. In: *Insulin-like growth factor: Molecular and cellular aspects.* pp. 49-85, Ed. by D. LeRoith, CRC press Boca Raton Ann Arbor Boston London.
- LUND, P.K., B.M. MOASTS, M.A. HYNES, J.G. SIMMONS, M. JANSEN, A.J. D'ERCOLE, and J.J. VAN, WYK. 1986. Somatomedin-c /insulin-like growth factor-I and IGF-II mRNAs in rat fetal and adult tissues. *J. Biol. Chem.* 31: 14539-14544.
- LÜSCHER, B., E. CHRISTENSON, D. LITCHFIELD, D.W. KREBS, and R.N. EISENMAN. 1990. Myb DNA binding inhibited by phosphorylation at a site deleted during oncogenic activation. *Nature* 344: 517-522.
- MAAKE, C., and M. REINECKE. 1993. Immunohistochemical localization of insulin-like growth factor 1 and 2 in the endocrine pancreas of rat, dog, and man, and their coexistence with classical islet hormones. *Cell Tissue Res.* 273: 249-259.

MARSHALL, M.S. 1995. Ras target proteins in eukaryotic cells. *FASEB. J.* 9: 1311-1318.

MARTI, U., S.J. BURWEN, and A.L. JONES. 1989. Biological effect of epidermal growth factor with emphasis on the gastrointestinal tract and liver: an update. *Hepatology* 9: 126-138.

MARAI, R., J. WYNNE, and R. TREISMAN. 1993. The SRF accessory protein Elk-1 contain a growth factor-regulated transcriptional activation domain. *Cell* 73: 381-393.

MATEJKA, G.L., and E. JENNISCHE. 1992. IGF-I binding and IGF-I mRNA expression in the postischemic regenerating rat kidney. *Kidney Int.* 42: 1113-1123.

MATHREW, L.S., G. NORSTED, and R.D. PALMITER. 1986. Regulation of insulin-like growth factor I gene expression by growth hormone. *Proc. Natl. Acad. Sci. USA* 83: 9343-9347.

MATHREW, L.S., G. NORSTED, and R.D. PALMITER. 1988. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. *Endocrinology* 123: 2827-2833.

MCCUSKER, R.H., and D.R. CLEMMONS. 1992. The insulin-like growth factor binding proteins: structure and biological functions. In: *The insulin-like growth factors*, pp. 111-150. Ed. by Schofield, P.N., Oxford University press

MIETTINEN, P.J., T. OTONKOSKE, and R. VOUTILAINEN. 1993. Insulin-like growth factor-II and transforming growth factor- α in developing human fetal pancreatic islets. *J. Endocrinol.* 138: 127-136.

MILLER, S.B., S.A. ROGERS, C.E. ESTES, and M.R. HAMMERMAN. 1992. Increased distal nephron EGF content and altered distribution of peptide in compensatory renal hypertrophy. *Am. J. Physiol.* 262 (Renal Fluid Electrolyte Physiol. 31): F1032-1038.

MOHN, K.L., A.E. MELBY, D.S. TEWARI, T.M. LAZ, and R. TAUB. 1991. The gene encoding rat insulin-like growth factor binding protein 1 is rapidly and highly induced in regenerating liver. *Mol. Cell. Biol.* 3: 1393-1401.

MORIN, N.J., G. LAURENT, D. NONCLERCQ, G. TOUBEAU, J-A. HEUSON-STIENNON, G. BERGERON, and D. BEAUCHAMP. 1992. Epidermal growth factor accelerates renal tissue repair in a model of gentamicin nephrotoxicity in rats. *Am. J. Physiol.* 263 (Renal Fluid Electrolyte Physiol. 32): F806-F811.

MORRISON, R.S., A. SHARMA, J. DE VELLIS, and R.A. BRADSHAW. 1986. Basic fibroblast growth factor supports the survival of cerebral cortical neurons in primary culture. *Proc. Natl. Acad. Sci. U.S.A.* 83: 7537-7541.

MOSES, A.C., S.P. NISSLEY, P.A. SHORT, M.M. RECHLER, R.M. WHITE, A.B. KNIGHT, and O.Z. HIGA. 1980. Increased levels of multiplication-stimulating activity, and insulin-like growth factor in fetal rat serum. *Proc. Natl. Acad. Sci. USA* 77: 3649-3653.

MULRONEY, S.E., A. HARAMATI, H. WERNER, C. BONDY, C.T.JR. ROBERTS, and D. ALEAROITH. 1992. Altered expression of insulin-like growth factor-I (IGF-I) and IGF receptor genes after unilateral nephrectomy in immature rats. *Endocrinology* 130: 249-256.

MURPHY, L.J., G.I., BELL, and H.G. FRIESEN. 1987. Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. *Endocrinology* 120: 1279-1282.

MURPHY, L.J., P. MOLNAR, X. LU, and H. HUANG. 1995. Expression of human insulin-like growth factor-binding protein-3 in transgenic mice. *J. Mol. Endocrinol.* 15: 293-303.

MYERS, M.G., X.J.JR. SUN, and M.F. WHITE. 1994. The IRS-1 signalling system. *TIBS* 19: 289-293.

NEXØ, E., and N. KRYGER-BAGGESON. 1989. The receptor for epidermal growth factor is present in human fetal kidney, liver and lung. *Regul. Pept.* 26: 1-8.

NISSLEY, P., W. KIESS, and M.M. SKLAR. 1991. The insulin-like growth factor-II/Mannose 6-phosphate receptor. In: *insulin-like growth factors: Molecular and Cellular Aspects*, pp111-150. Ed. by LeRoith, D., CRP press, Boca Raton Ann Arbor Boston London

NOGUCHI, S., Y. OHBA, and T. OKA. 1990. Influence of epidermal growth factor on liver regeneration after partial hepatectomy in mice. *Endocrinology* 128: 425-431.

NOUWEN, E., and M.E. DE BROE. 1994. EGF and TGF- α in the human kidney: Identification of octopal cells in the collecting duct. *Kidney Int.* 45: 1510-1521.

NOWAK, G., and R.C. SCHNELLMANN. 1995. Integrative effects of EGF on metabolism and proliferation in renal proximal tubular cells. *Am. J. Physiol.* 269 (Cell Physiol. 38): C1317-1325.

O'MAHONEY, J.V., M.R. BRANDON, and T.E. ADAMS. 1991. Developmental and tissue-specific regulation of ovine insulin-like growth factor II (IGF-II) mRNA expression. *Mol. Cell. Endocrinol.* 78: 87-96.

OOI, G.T., C.C. ORLOWSKI, A.L. BROWN, R.E. BECKER, T.G. UNTERMAN, and M.M. RECHLER. 1990. Different tissue distribution and hormonal regulation of messenger RNAs encoding rat insulin-like growth factor binding protein-1 and -2. *Mol. Endocrinol.* 4: 321-328.

OPLETA, K., E.V. O'LOUGHLIN, E.A. SHAFFER, J. HAYDEN, M. HOLLENBERG, and D.G. GALL. 1987. Effect of epidermal growth factor on growth and postnatal development of the rabbit liver. *Am. J. Physiol.* 253 (Gastroint. Liver Physiol. 16): G622-626.

ORLOWSKI, C.C., A.L. BROWN, G.T. OOI, Y.W-H. YANG, L.Y.H. TSENG, and M.M. RECHLER. 1990. Tissues, developmental, and metabolic regulation of messenger ribonucleic acid encoding a rat insulin-like growth factor-binding protein. *Endocrinology* 126: 644-652.

PAWSON, T. 1992. Tyrosine kinases and their interactions with signalling proteins. *Curr. Opin. Gene. Dev.* 2: 4-12.

PAWSON, T. 1993. Signal transduction-A conserved pathway from the membrane to the nucleus. *Dev. Gene.* 14: 333-338.

PELL, J.M., J.C. SAUNDERS, and R.S. GILMOUR. 1993. Differential regulation of transcription initiation from insulin-like growth factor (IGF-I) leader exons and of tissue IGF-I expression in response to changed growth hormone and nutritional status in sheep. *Endocrinology* 132: 1797-1807.

PERHEENTUPA, J., J. LAKSHMAN, and D.A. FISHER. 1985. Urine and kidney EGF: ontogeny and sex differences in the mouse. *Pediatr. Res.* 19: 428-432.

POUYSSÉGUR, J., C. KAHAN, I. MAGNALDO, and K. SEUWEN. 1992. G-proteins and cell growth signalling. In *Transmembrane signalling intracellular messengers and implications for drug development*. pp.119-132. Ed. by S.R. Nahorski, A Wiley-Interscience publication, John Wiley & Sons, Chichester New York Brisbane Toronto Singapore.

POWELL-BRAXTON, L., P. HOLLINGSHEAD, C. WARBURTON, M. DOWD, S. PITTS-MEEK, D. DALTON, N. GILLETT, and T.A. STEWART. 1993. IGF-I is required for normal embryonic growth in mice. *Genes & Dev.* 7: 2609-2617.

PRICE, G.J., J.L. BERKA, S.R. EDMONDSON, G.A. WERTHIR, and L.A. BACH. 1995. Localization of mRNAs for insulin-like growth factor binding proteins 1-6 in rat kidney. *Kidney Int.* 48: 402-411.

PRIGENT, S.A., and N.R. LEMOINE. 1992. The type 1 (EGFR-related) family of growth factor receptors and their ligands. *Prog. Growth Factor Res.* 4: 1-24.

RAJKUMAR, K., D. RARRON, M.S. LEWITT, and L.J. MURPHY. 1995. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. *Endocrinology* 136: 4029-4034.

RALL, L.B., J. SCOTT, B.I. BELL, R.J. GRAWFORD, J.D. PENCSHOW, H.D. NIAL, and J.P. COGHLAN. 1985. Mouse pre pro-epidermal growth factor synthesis by the kidney and other tissues. *Nature* 313: 228-231.

RECHLER, M.M., and S.P. NISSLEY. 1985. The nature and regulation of the receptors for insulin-like growth factors. *Annu. Rev. Physiol.* 47: 425-442.

ROMANUS, J.A., A. RABINOVITCH, and M.M. RECHLER. 1985. Neonatal rat islet cell cultures synthesize insulin-like growth factor I. *Diabetes* 34: 696-702.

ROSEN, K.M., B.M. WENTWORTH, N. ROSENTHAL, and K.L. VILLA. 1993. Specific, temporally regulated expression of the insulin-like growth factor II gene during muscle cell differentiation. *Endocrinology* 133: 474-481.

ROSENBAUM, J., P. MAVIER, A-M. PREAUX, and D. DHUMEAUX. 1989. Demonstration of a fibroblast growth factor-like molecule in mouse hepatic endothelial cells. *Biochem. Biophys. Res. Commun.* 164: 1099-1104.

ROSS, J. 1995. Control of messenger RNA stability in higher eukaryotes. *Trends Genet. (TIG)* 12: 171-175.

ROTWEIN, P., K.M. POLLOCK, M. WATSON, and J.D. MILBRANDT. 1987. Insulin-like growth factor gene expression during rat embryonic development. *Endocrinology* 121: 2141-2144.

ROTWEIN, P., and L.J. HALL. 1990. Evolution of insulin-like growth factor-II: Characterization of the mouse IGF-II gene and identification of two pseudo-exons. *DNA Cell Biol.* 192: 725-735.

RUTANEN, E.M., and F. PEKONEN. 1990. Insulin-like growth factors and their binding proteins. *Acta Endocrinol (Copenh)* 123: 7-13.

SANTOS, A., B. YUSTA, M.D. FERNÁNDEZ-MORENO, and E. BLÁZQUEZ. 1994. Expression of insulin-like growth factor-I (IGF-I) receptor gene in rat brain and liver during development and in regenerating adult rat liver. *Mol. Cell. Endocrinol.* 101: 85-93.

SARFATI, P., C. SEVA, J.L. SCEMAMA, L. PRADAYROL, and N. VAYSSE. 1992. Effect of basic fibroblast growth factor on ornithine decarboxylase activity and mRNA expression in a pancreatic tumoral cell line (AR4-2J). *Pancreas* 7: 657-663.

SASSONE-CORSI, P. 1994. Goals for signal transduction pathways: Linking up with transcriptional regulation. *EMBO J.* 13: 4717-4728.

SCHARF, J-G., W. SCHMIDT-SANDTE, S.A. PAHERNIK, H-G. KOEBE, and H. HARTMAN. 1995. Synthesis of insulin-like growth factor binding proteins and of the acid-labile subunit of the insulin-like growth factor ternary binding protein complex in primary cultures of human hepatocytes. *J. Hepatol.* 23: 424-430.

SCHARFMANN, R., M. CORVOL, and P. CZERNICHOW. 1989. Characterization of insulin-like growth factor I in produced by fetal rat pancreatic islets. *Diabetes* 38: 686-690.

SCHAUDIES, R.P., J. GRIMES, D. DAVIS, R.K. RAO, and O. KOLDOVSSKY. 1989. EGF content in the gastrointestinal tract of rats effect of age and fasting/feeding. *Gastrointest. Liver Physiol.* 19: G856-861.

SCHIAVI, S. C., J. G. BELASOCO, and M. E. GREENBERG. 1992. Regulation of proto-oncogene mRNA stability. *Biochem. Biophys. Acta.* 1114: 95-106.

SCHINDLER, C. 1995. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. *Annu. Rev. Biochem.* 64: 621-651.

SCHULTZ, G., D.S. ROTATORI, and W. CLARK. 1990. EGF and TGF- α in wound healing and repair. *J. Cell. Biochem.* 45:346-352.

SHIMASAKI, S., and N. LING. 1991. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). *Prog. Growth Factor Res.* 3: 243-266.

SKLAR, M.M., C.L. THOMAS, G. MUNICCHI, C.T.JR. ROBERTS, D. LEROITH, W. KIESS, and P. NISSEY. 1992. Developmental expression of rat insulin-like growth factor-

II/mannose 6-phosphate receptor messenger ribonucleic acid. *Endocrinology* 130: 3484-3491.

ST. HILAIRE, G.T. HRADEK, and A.L. JONES. 1983. Hepatic sequestration and biliary secretion of epidermal growth factor:evidence for a high-capacity uptake system. *Proc.Natl. Acad. Sci. USA* 80: 3797-3801.

STRADER, C.D., T.M. FONG, M.R. TOTA, and D. UNDERWOOD. 1994. Structure and function of G protein-coupled receptors. *Annu. Rev. Biochem.* 63: 101-132.

STRAUS, D.S., and C.D. TAKEMOTO. 1990. Effect of fasting on insulin-like growth factor-I (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene transcription in rat liver. *Mol. Endocrinol.* 4: 91-100.

STRECK, R.D., and J.E. PINTAR. 1992. The embryonic pattern of rat insulin-like growth factor-I gene expression suggests a role in induction and early growth of the liver. *Endocrinology* 131: 2030-2032.

STYLIANOPOULOU, F., A. EFSTRATIADIS, J. HERBERT, and J. PINTAR. 1988. Pattern of the insulin-like growth factor II gene expression during rat embryogenesis. *Development* 103: 497-506.

SUIKKARI, A-M., I. LEIVO, M. KAMARAINEN, H. HOLTHOFER, M. SEPPALA, M. JULKUNEN, and R. KOISTINEN. 1992. Expression of insulin-like growth factor binding protein-1 mRNA in human fetal kidney. *Kidney Int.* 42: 749-754.

SUN, X.J. 1992. Expression and function of IRS-1 in insulin signal transmission. *J. Biol. Chem.* 267: 22662-22672.

SUSSENBACH, J.S., P.H. STEENBERGH, E. JANSEN, D. MEINSMA, M.A. VAN DIJK, P. HOLTHUIZEN, C.H. DE MOOR, M.J. JANSEN, and J.L. VAN DEN BRANDE. 1991. Structure and post-transcriptional regulation of expression of the human IGF-I and -II genes. In: *Modern Concepts of Insulin-like Growth Factors*. pp.639-654. Ed. by E.M. Spencer, Elsevier Science Publishing Co., Inc.

THISSEN, J-P., J-M. KETELSLEGERS, and L.E. UNDERWOOD. 1994. Nutritional regulation of the insulin-like growth factors. *Endocr. Rev.* 15: 80-101,

THOMPSON, J.A., C. HAUDENSCHILD, K.D. ANDERSON, J.M. DIPIETRO, W.F. ANDERSON, and T. MACIAG. 1989. Heparin-binding growth factor I induces the formation of organoid neovascular structures *in vivo*. *Proc. Natl. Acad. Sci. USA* 86: 7928-7932.

THORBURN, G.D., M.J. WATERS, I.R. YOUNG, M. DOLLING, D. BUNTINE, and P.S. HOPKINS. 1981. Epidermal growth factor : a critical factor in fetal maturation? Ciba Found. Symp. 86: 172-186.

THREADGILL, D.W., A.A. DLUGOSZ, L.A. HANSEN, T. TENNENBAUM, U. LICHTI, D. YEE, C. LAMANT, T. MOURTON, K. HERRUP, R.C. HARRIS, J.A. BARNARD, S.H. YUSPA, R.J. COFFEY, and T. MAGNUSON. 1995. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. *Science* 269: 230-234.

TOMAS, F.M., S.E. KNOWLES, C.S. CHANDLER, G.L. FRANCIS, P.C. OWENS, and F.J. BALLARD. 1993. Anabolic effects of insulin-like growth factor-I (IGF-I) and IGF-I variant in normal female rats. *J. Endocrinol.* 137: 413-421.

VANDEHAAR, M., M.M. MOATS-STAAS, M.L. DAVENPORT, J.L. WALKER, J.M. KETELSLEGERS, B.K. SHARMA, and L.E. UNDERWOOD. 1991. Reduced serum concentrations of insulin-like growth factor-I (IGF-I) in protein-restricted growing rats are accompanied by reduced IGF-I mRNA levels in liver and skeletal muscle. *J. Endocrinol.* 130: 305-312.

VAN SCHRAVENDIJK, C.F.H., A. FORIER, J.L. VAN DEN BRANDE, and D.G. PIPELEERS. 1987. Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells. *Endocrinology* 121: 1784-1788.

VAUGHAN, T.J., J.C. PASCALL, J.C., P.S. JAMES, and K.D. BROWN. 1991. Expression of epidermal growth factor and its mRNA in pig kidney, pancreas and other tissues. *Biochem. J.* 279: 315-318.

VAUGHAN, T.J., C.J. LITTLEWOOD, J.C. PASCALL, and K.D. BROWN. 1992. Epidermal growth factor concentrations in pig tissues and body fluids measured using a homologous radioimmunoassay. *J. Endocrinol.* 135: 77-83.

VEHASKARI, V.M., K.S. HERING-SMITH, D.W. MOSKOWITZ, I.D. WEINER, and L.L. HAMM. 1989. Effect of epidermal growth factor on sodium transport in the cortical collecting tubule. *Am. J. physiol.* 256 (Renal Fluid Electrolyte Physiol.25): F803-809.

VELU, T.J. 1990. Structure, function and transforming potential of the epidermal growth factor receptor. *Mol. Cell. Endocrinol.* 70: 205-216.

WANDJI, S., G. PELLETIER, and M. SIRARD. 1992. Ontogeny and cellular localization of ¹²⁵I-labelled bFGF and ¹²⁵I-labelled EGF binding sites in ovaries from bovine fetuses and

neonatal calves. Biol. Reprod. 47: 807-813.

WERNER, H., M. WOLOSCHAK, M. ADMO, Z. MHEN-ORR, and C.T.JR. ROBERTS. 1989. Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA 86: 7451-7455.

WELLER, P.A., M.C. DICKSON, N.S. HUSKISSON, M.J. DAUNCEY, P.J. BUTTERY, and R.S. GILMOUR. 1993. The porcine insulin-like growth factor-I gene: characterization and expression of alternate transcription sites. J. Mol. Endocrinol. 11: 201-211.

WERNER, H., M. WOLOSCHAK, B. STANNARD, S. SHEN-ORR, T. CHARLES, JR, ROBERTS, and D. LEROITH. 1991. The insulin-like growth factor I recaptor: molecular biology, heterogeneity, and regulation. In: Insulin-like growth factor:molecular and cellular aspects, pp.18-38. Ed. by LeRoith, D., CRC press, Boca Raton Ann Arbor Boston London

WHITE, M.E., T.G. RAMSAY, J.M. OSBOME, K.A. KAMPMAN, and D.W. LEAMAN. 1991. Effect of weaning at different age on serum insulin-like growth factor I (IGF-I), IGF binding proteins and serum *in vitro* mitogenic activity in swine. J. Anim. Sci. 69: 134-145.

WILEY, L.M., J.X. WU, I. HARARI, and E.D. ADAMSON. 1992. Epidermal growth factor receptor mRNA and protein increase after the four-cell preimplantation stage in murine development. Dev. Biol. 149: 247-260.

WILLIAMS, J.A., A. BAILEY, R. HUMBEL, and L.D. GOLDFINE. 1984. Insulin-like growth factors bind to specific receptors in isolated pancreatic acini. Am. J. Physiol. 246 (Gastrointest. Liver Physiol.9): G96-99.

WINTERS, T.A., F.G. FEBRES, D.L. FULGHAM, P.J. BERTIC, T.M. DUELLO, and J. GORSKI. 1993. Ontogeny of the epidermal growth factor receptor during development of the fetal bovine mesonephros and associated organs of the urogenital tract. Biol. Reprod. 48: 1395-1403.

WOLF, E., R. KRAMER, W.F. BLUM, J. FÖLL, and G. BREM. 1994. Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice:endocrine changes and effects on body and organ growth. Endocrinology 135: 1877-1994.

YEH, J., R. OSATHANONDH, and L. VILLA-KOMAROFF. 1993. Expression of messenger ribonucleic acid for epidermal growth factor receptor and its ligands, epidermal growth factor and transforming growth factor- α , in human first- and second-trimester fetal ovary and uterus. Am. J. Obstet. Gynecol. 168: 1569-1573.

ZARRILLI, R., V. COLANTUONI, and C.B. BRUNI. 1992. Regulation of insulin-like growth factor II gene expression in rat liver cells. *Eur. J. Biochem.* 209: 445-452.

ZHANG, Y., B.C. PARIA, S.K. DEY, and D.L. DAVIS. 1992. Characterization of the epidermal growth factor receptor in preimplantation pig conceptuses. *Dev. Biol.* 151: 617-621.

ZSCHIESCHE, W. 1989. Retardation of growth and epithelial differentiation in suckling mice by anti-EGF antisera. *Biomed. Biochem. Acta.* 48: 103-109.

ANNEXE

0022-1554/96/\$3.30
The Journal of Histochemistry and Cytochemistry
Copyright © 1996 by The Histochemical Society, Inc.

Vol. 44, No. 5, pp. 481-499, 1996
Printed in U.S.A.

Original Article

Development of GP-2 and Five Zymogens in the Fetal and Young Pig: Biochemical and Immunocytochemical Evidence of an Atypical Zymogen Granule Composition in the Fetus¹

JEAN LAINÉ, GHISLAIN PELLETIER, GILLES GRONDIN, MANLI PENG,
and DENIS LEBEL²

Centre de Recherche sur les Mécanismes de Sécrétion, Université de Sherbrooke, Sherbrooke, Québec, Canada (JL,GG,DL), and Dairy and Swine Research and Development Center, Agriculture and Agri-Food Canada, Lennoxville, Québec, Canada (GP,MP).

Received for publication June 15, 1995 and in revised form December 20, 1995; accepted December 28, 1995 (5A3702).

To uncover the mechanisms involved in the biogenesis of secretory granules, we studied development of the exocrine pancreas in the pig from the fetus up to the mature animal by following the enzyme activities and expression (Northern blot) of five zymogens and GP-2, the major protein of the granule membrane. Fetal pancreas mainly contained chymotrypsinogen and barely detectable amounts of amylase, trypsin, lipase, and elastase. GP-2 was not notably expressed before the Day 21 of life. Ultrastructural examination of the fetal tissue embedded in Epon with osmium postfixation or in Lowicryl at -20°C without postfixation showed that most granules had uncondensed contents, with the aspect of immature granules, or had a dense core sur-

rounded by light material. With immunogold cytochemistry, the concentration of chymotrypsinogen was directly associated with the acquisition of electron density by the granule matrix. These observations suggest that fetal granules have a slower rhythm of zymogen condensation and an irregular shape that could be due to the particular composition of the matrix and the absence of GP-2. We conclude that, in the exocrine pancreas, secretory granules can be formed under various conditions, even with a matrix containing a ratio of components very different from that of the normal mature animal. (*J Histochem Cytochem* 44:481-499, 1996)

KEY WORDS: Secretion granule; *Trans*-Golgi network; Exocrine pancreas; Regulated secretion; Electron microscopy; Immunocytochemistry; Pig.

APPENDIX I

Comparison of IGFs and IGFBPs mRNA levels in rat and pig during fetal and postnatal life

mRNA levels	Periods	Pancreas		Liver		
		Rat	Pig	Rat	Pig	
IGF-I	Fetal	High	High	Low	Peaked at P21	
	Postnatal	Low	Low	High		
IGF-II	Fetal	High	High	High	High	
	Postnatal	Low	Low	Low	Low	
IGFBP-1	Fetal	Peaked at P21	barely detectable	High	Peaked at P1	
	Postnatal			Low		
IGFBP-3	Fetal	No change	High	Low	No change	
	Postnatal		Low	High		
IGFI-R	Fetal	Not determined	High	Undetectable		
	Postnatal		Low			
IGFII-R	Fetal		Undetectable	High	No change	
	Postnatal			Low		

REFERENCES:

- CALVO, E.L., G. BERNATECHEZ, G. PELLETIER, J.L. IOVANNA, and J. MORISSET. 1996. J. Mol. Biol. (In press.)
- HOGG, J., D.J. HILL, and V.K.M. HAN. 1994. J. Mol. Endocrinol. 13: 49-58.
- LEE, C.Y., C.S. CHUNG, and F.A. SIMMEN. 1993. Mol. Cell. Endocrinol. 93: 71-80.
- SKLAR, M.M., C.L. THOMAS, G. MUNICCHI, C.T.JR. ROBERTS, D. LEROITH, W. KIESS, and P. NISSEY. 1992. Endocrinology 130: 3484-3491.
- WERNER, H., M. WOLOSCHAK, M. ADAMO, Z. SHEN-ORR, C.T. ROBERTS, JR., and D. LEROITH. 1989. Proc. Natl. Acad. Sci. USA 86: 7451-7455.

Present study manuscripts 2.1 and 2.2

APPENDIX II




Body weight and food consumption of piglets around the weaning period

Age (Days)	21	24	27	30
Piglets	Body weight (g) / Piglet			
Suckling	5546±229.9	6045±289.9	7002±454.2	7793±684.1
Weaned	5587±274.2	5678±284.1	6674±416.5	7708±628.1
n	9	9	6	3
Period (Days)	14-21	21-24	24-27	27-30
Piglets	Average daily body weight gain (g) / Piglet			
Suckling	201.9±27.3	156.1±45.7	243.6±34.1	133.9±92.8
Weaned	238.6±20.9	24.7 ±38.5	282.2±65.6	244.4±100.9
n	9	9	6	3
Period (Days)	19-21	22-24	25-27	28-30
Daily dry matter consumption (g) / Piglet				
Weaned piglets	50	300	312.5±44.1	410.6±68.1
Daily dry matter consumption / Body weight (%)				
Weaned piglets	0.9	5.0	4.7	5.3

Daily milk consumption for suckling piglets was estimated using the weigh-suckling-weigh method. Daily milk dry matter consumption of suckling piglets at 21 days of age was 185.7 ± 22.1 g/piglet (n=6) (The dry mater content of the milk and the dry feed were 18% and 90%, respectively). The commercial name of the dry feed was Poupon which is produced by Coopérative Fédérée de Québec, Ste-Rosalie, Québec. The milk dry matter consumption / body weight of suckling piglets at 21 days of age was 3.3%.


APPENDIX III

INSULIN-LIKE GROWTH FACTOR-1 (IGF-1)




APPENDIX IV

INSULIN-LIKE GROWTH FACTOR-2 [IGF-2]



APPENDIX V

INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGF-BP3)



APPENDIX VI

INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-R)

